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GENERAL INTRODUCTION
Compared with the general population, patients with rheumatic diseases are at 
increased risk of developing several comorbid conditions, of which cardiovascular 
comorbidities are the most common and have the greatest effect on mortality (1). The 
epidemiology and pathogenesis of cardiovascular comorbidities in inflammatory 
joint diseases (IJDs) are particularly well-studied for rheumatoid arthritis (RA), 
but have also been investigated for rheumatic diseases such as ankylosing 
spondylitis (AS), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE). 
Growing awareness of this increased cardiovascular risk has led to several efforts 
to unravel the underlying mechanisms, especially in RA. The elevated risk is only 
partly explained by increased prevalence of traditional cardiovascular risk factors 
such as age, gender, dyslipidaemia, hypertension, smoking, obesity and diabetes 
mellitus; systemic inflammation, genetic factors and treatment effects might also 
have important roles (Figure 1). Pathogenic mechanisms and clinical expression of 
cardiovascular comorbidities vary greatly between different rheumatic diseases, 
but atherosclerosis seems to be a shared factor in all IJDs.  
A logical consequence of the increased awareness of cardiovascular comorbidity in 
rheumatic disease is a shift from its recognition towards prevention and treatment. 
Development of cardiovascular risk assessment models in patients with IJD has 
been attempted, and more evidence is emerging of the effects of rheumatological 
and cardiovascular treatments on cardiovascular risk and outcomes. However, 
despite these advances, much remains to be learned in this field.
Rheumatoid arthritis and cardiovascular disease burden
Patients with RA have an increased risk of premature death compared with the 
general population (2). The main cause for this increase in mortality is cardiovascular 
disease. Several observational cohort studies have examined the magnitude of 
the increased risk by studying the occurrence of cardiovascular events in patients 
with rheumatic diseases. In a meta-analysis (1), an overall 48% (pooled RR 1.48, 95% 
CI 1.36–1.62) increased risk for incident cardiovascular disease was observed in 
patients with RA, compared with the general population. The results of a prospective 
study of a Dutch RA cohort suggested that the magnitude of the cardiovascular 
risk increase in RA (around twofold) is similar to that observed in patients with type 
2 diabetes (3). This finding was corroborated by the results of a Danish nationwide 
study (4) and attributed to a similar rate of acceleration of atherosclerosis in these 
two conditions (5). In patients with RA the increased risk of myocardial infarction 
9
(MI) is greater (around 68%) than that of cerebrovascular accident (around 41%), 
compared to persons without RA (6-8). In addition, an 87% increased risk of 
congestive heart failure in RA was observed, mostly in rheumatoid-factor-positive 
patients, but whether this level of risk would exist in contemporary RA cohorts 
is unclear. Evidence derived from observational studies suggests that effective 
control of inflammation - either with biologic or nonbiologic DMARDs, particularly 
anti-TNF agents and methotrexate - is associated with reduction of cardiovascular 
disease risk (9). Although developments in therapeutic strategies in the past 
decades are reflected by a decline in mortality rates, the mortality gap between 
patients with RA and the general population has not improved, demonstrating that 
cardiovascular disease is still a major issue in these patients (10). 
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cohort suggested that the magnitude of the cardiovascular 
risk increase in RA (around twofold) is similar to that 
observed in patients with diabetes mellitus.4 This finding 
was corroborated by the results of a Danish nationwide 
study5 and attributed to a similar rate of acceleration of 
atherosclerosis in these two conditions.6
In patients with RA, relative to unaffected indivi-
duals, the increased risk of myocardial infarction (MI) 
is greater (around 68%) than that of cerebrovascular 
accident (around 41%).7–9 In one study,10 compared with 
unaffected controls, an 87% increased risk of congestive 
HF in RA was observed, mostly in rheumatoid-factor-
positive patients, but whether this level of risk would 
exist in contemporary RA cohorts is unclear. Evidence 
derived from observational studies suggests that effec-
tive control of inflammation—either with biologic or 
non biologic DMARDs, particularly anti-TNF agents 
and methotrexate—is associated with reduction of 
cardio vascular disease risk. Although developments in 
therapeutic strategies in the past couple of decades are 
reflected by a decline in mortality rates,11 the mortality 
gap between patients with RA and the general popu lation 
Key poin s
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has not improved, demonstrating that cardiovascular 
disease is still of major importance in these patients.12 
Reports of studies in this field focus on the incidence of 
athero sclerotic and ischaemic events rather than non-
ischaemic cardiovascular disease. However, patients 
with RA and other IJDs are not just at increased risk 
for ischaemic cardio vascular disease: a range of cardiac 
manifestations can present during the course of rheu-
matic disease (Table 1). Classic cardiac complications 
of RA owing to inflammation, such as pericarditis and 
endocarditis, or long-term development of amyloid-
osis are rare and seldom cause clinically overt disease 
now adays.13 However, recent developments in cardiac 
imaging suggest that microvascular disease and myo-
carditis are common,14 as is cardiac autonomic neuro-
pathy,15,16 particularly during active phases of the disease. 
The effects of these pathologies on cardiac function and 
risk of sudden cardiac death need to be further evaluated.
Spondylarthropathies
Available data on spondylarthropathies indicate that, 
compared with unaffected individuals, patients with 
psor iatic arthritis and AS have an increased cardio-
vascular risk,17,18 which approaches the magnitude seen 
in RA. A meta-analysis assessing the occurrence of MI or 
stroke in patients with AS showed significant increases in 
MI (OR 1.60, 95% CI 1.32–1.93) and in stroke (OR 1.50, 
95% CI 1.39–1.62) relative to control groups.19 For psor-
iatic arthritis, compared with the general population, a 
meta-analysis showed an increased risk of MI (OR 1.57, 
95% CI 1.08–2.27) and inconclusive results for stroke; 
pooled results included all patients with psoriasis and 
did not focus on patients with psoriatic arthritis.20 As 
with RA, not all cardiovascular morbidity and mortal-
ity in spondyl arthropathies can be attributed to athero-
sclerosis. In patients with AS, aortitis involving the aortic 
root and the ascending aorta (leading to valvular insuf-
ficiency) can occur, but it rarely does so nowadays.21 
The fibrosis that occurs with aortitis can extend into the 
cardiac tissue and cause conduction abnormalities.
SLE
In SLE, cardiac comorbidities are also common. SLE is 
associated with a bimodal mortality distribution, and 
cardiovascular disease is by far the most important 
contributor to the second (late) peak in mortality.22 In 
fact, amongst rheumatic diseases, SLE is associated with 
the greatest increase in cardiovascular disease risk, and 
the results of an epidemiological study showed that 
women 44–50 years old with SLE have a 50-fold increased 
risk of MI compared with women of similar age in the 
general population.23 The cause of the increased cardio-
vascular disease risk in SLE is multifactorial (more so 
than in IJDs). Traditional risk factors and inflamma-
tion are important, but other mechanisms of endothelial 
damage, such as the prothrombotic environment wherein 
auto antibodies against phospholipids and endothelial 
cells contribute to a vulnerable plaque phenotype also 
add to the cardio vascular disease burden.24 In addition, 
treatment can lead to substantial corticosteroid exposure.
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Figure 1 | Contributors to cardiovascular risk in IJDs. Pati nts with IJDs have 
increased risk of cardiovascular disease compared with the general population, 
mainly resulting from traditional risk factors and inflammation. Traditional 
cardiovascular risk factors include age, gender, dyslipidaemia, hypertension, 
smoking, obesity, lack of exercise and diabetes mellitus. Medication can affect 
cardiovascular risk by targeting inflammation, but can also have undesired 
effects—glucocorticosteroids, for example, are associated with dyslipidaemia 
and hypertension. Inflammation can modify some traditional risk factors, the 
best-known example being the influence on lipid profile. Abbreviations: COXIB, 
cyclooxygenase-2 selective inhibitor; IJD, inflammatory joint disease.
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Figure 1 | Contributors to cardiovascular risk in IJDs. Patients with IJDs have increased 
risk of cardiovascular disease compared with the general population, mainly resulting 
from tradition l ri  fa t r  and inflammation. Tradition l cardiovascular risk factors 
include age, gender, dyslipidaemia, hypertension, smoking, obesity, lack of exercise and 
diabetes mellitus. Medication can affect cardiovascular risk by targeting inflammation, but 
can also hav  undesired effec s—glucocorticosteroids, for example, are as ociated with 
dyslipidaemia,  hypertension, hyperglycaemia, and osteoporosis. Inflammation can modify 
some traditional risk factors, the best-known example being the influence on lipid profile. 
Abbreviations: COXIB, cyclooxygenase- 2 selective inhibitor; IJD, inflammatory joint disease.
Contributions of known risk fact s
Traditional risk factors are important contributors to the cardiovascular risk 
in the general population as well as in patients with IJD. Despite this fact, when 
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adjusting for traditional risk factors, the absolute cardiovascular risk for patients 
with RA is still increased when compared with the general population. As such, RA 
(and possibly other IJDs) is an independent risk factor for cardiovascular disease. 
Traditional cardiovascular risk factors contribute to the excess cardiovascular 
disease seen in IJD, albeit in a different way than in the general population. 
Cholesterol
Cholesterol is an example of a risk factor with specific characteristics in patients 
with RA. Hypercholesterolaemia is an important risk factor for cardiovascular 
disease in the general population. However, assessment of cholesterol is 
complicated in patients with RA. Several studies have evaluated lipid profiles 
in patients with IJDs, especially RA (11), and the overall consensus is that active 
inflammation in RA leads to a decline in levels of total cholesterol, LDL cholesterol, 
and HDL cholesterol compared with individuals without RA (12). The greatest 
suppression occurs in levels of HDL cholesterol, leading to an unfavourable lipid 
profile. This ‘lipid paradox’, where lower lipid levels are associated with higher 
cardiovascular risk, has also been reported in other inflammatory diseases (13). The 
lipid paradox in RA could be explained by modification of lipids by inflammation, 
which not only lowers lipid levels, but also alters lipid structure and function, 
changing the usual antiatherogenic effects of HDL cholesterol into proatherogenic 
effects (14). In the context of cardiovascular risk assessment in patients with RA, 
measurement of the ratio of total cholesterol to HDL cholesterol is recommended 
in clinical practice, and it might be reasonable to suggest that lipid measurements 
during inactive stages of the disease are the most representative of the overall 
situation in a given patient. Evidence suggests that lipid-lowering (statin) therapy 
is substantially underutilized in patients with RA who fulfil the general population 
thresholds for this treatment and could have adverse consequences in terms of 
cardiovascular outcome (15).
Cigarette smoking
Smoking is a known environmental risk factor for RA, and a higher prevalence 
of smokers has been observed in patients with RA than in matched controls 
without RA (16). In RA, smoking is associated with both inflammation (17) and 
factors that are predictive of cardiovascular outcome, such as rheumatoid factor 
and anti-citrullinated protein antibody (ACPA) positivity, rheumatoid nodules, 
lower response to anti-TNF treatment and rheumatoid cachexia (18-22). These 
interacting mechanisms make it difficult to determine the contribution of smoking 
to cardiovascular risk in this population, raising the question of whether population-
11
based risk-prediction models are also applicable to patients with IJD.
Hypertension
The reported prevalence of hypertension in patients with RA ranges between 
4 and 73% (23). In a meta-analysis no difference was found in the prevalence of 
hypertension between 2,956 patients with RA and 3,713 matched controls (OR 1.09, 
95% CI 0.91–1.31) (24). In contrast, in a study designed to evaluate hypertension 
associated with RA, the prevalence of hypertension was substantially higher in 
individuals with RA than in matched controls (25). The results of the international, 
cross-sectional COMORA study showed that hypertension is prevalent in 40% of 
patients with RA, although interpretation of this value is hampered by the lack of a 
control population (26). Nowadays, mean asleep systolic blood pressure and sleep-
time relative systolic blood pressure decline are the most significant predictors 
of CVD events (27), and some studies have performed 24-hour ambulatory blood 
pressure monitoring in RA patients. One of these studies found no difference in 
24-hour blood pressure patterns, including nocturnal blood pressure decline (28), 
but there is evidence that this is outcome is related to disease activity and use 
of anti-rheumatic medication. Nevertheless, hypertension is both underdiagnosed 
and undertreated in patients with RA. 
Diabetes and insulin resistance
The association between RA and insulin resistance is strongly supported by the 
results of many studies (29-31), and is most likely mediated by inflammation, 
because insulin resistance correlates with levels of markers of inflammation and 
disease activity. Insulin resistance often precedes diabetes, and diabetes is more 
prevalent in RA compared to controls (32). Control of inflammation with potent 
anti-inflammatory therapies, such as anti-TNF agents, seems to reverse insulin 
resistance (33). Anti-inflammatory agents can also be effective in preventing 
diabetes, and in a study of patients with RA or psoriasis, the risk of new diabetes was 
lower for individuals initiating therapy with a TNF inhibitor or hydroxychloroquine 
compared with other (nonbiologic) DMARDs (34). 
Thyroid disease
Coexistence of autoimmune hypothyroidism with RA can affect cardiovascular 
risk. Among patients with RA, those with hypothyroidism have an increased 
cardiovascular risk compared with those having normal thyroid function (35). 
This effect of hypothyroidism has traditionally been attributed to impaired 
vascular endothelial function, hypertension and adverse effects on lipid profiles. 
Chapter 1. General introduction and thesis outline
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In patients with RA, the presence of thyroid peroxidase (TPO) antibodies, which 
is strongly predictive of autoimmune hypothyroidism, is associated with greater 
cIMT progression (36). This association suggests that assessment of thyroid 
function and the TPO antibodies is important in the context of cardiovascular risk 
management in patients with IJD.
Inflammation and cardiovascular risk
In addition to traditional risk factors, inflammation is an important, independent, 
contributor to cardiovascular risk. The link was first established in the general 
population, where C-reactive protein (CRP) levels are associated with cardiovascular 
risk (37). In patients with IJD, markers of active inflammation, including levels of 
CRP, erythrocyte sedimentation rates, numbers of affected joints and disease 
activity scores, as well as disease severity or cumulative inflammation (estimated 
by radio graphic scores), have all been linked to cardiovascular risk (38-43). IJDs 
and atherosclerosis are considered to have an inflammatory pathogenesis, in 
which the mechanisms of formation, progression, instability and rupture of the 
atherosclerotic plaque resemble the mechanisms observed in synovitis (44)
(Figure 2). Although high-grade systemic inflammation seems to be central to 
the cardiovascular risk in patients with IJD (Figure 3), the interaction between 
inflammation, traditional risk factors, genetic factors and medication effects has 
not yet been fully elucidated. 
Figure 2 | Similarities between the atherosclerotic plaque and rheumatoid arthritis joint. 
The (a) atherosclerotic plaque has many features in common with (b) rheumatoid arthritic 
synovium. First, in both diseases, blood-borne mononuclear cells are recruited to sites that 
are devoid of any significant inflammation in physiological conditions. Second, upregulation 
of cytokines and matrix-degrading enzymes is central to the pathogenesis of both diseases. 
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Third, both in rheumatoid arthritis and atherosclerosis, immune cells do not target resident 
cells in the same way that diabetogenic T cells directly destroy pancreatic islets. Instead, 
immune cells begin complex interactions with the resident cell types, which proliferate, 
change their properties and phenotype, and contribute to the inflammatory process and 
tissue destruction. Adapted from: Full, L.E., Ruisanchez, C. & Monaco, C. The inextricable link 
between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and 
systemic lupus erythematosus. Arthritis Res Ther 11, 217 (2009). https://doi.org/10.1186/ar2631
Effects on prothrombotic phenomena
The immune and coagulation systems are closely linked: inflammatory cytokines 
induce expression of tissue factor, inhibit the protein C system and act as inhibitors 
of fibrinolysis, promoting a hypercoagulable state (45). Platelets are important 
factors in normal homeostasis and also have a role in inflammation with the 
release of a range of thrombotic and inflammatory molecules; the adhesion and 
aggregation of platelets are key to the processes that occur at the onset of MI after 
plaque rupture (46). Although data relating to venous thrombotic events in IJDs are 
scarce, it seems that the risks of pulmonary embolism and deep-vein thrombosis 
are increased in patients with RA when compared with the general population (47). 
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Thyroid disease
Autoimmunity is often a cause of hypothyroidism, and 
the coexistence of these two diseases can affect cardio-
vascular risk.77 Among patients with RA, those with 
hypothyroidism have an increased cardiovascular risk 
compared with those having normal thyroid function. 
This effect of hypothyroidism has traditionally been 
attributed to impaired vascular endothelial function, 
hypertension and adverse effects on lipid profiles. In 
patients with RA, the presence of thyroid peroxidase anti-
bodies, which is strongly predictive of autoimmune hypo-
thyroidism, is associated with greater cIMT progression 
than in the absence of such antibodies.78 This association 
suggests that assessment of thyroid function is impor-
tant in the context of cardiovascular risk management in 
patients with IJD.
Genetic factors
Genetic factors have a potential role in the link between 
atherosclerosis and IJDs, in particular RA. Several 
poly morphisms at loci both inside and outside the 
MHC region of the genome are associated with sub-
clinical athero sclerosis and cardiovascular events.79–81 
In this regard, associations have been found between 
HLA-DRB1*04 shared epitope alleles and endothelial 
dysfunction80 or cardiovascular morbidity.79 In the pres-
ence of the shared epitope, the TNF-308 (rs1800629) 
polymorphism predisposes patients with RA to cardio-
vascular disease.81 Polymorphisms at loci outside the 
MHC region seem to be associated with the risk of 
cardiovascular events independently of the presence 
of traditional cardiovascular risk factors.76,82,83 In patients 
with RA, polymorphisms have also been linked to dyslipi-
daemia,38,84,85 hyper tension65–67 and biomarkers of endo-
thelial function such as asymmetric dimethyl arginine.86 
Some of these associ ations might be modified by life-
style factors, such as obesity or smoking. These studies 
of genetic risk factors suggest new avenues of scientific 
enquiry in this field.
Inflammation and cardiovascular risk
In addition to traditional risk factors, inflammation is 
an important independent contributor to cardio vascular 
risk. The link was first established in the general popula-
tion, in which C-reactive protein (CRP) levels are asso-
ciated with cardiovascular risk.87 In patients with IJD, 
markers of active inflammation, including levels of CRP, 
erythrocyte sedimentation rates, numbers of affected 
joints and disease activity scores, as well as disease sever-
ity or cumulative inflammation (estimated by radio-
graphic scores), have all been linked to cardio vascular 
risk.79,88–92 IJDs and atherosclerosis are considered to 
have an inflammatory pathogenesis, in which the mecha-
nisms of formation, progression, instability and rupture 
of the atherosclerotic plaque resemble the mechanisms 
observed in synovitis.93 Although high-grade systemic 
inflammation seems to be central to the cardio vascular 
risk in patients with IJD (Figure 2), the interaction 
between inflammation, traditional risk factors, genetic 
factors and medication effects has not yet been elucidated.
Effects on vascular function and morphology
The striking similarities between the inflammatory pro-
cesses in blood vessels and in joints of individuals with 
IJDs, together with the links between markers of inflam-
mation and cardiovascular disease in the general popu-
lation, have led to the hypothesis that inflammation is 
a major contributor to accelerated atherosclerosis.94 
The pathways by which rheumatic inflammation leads 
to accelerated atherosclerosis are not completely clear. 
The endo thelium has a key role in vascular function as 
an endocrine organ, producing vasoactive factors that 
control vasomotor tone, homeostasis and interactions 
between the vessel wall and circulating blood cells. Nitric 
oxide is one of the most important of these factors, and 
inflammation can disrupt the equilibrium between the 
production of nitric oxide and other vasoactive factors, 
leading to endothelial-cell dysfunction, which in turn is 
associated with atherosclerosis.95
Noninvasive techniques for the assessment of periph-
eral vascular function and morphology, which correlate 
with coronary circulation, provide the means to assess 
vascular health without compromising patient safety.96 
Endothelial function can be assessed by testing the ability 
of endothelial cells to release nitric oxide in response to 
various stimuli, which is determined by quantification 
of vessel dilation. Assessment of pulse-wave velocity 
and pulse-wave analysis provide infor mation on arterial 
stiffness as an outcome of functional and morpho logical 
changes in the vasculature. Structural changes result-
ing from advanced atherosclerosis can be assessed by 
measurement of cIMT.






Stable plaque Unstable, ruptured plaque
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Figure 2 | Contribution of inflammation to cardiovascular dis ase. Rheumatic 
inflammation is thought to be a major contributor to accelerated atherosclerosis. 
IJD is associated with frequency, severity and vulnerability of coronary plaques. 
Patients with IJD have higher risk of infarction after plaque rupture than individuals 
without IJD, because of a hypercoagulable state induced by inflammation. 
Nonischaemic heart disease like myocarditis, heart failure and myocardial 
dysfunction also contributes to the burden of cardiovascular disease in IJD. 
Abbreviation: IJD, inflammatory joint disease.
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Figure 3 | Contribution of inflamm tion o ca diova cular disease. Rheumatic inflammation 
is thought to be a major contributor to accelerated atherosclero is. IJD is as ociat d with 
frequency, severity and vulnerability of coronary plaques. Patients with IJD have higher risk 
of infarction after plaque rupture than in ividuals without IJD, because of a hypercoagulable 
state induced by inflammation. Nonischaemic heart disease like myocarditis, heart failure 
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and myocardial dysfunction also contributes to the burden of cardiovascular disease in IJD. 
Abbreviation: IJD, inflammatory joint disease.
Predicting cardiovascular risk in IJD
Risk-prediction models
The well-established cardiovascular risk in patients with RA, and to a lesser extent 
in other IJDs, implies that cardiovascular risk assessment should be part of routine 
care in these patients. Clinicians should be able to identify those patients at 
highest risk, to adapt their management accordingly. Unfortunately, cardiovascular 
risk in patients with RA is still underestimated in clinical practice (48), and despite 
improvements in the understanding of the risk and the recommendations given by 
the European League Against Rheumatism (EULAR) Task Force, the management 
of cardiovascular risk remains unsatisfactory (49). In the past 12 years, several 
algorithms have been developed to aid the prediction of risk for cardiovascular 
disease, such as the Framingham Risk Score, the Reynolds Risk Score, QRISK®3 
and SCORE (50-54). These risk models are largely based on longitudinal cohort 
studies performed in the general population, raising the question of whether they 
can also be of use in patients with IJD. QRISK®3 was developed in a population that 
included patients with RA, and RA is an independent risk factor in the algorithm. 
The Reynolds Risk score incorporates CRP levels, but not within the range seen 
in high-grade inflammatory diseases. None of these risk models takes into 
account the influence of inflammation and antirheumatic medication on lipids 
and other classic risk factors, nor considers systematic differences between 
IJD populations (which are predominantly female, with restricted age ranges) 
and the general population. Some attempts have been made to address these 
problems. For instance, the EULAR Task Force has recommended adapting risk 
models when calculating cardiovascular risk in patients with RA by incorporating 
a multiplication factor of 1.5 (55). The 2012 ESC guidelines (56), as well as QRISK®3, 
incorporate RA as an independent cardiovascular risk factor in their models, 
although in the ESC recommendations presence of RA has no influence on clinical 
management, in contrast to QRISK®3. However, neither of these approaches 
seems to improve accuracy in estimates of cardiovascular risk in patients with 
IJD relative to models that do not include RA (57, 58), and risk-stratification 
models for this group of patients require improvement. The 2013 guidelines of the 
joint task force of the American College of Cardiology (ACC) and American Heart 
Association (AHA) used the novel Pooled Cohort Equations to calculate the 10-
year risk of atherosclerotic cardiovascular disease (59). Compared with previous 
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guidelines, in patients with RA, this calculation considerably increased the number 
who would be recommended for cholesterol-lowering statin treatment, but did not 
improve prediction of cardiovascular risk (60, 61). Patients with RA often suffer 
from asymptomatic atherosclerosis and silent ischaemic disease in the presence 
of an unstable plaque, which can lead to sudden death (62). An early diagnosis of 
atherosclerosis, before the onset of clinically evident cardiovascular disease, can 
enable earlier and more aggressive primary prevention measures. Imaging studies 
and specific biomarkers could potentially help with early diagnosis. Alternatively, 
IJD-specific risk-prediction models might not be necessary if an approach of 
‘blanket primary prevention’ of specific lipid and blood-pressure targets was 
taken in all patients with IJD, similar to the practice associated with diabetes (56). 
Whereas such an approach would be simpler than developing specific models, its 
safety, effectiveness and cost-effectiveness in these populations would need to be 
formally assessed.
Biomarkers
In addition to imaging techniques, the value of a number of biomarkers in 
cardiovascular-risk prediction has been investigated, at least in the general 
population. These biomarkers include genetic factors, markers of inflammation, 
immunological markers and markers of endothelial function (5). Serum uric acid 
levels have associations with hypertension, renal dysfunction and cardiovascular 
disease in patients with RA, in the general population and in other at-risk 
populations, but it remains unclear whether they reflect specific pathogenic 
pathways or are epiphenomena (63). Researchers have evaluated the utility of 
B-type natriuretic peptide as a marker for cardiovascular risk in the presence of 
rheumatic disease (64). The use of biomarkers in risk-prediction models to improve 
cardiovascular risk stratification was demonstrated in a large European population 
wherein additional measurement of the combination of N-terminal pro-brain 
natriuretic peptide, CRP and troponin I led to an improved 10-year-risk estimation, 
compared with a conventional-risk-factor model alone (65). The value of these 
biomarkers for risk prediction in the presence of IJDs is not known. A difficulty in 
the assessment of this value is that the influence of IJD activity and treatment on 
biomarker levels has not yet been determined. Another issue is that, whereas in the 
general population large sample sizes are available, IJD cohorts are much smaller, 
making it more difficult to validate biomarkers against specific end points (such as 
MI), meaning that international collaborations are likely to be required in this field. 
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Cardiovascular risk management
Cardiovascular risk assessment provides opportunities for disease prevention. 
From the perspective of the rheumatologist, management of cardiovascular 
comorbidity of patients with IJD has three main principles: pharmacological 
management and nonpharmacological management of cardiovascular risk 
factors, and tight control of disease activity (Figure 4). Unfortunately, the risk of 
cardiovascular disease in patients with RA is still not fully recognized, and these 
patients receive preventive measures less often than the general population. 
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Cardiovascular risk management
Risk assessment provides opportunities for disease pre-
vention. From the perspective of the rheumatologist, the 
management of cardiovascular comorbidity of patients 
with IJD has three main principles: pharmacological 
management and nonpharmacological management of 
cardiovascular risk factors, and tight control of disease 
activity (Figure 3). Unfortunately, the risk of cardio-
vascular disease in patients with RA is still not fully rec-
ognized, and these patients receive preventive measures 
less often than the general population.
Lifestyle interventions
Lifestyle interventions should be the first steps in cardio-
vascular risk management, and patients should be advised 
to quit tobacco smoking and to engage in regular physi-
cal activity. Evidence pertaining to lifestyle interventions 
demonstrates that exercise has several cardio vascular 
benefits in patients with RA.46 Structured exercise 
therapy improves microvascular and macro vascular 
function and cardiorespiratory fitness, and decreases 
cardiovascular risk.46,47
Pharmacological interventions
In the general population, and also in patients with dia-
betes, preventive measures such as lowering blood pres-
sure and lipid levels are effective in reducing the burden of 
cardiovascular disease.147 Whether these measures are also 
beneficial for patients with IJD has not yet been studied 
sufficiently, although, notably, it seems that statins have a 
moderate anti-inflammatory effect in RA.148 Large, ran-
domized, controlled trials are necessary to compare the 
effects of preventive measures, with cardio vascular disease 
outcomes as end points. Such trials require large numbers 
of patients and several years of follow-up observation, and 
are very diffi cult to conduct in populations of patients with 
IJDs. Despite the limited availability of evidence relating 
to the management of traditional risk factors in patients 
with rheumatic diseases, wide-ranging support exists for 
the practice of offering cardiovascular risk management 
to all patients meeting the criteria set for risk reduction in 
the general population. This strategy would require that 
all patients with IJD are screened regularly, and when an 
increase in risk is identified, patients should be managed 
accordingly. However, a key question remains regarding 
who is responsible for the preventive care of this group of 
patients. In most countries, primary-care physicians carry 
out cardiovascular risk management. Currently, aware-
ness of the high risk in this group of patients is inadequate 
among all health-care professionals, from primary-care 
physicians to cardiologists and even rheumat ologists. 
Therefore, achieving adequate awareness is an important 
objective, which should lead to appropriate cardiovascular 
risk screening and preventive measures.
Control of disease activity
Tight disease control is thought to improve all outcomes 
in IJDs, including cardiovascular outcomes, although ran-
domized trials investigating cardio vascular outcomes in 
this disease management approach are lacking. Chronic 
systemic inflammation contributes substantially to the 
cardiovascular risk associated with IJDs, and adequate 
suppression of disease activity is necessary to reduce this 
risk. This goal can be achieved by early diagnosis and 
treatment of IJDs. However, from the cardiovascular point 
of view, the best way to control inflammation is unknown. 
Several DMARDs are available for treatment of IJDs, and 
although they might all decrease cardiovascular risk by 
reducing inflammation, other possible cardioprotective 
or deleterious properties are also important to consider. 
The influence of antirheumatic therapies on lipid levels 
has received particular attention because of the inter-
action between lipids and inflammation, although the 
clinical relevance of this influence is uncertain. Notably, 
all the available evidence relating to the effects of anti-
rheumatic therapy on cardiovascular disease is derived 
from obser vational studies, and caution is required when 
making conclusions on the basis of this evidence, because 
of potential sources of bias.
NSAIDs and cyclooxygenase‑2 inhibitors
Although the development of synthetic and biologic 
DMARDs has led to substantial reductions in the chronic 
use of NSAIDs and cyclooxygenase-2 selective inhibi-
tors (COXIBs) in the treatment of IJDs, these agents still 
have important roles in disease management. However, 
the use of NSAIDs and COXIBs is associated with cardio-
vascular risk in the general population.149 Subgroup ana-
lysis150 identified patients with RA as a cardio vascular-risk 
group, but only in association with the use of rofecoxib 





















Figure 3 | Principles of cardiovascular risk management by rheumatologists. 
From the perspective of the rheumatologist, the management of cardiovascular 
comorbidity of patients with IJD has three main principles. Pharmacological 
management of cardiovascular risk factors includes medication to control blood 
pressure and lipid levels. Nonpharmacological management of cardiovascular risk 
factors includes lifestyle interventions such as cessation of tobacco smoking and 
engagement in regular physical activity. Control of disease activity consists of 
strategies to control the chronic systemic inflammation in IJD, by means of 
DMARDs, NSAIDs, cyclooxygenase-2 selective inhibitors and glucocorticosteroids. 
Abbreviation: IJD, inflammatory joint disease.
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Figur  4 | Principles of cardiovascular risk management by rheumatologists. From the 
perspective of the rheumatologist, the management of cardi vascular comorbidity 
of patients with IJD has three main principles. Pharmacological management of 
cardiovascular ri k factors includes medication to control blood pressure and lipid 
levels. onpharmacological management f ca diovascular risk fa tors includes lifestyle 
interventions such as cessation of tobacco smoking and engagement in regular physical 
activity. Control of disease activity consists of strategie  to control the chronic ys emic 
inflammation in IJD, by means of DMARDs, NSAIDs, cyclooxygenase-2 selective inhibitors 
and glucocorticosteroids. Abbreviations: IJD, inflammatory joint disease.
Lifestyle intervention
Lifestyle interventions should be the first steps in cardiovascular risk management, 
and patients should be advised to quit tobacco smoking and to engage in regular 
physical activity. Evidence pertaining to lifestyle interventions demonstrates 
that exercise has several cardiovascular nefits in patients with RA. Structured 
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exercise therapy improves microvascular and macrovascular function and 
cardiorespiratory fitness, and decreases cardiovascular risk (66). Although data on 
exercise are emerging, data on dietary interventions are still sparse. 
Pharmacological interventions 
In the general population, and also in patients with diabetes, preventive measures 
such as lowering blood pressure and lipid levels are effective in reducing the 
burden of cardiovascular disease (67). Whether these measures are also beneficial 
for patients with IJD has not yet been studied sufficiently, although, notably, it 
seems that statins have a moderate anti-inflammatory effect in RA (68). Large, 
randomized, controlled trials are necessary to compare the effects of preventive 
measures, with cardiovascular disease outcomes as end points. Such trials require 
large numbers of patients and several years of follow-up observation, and are 
very difficult to conduct in populations of patients with IJDs. Despite the limited 
availability of evidence relating to the management of traditional risk factors in 
patients with rheumatic diseases, wide-ranging support exists for the practice of 
offering cardiovascular risk management to all patients meeting the criteria set 
for risk reduction in the general population. This strategy would require that all 
patients with IJD are screened regularly, and when an increase in risk is identified, 
patients should be managed accordingly. However, the key question   remains 
who is responsible for the preventive care of this group of patients. In most 
countries, primary-care physicians carry out cardiovascular risk management. 
Currently, awareness of the high risk in this group of patients is inadequate among 
all health-care professionals, from primary-care physicians to cardiologists and 
even rheumatologists. Therefore, achieving adequate awareness is an important 
objective, which should lead to appropriate cardiovascular risk screening and 
preventive measures.
Control of disease activity 
Tight disease control is thought to improve all outcomes in IJDs, including 
cardiovascular outcomes, although randomized trials investigating cardiovascular 
outcomes in this disease management approach are lacking. Chronic systemic 
inflammation contributes substantially to the cardiovascular risk associated with 
IJDs, and adequate suppression of disease activity is necessary to reduce this 
risk. This goal can be achieved by early diagnosis and treatment of IJDs. However, 
from the cardiovascular point of view, the best way to control inflammation is 
unknown. Several DMARDs are available for treatment of IJDs, and although they 
might all decrease cardiovascular risk by reducing inflammation, other possible 
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cardioprotective or deleterious properties are also important to consider. The 
influence of antirheumatic therapies on lipid levels has received particular attention 
because of the interaction between lipids and inflammation, although the clinical 
relevance of this influence is uncertain. Notably, all the available evidence relating 
to the effects of antirheumatic therapy on cardiovascular disease is derived from 
observational studies, and caution is required when making conclusions on the 
basis of this evidence, due to potential bias.
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THESIS OUTLINE
The focus of part I of this thesis is on cardiovascular risk and its management. 
Chapter two consists of recommendations on cardiovascular risk management 
from the European League Against Rheumatism (EULAR) taskforce. In these 
recommendations are defined to provide assistance in CVD risk management 
in IJD, based on expert opinion and scientific evidence. Chapter three and four 
contain the results from the I-CaRe study in with the cardiovascular risk profile of 
patients with rheumatoid arthritis was assessed in order to optimize cardiovascular 
risk management in these patients. In chapter five we examined the differences 
in cardiovascular risk when calculated with different risk models at different 
times in the course of the disease; that is before and after treatment with anti-
rheumatic drugs. Not only patients with RA suffer from a higher cardiovascular 
burden, but also patients with other inflammatory autoimmune disorders, such 
as psoriasis and IBDs (e.g. Crohn’s disease and ulcerative colitis), especially when 
more autoimmune disorders co-exist. Therefore, in chapter six we assessed the 
prevalence proportion and incidence rate of cardiovascular morbidity in patients 
with inflammatory arthritis and co-existent autoimmune disorders. As autoimmune 
thyroid disease often coexists with rheumatoid arthritis, we investigated in chapter 
seven whether RA patients with thyroid dysfunction have an increased risk of new 
cardiovascular disease compared to euthyroid RA patients.
Part II outlines the effects of different treatment regiments on cardiovascular 
outcomes or markers. Chapter eight describes the associations between the 
biomarkers NT-proBNP and sRAGE with disease activity in early RA patients before 
and during antirheumatic treatment.. In chapter nine the effects of etanercept on 
lipid metabolism and other cardiovascular risk factors in patients with psoriatic 
arthritis are investigated in an observational cohort. Chapter ten describes the 
changes that occur in markers of coagulation and fibrinolysis in patients with AS 
starting golimumab treatment. Chapter eleven summarizes the findings of the 
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ABSTRACT
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders 
(IJD) have increased cardiovascular disease (CVD) risk compared with the 
general population. In 2009, the European League Against Rheumatism (EULAR) 
taskforce recommended screening, identification of CVD risk factors and 
CVD risk management largely based on expert opinion. In view of substantial 
new evidence, an update was conducted with the aim of producing CVD risk 
management recommendations for patients with IJD that now incorporates an 
increasing evidence base. A multidisciplinary steering committee (representing 
13 European countries) comprised 26 members including patient representatives, 
rheumatologists, cardiologists, internists, epidemiologists, a health professional 
and fellows. Systematic literature searches were performed and evidence was 
categorised according to standard guidelines. The evidence was discussed 
and summarised by the experts in the course of a consensus finding and voting 
process. Three overarching principles were defined. First, there is a higher risk 
for CVD in patients with RA, and this may also apply to ankylosing spondylitis 
and psoriatic arthritis. Second, the rheumatologist is responsible for CVD 
risk management in patients with IJD. Third, the use of non-steroidal anti-
inflammatory drugs and corticosteroids should be in accordance with treatment-
specific recommendations from EULAR and Assessment of Spondyloarthritis 
International Society. Ten recommendations were defined, of which one is new and 
six were changed compared with the 2009 recommendations. Each designated an 
appropriate evidence support level. The present update extends on the evidence 
that CVD risk in the whole spectrum of IJD is increased. This underscores the need 
for CVD risk management in these patients. These recommendations are defined 




Cardiovascular disease (CVD) risk in patients with rheumatoid arthritis (RA) and 
other inflammatory joint disorders (IJD), in particular ankylosing spondylitis (AS) 
and psoriatic arthritis (PsA), is  substantially elevated compared with the general 
population. For RA, the magnitude of this excess risk appears comparable to that 
reported for patients with diabetes mellitus (1–3) necessitating aggressive and 
targeted CVD risk management. In 2009, the European League Against Rheumatism 
(EULAR) task force was convened to critically appraise existing evidence on CVD 
risk in patients with IJD. This EULAR task force formulated 10 recommendations for 
the screening and identification of CVD risk factors and the implementation of CVD 
risk management in IJD (see online supplementary file 1) (4). In view of substantial 
new evidence, an update of the CVD risk management recommendations was 
performed. In general, CVD risk management involves the determination of a 
cardiovascular risk profile of an individual patient by using values including gender, 
age, smoking status, blood pressure, lipid values and diabetes mellitus status. 
These variables are used in risk prediction algorithms such as Framingham (5) and 
the Systematic Coronary Risk Evaluation (SCORE) (6) to calculate a 10-year risk of 
CVD events. When this CVD risk exceeds a certain value, that is, a 10-year risk of 
10% for a fatal or non-fatal CVD event (Framingham) or a 10-year risk of 5% for fatal 
CVD events (SCORE), lifestyle changes and treatment with lipid-lowering agents is 
recommended. The importance of a healthy lifestyle is emphasised for all persons, 
including patients at low and intermediate cardiovascular risk. Additionally, the 
European Society of Cardiology (ESC) guideline on CVD prevention in clinical 
practice also recommends CVD risk stratification for patients with hypertension 
(7). The initiation of antihypertensives depends on the grade of hypertension and 
total cardiovascular risk. Drug treatment is recommended for patients with grade 
3 hypertension, but also grade 2 and grade 1 hypertension with a high CVD risk 
(7). Validated RA-specific CVD risk prediction models with a proven superiority 
over general population CVD risk prediction algorithms are currently lacking (7). 
Furthermore, the existing general population risk prediction models that aid the 
identification of patients who would benefit from primary prevention of CVD have 
been shown to inaccurately estimate the CVD risk in RA (8-9). Therefore, in 2009 
the EULAR task force advocated the use of a 1.5 multiplication factor for these 
risk prediction models when certain RA disease characteristics were present 
(4). In addition, certain commonly used variables in existing CVD risk prediction 
algorithms are influenced by inflammation and anti-inflammatory therapy. These 
risk factors behave differently in patients with IJD than in the general population, 
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necessitating clarification and practical guidelines for rheumatologists in daily 
clinical practice. For this update, a new EULAR task force reviewed all the previous 
recommendations from 2009 on CVD risk management in IJD. New areas were 
addressed, including the value of imaging in the routine assessment of CVD risk.  
METHODS
Task force
With the approval of the EULAR Executive Committee, the convenor (MTN) and 
methodologist (DPMS) who guided the task force in 2009 formed a new task force 
with the aim of reviewing and updating the 2009 EULAR recommendations for 
CVD risk management in RA and other IJD (see online supplementary file 1) (4). The 
task force comprised 26 members from 13 European countries, including 2 patient 
representatives, 14 rheumatologists, 2 cardiologists, 3 internists, 1 healthcare 
professional and 4 fellows. The entire process was conducted in accordance with 
the 2014 EULAR standardised operating procedures (10).
Literature search
The convenor (MTN) started by formulating a list of potential research questions. 
These were discussed and refined during a teleconference with other members 
of the task force. Thereafter, the fellows (RA, SCH, SR, MH) under guidance of the 
convenor (MTN) and the methodologist (DPMS) compiled the search terms for a 
comprehensive systematic literature review to cover all the research questions. 
The protocol for the literature search was based on the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis statement (http://www. prisma-
statement.org). The Wiley/Cochrane Library, Pubmed/ Medline and Embase were 
searched from inception (by RA, SCH, MH and librarians LJS and JCFK). The Wiley/
Cochrane Library was searched up to 9 February 2015, PubMed up to 10 February 
2015 and Embase up to 13 February 2015. A single search was conducted embracing 
all aspects of the different research questions. The following search terms were 
used (including synonyms and closely related words) as index terms or free-text 
words: ‘rheumatoid arthritis’ or ‘spondyloarthritis’ and ‘cardiovascular disease’ 
and ‘cholesterol’ or ‘blood pressure’ or ‘smoking’ or ‘diabetes’ or ‘chronic kidney 
insufficiency’ or ‘sex factors’ or ‘vitamin D’ or ‘adrenal cortex hormones’ or ‘tumor 
necrosis factor’ or ‘anti-inflammatory agents’ or ‘inflammation’ or ‘carotid intima 
media’. The full search strategies for the Wiley/Cochrane Library, PubMed and 
Embase are shown in online supplementary file 2. All duplicates were removed 
from the results of the first search (figure 1). The remaining studies were screened 
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by title and abstract by six investigators (RA, SCH, SR, MH, DPMS and MTN) for 
suitability. Titles and abstracts were eligible if the abstract contained clear 
information about the aims and objectives of the study. From this selection of 
abstracts, full-text articles were assessed for eligibility by the fellows (RA, SCH, SR 
and MH). References of included articles were manually scanned for other relevant 
studies. The included articles were evenly divided among the four fellows, based on 
their area of expertise. Each fellow read the full texts and distilled and summarised 
the most important results. From these results, also taking into account the ten 
2009 recommendations, 10 concept recommendations were derived.
Consensus finding
The EULAR task force held a 1-day meeting with all members on 31 March 2015. 
During this meeting, the 10 concept recommendations were presented by the four 
fellows. All 10 concept recommendations were discussed and subsequently adapted 
or dropped, and new recommendations were formulated. The principles guiding the 
consensus meeting were: (1) all of the 2009 recommendations were reconsidered 
on the basis of new evidence, (2) any of the 2009 recommendations could be 
kept unchanged, be modified or be totally abandoned, (3) new recommendations 
could be added. After the meeting, the updated and new recommendations were 
graded based on the methodological strength of the underlying literature and 
were categorised according to the Grades of Recommendation, Assessment, 
Development and Evaluation (GRADE) Working Group system (11). Thereafter, the 
10 concept recommendations  were sent out by email for anonymous voting. All 
members of the task force were asked to indicate their level of agreement (LOA) for 
each recommendation on a 0–10 scale (0, no agreement at all; 10, full agreement). 
The results on agreement were averaged and are hence presented as mean (SD).  
RESULTS
Literature search
In total, 9328 articles were identified. After removal of duplicates, 6783 articles 
were screened by title and abstract. In total, 961 full-text articles were assessed 
for eligibility by the fellows (RA, SCH, SR and MH). Ultimately, 264 articles were 
included (figure 1).
Overarching principles
The task force defined three overarching principles of CVD risk management in RA 
and other IJD (table 1).  
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Figure 1 | Flow chart of the search process. RA, rheumatoid arthritis; AS, ankylosing 
spondylitis; PsA, psoriatic arthritis.
 
A. Clinicians should be aware of the higher risk for CVD in patients with RA compared 
with the general population. This may also apply to AS and PsA 
Acknowledging the increased CVD risk in IJD was included as a recommendation 
in our previous guideline of 2009. However, in view of its generic nature, this 
‘recommendation’ was moved to the Overarching principles section of this paper. 
Since the publication of the 2009 EULAR recommendations, the evidence for 
an enhanced CVD risk in IJD has increased. For example, it was shown in a large 
Danish cohort study that the risk of myocardial infarction (MI) in patients with RA is 
comparable to that in patients with diabetes mellitus (2). Furthermore, in the same 
study the risk of MI in RA was found to be approximately 70% higher than in the 
general population, which corresponds with the risk of non-RA subjects who are 10 
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years older (2). Regarding mortality in RA, a meta-analysis including eight studies 
with follow-up ranging from the year 1955 to 1995 concluded that the standardised 
mortality rates (SMRs) in RA were elevated compared with the general population 
(ie, pooled SMR 1.47, 95% CI 1.19 to 1.83) and that these SMRs did not change over 
time (12). Data from the Norfolk Arthritis Register with follow-up until 2012 revealed 
comparable results with increased all-cause mortality in patients with RA compared 
with the general population along with stable SMRs over the past 20 years (13). New 
evidence strengthens the notion that the excess risk of CVD morbidity and mortality 
in patients with RA is related to both traditional and novel CVD risk factors. Novel 
risk factors include inflammation, presence of carotid plaques, anticitrullinated 
protein antibody (ACPA) and rheumatoid factor (RF) positivity, extra-articular RA 
manifestations, functional disability and hypothyroidism (14-15). Recent studies 
reveal increased SMRs in AS, ranging from 1.6 to 1.9 (16–18). These studies report 
either death of circulatory origin or infection as the main cause of death in these 
patients (16–18). Compared with controls, patients with AS have an increased risk 
of vascular death and CVD events (19–27). Dyslipidaemia (27), increased prevalence 
of hypertension (19), diabetes mellitus (19) and increased carotid intima media 
thickness (cIMT) or atherosclerotic plaques (29–31) have all been reported in AS. 
Furthermore, an increased prevalence of (non-) atherosclerotic cardiac disease is 
reported in AS, such as aortic valve dysfunction and conduction disorders, but it is 
currently unknown whether and to what extent this affects CVD risk (32-33). In PsA, 
reported SMRs range from 0.8 to 1.6 (17, 34-35). Overall, patients with PsA are at an 
increased risk of CVD events; however, data (36–38) on stroke are more conflicting 
(34). Likewise, in PsA CVD risk seems to be influenced by an increased prevalence of 
CVD risk factors such as hypertension (37–40) and increased arterial stiffness (41–43). 
B. The rheumatologist should ensure that CVD risk management is performed in 
patients with RA and other IJD.
The responsibility for CVD risk management should be defined locally due to different 
healthcare systems and economic priorities in each country. Therefore, CVD risk 
management may include healthcare professionals other than rheumatologists. 
In clinical practice, it is not always clear who is taking responsibility for CVD risk 
assessment and management in patients with IJD and the task force therefore 
recommends that the treating rheumatologist should ensure that CVD risk 
assessment and management is being performed regularly, should record who is 
performing it and should make sure that the patient is aware of the need for regular 
risk assessment.
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C. The use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids 
should be in accordance with treatment specific recommendations from EULAR and 
the Assessment of Spondyloarthritis International Society (ASAS) (44-45)
NSAIDs and corticosteroids are commonly used for the treatment of IJD and 
these agents effectively lower disease activity and inflammation. However, both 
treatment options have been associated with an increased CVD risk (46–48). As 
these medications are often indispensable in tackling disease activity in patients 
with IJD, the task force feels that their use should be evaluated on an individual 
patient level. Furthermore, lowering disease activity may have beneficial effects 
on the CVD risk. Therefore, the task force recommends to use NSAIDs and 
corticosteroids according to treatment-specific guidelines.  



































A. Clinicians should be aware of the higher risk for CVD in 
patients with RA compared with the general population. This 
may also apply to AS and PsA.
B. The rheumatologist is responsible for CVD risk management in 
patients with RA and other IJD.
C. The use of NSAIDs and corticosteroids should be in 
accordance with treatment-specific recommendations from 
EULAR and ASAS.
Recommendations
1. Disease activity should be controlled optimally in order to 
lower CVD risk in all patients with RA, AS or PsA
2b-3 B 9.1 
(1.3)
2. CVD risk assessment is recommended for all patients with 
RA, AS or PsA at least once every 5 years and should be 
reconsidered following major changes in antirheumatic 
therapy
3–4 C–D 8.8 
(1.1)
3. CVD risk estimation for patients with RA, AS or PsA should be 
performed according to national guidelines and the SCORE 
CVD risk prediction model should be used if no national 
guideline is available





































4. TC and HDLc should be used in CVD risk assessment in RA, 
AS and PsA and lipids should ideally be measured when 
disease activity is stable or in remission. Non-fasting lipids 
measurements are also perfectly acceptable
3 C 8.8 
(1.2)
5. CVD risk prediction models should be adapted for patients 
with RA by a 1.5 multiplication factor, if this is not already 
included in the model
3–4 C 7.5 
(2.2)
6. Screening for asymptomatic atherosclerotic plaques by use of 
carotid ultrasound may be considered as part of the CVD risk 
evaluation in patients with RA
3-4 C-D 5.7 
(3.9)
7. Lifestyle recommendations should emphasise the benefits of 
a healthy diet, regular exercise and smoking cessation for all 
patients 
3 C 9.8 
(0.3)
8. CVD risk management should be carried out according to 
national guidelines in RA, AS or PsA, antihypertensives and 
statins may be used as in the general population
3–4 C–D 9.2 
(1.3)
9. Prescription of NSAIDs in RA and PsA should be with caution, 
especially for patients with documented CVD or in the 
presence of CVD risk factors
2a-3 C 8.9 
(2.1)
10. Corticosteroids: for prolonged treatment, the glucocorticoid 
dosage should be kept to a minimum and a glucocorticoid 
taper should be attempted in case of remission or low disease 
activity; the reasons to continue glucocorticoid therapy 
should be regularly checked
3–4 C 9.5 
(0.7)
AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; 
CVD, cardiovascular disease; EULAR, European League against Rheumatism; HDLc, high-
density
lipoprotein cholesterol; IJD, inflammatory joint disorder; NSAID, non-steroidal anti-
inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SCORE, Systematic 
Coronary Risk Evaluation; TC, total cholesterol.
Recommendations
In line with the 2009 guidelines, we opted to give again 10 recommendations for 
CVD risk management. In total, three recommendations remained unchanged, six 
recommendations were altered and there is one new recommendation. One of the 
2009 recommendations (#1) was moved to the overarching principles as described 
previously. A list of the updated recommendations, including the levels of evidence 
with the strength of recommendation and the LOA based on voting by the task 
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force, is shown in table 1. The recommendations follow a logical sequence, and they 
are not listed in sequence of importance. All recommendations are discussed in 
detail below.
1. Disease activity should be controlled optimally in order to lower CVD risk in all 
patients with RA, AS or PsA (unchanged, LOA 9.1 (1.3)). 
In the previous recommendations from 2009, the importance of control of disease 
activity to lower CVD risk was emphasised. New evidence still portrays an association 
between higher cumulative inflammatory burden and increased CVD risk in RA (49–
54). Disease duration does not seem to affect CVD risk independently (50). However, 
disease activity as well as the number and duration of flares over time do contribute 
to the risk of CVD (49–52). There is now additional evidence showing a reduction of 
CVD risk in patients treated with disease-modifying antirheumatic drugs (DMARDs). 
Reducing inflammation is important in RA for CVD risk management, but the type 
of treatment may be less important. Conventional synthetic DMARDs (csDMARDs), 
in particular methotrexate (MTX), as well as biological DMARDs (bDMARDs), such as 
the TNF inhibitors (TNFi), are often associated with a significant reduction in CVD 
risk in patients with RA (46, 49, 51, 53, 55–62). The CVD risk appears to decrease even 
further after long-term use (53-56). Reduction of disease activity after treatment 
with tocilizumab or rituximab (RTX) shows a beneficial effect on cIMT, a surrogate 
marker for CVD (63–65), and CVD risk in a limited number of studies (54). Beneficial 
effects of TNFi and MTX on arterial stiffness have also been described (43, 66–71). 
One study described a reduction in aortic inflammation and stiffness measured by 
18F-FDG positron emission tomography-CT after TNFi treatment in patients with 
RA (72). For both AS and PsA, evidence for the association between inflammation 
and an enhanced CVD risk is less abundant compared with RA. In view of shared 
pathogenic mechanisms, it is plausible that decreasing the inflammatory burden 
in AS and PsA will also have favourable effects on the CVD risk in these patients. 
Therefore, control of disease activity, as is routinely recommended, is expected to 
lower CVD risk for both AS and PsA. 
2. CVD risk assessment is recommended for all patients with RA, AS or PsA at 
least once every 5 years and should be reconsidered following major changes in 
antirheumatic therapy (changed, LOA 8.8 (1.1)).
CVD risk assessment is recommended for all patients with RA, AS or PsA at least 
once every 5 years, so that lifestyle advice and CVD preventive treatment can be 
39
initiated when indicated. The advice to screen patients with IJD for CVD risk on 
a yearly basis has been changed to screening every 5 years, which is in line with 
the latest ESC guidelines (7). Currently, there is no evidence that annual CVD risk 
assessment compared with 5-year risk assessment leads to a more significant 
reduction in CVD mortality or morbidity in patients with IJD. Depending on the CVD 
risk algorithm that is used for screening, patients can be categorised as having low 
to moderate risk (eg, SCORE <5%), high risk (eg, SCORE ≥5% and <10%) and very high 
risk (eg, SCORE ≥10%).7 Once screened, patients with a low risk can be routinely 
screened again after 5 years. However, if the risk is intermediate rescreening may 
be done sooner, especially if disease progression is more rapid. Patients with a high 
risk or established CVD should be treated for all present CVD risk factors according 
to existing guidelines. A healthy lifestyle should be recommended to all persons, 
including patients with low and intermediate cardiovascular risk (7). CVD risk 
evaluation should be reconsidered after major changes in antirheumatic therapy, 
that is, the initiation of bDMARDs or other drugs that may cause pronounced 
increases in low-density lipoprotein cholesterol (LDLc) or alter other CVD risk 
factors, so that doctors can act accordingly (73-74).
3. CVD risk assessment for patients with RA, AS or PsA should be performed according 
to national guidelines and the SCORE CVD risk prediction model should be used if no 
national guideline is available (unchanged, LOA 8.7 (2.1)).
Evidence is scarce with regard to the validity of disease specific CVD risk prediction 
models to accurately predict risk in individual patients with RA, and it is therefore 
currently recommended to perform risk evaluation according to general population 
guidelines. Several novel and RA disease-specific factors have been associated 
with an increased risk of CVD, but at present it is uncertain if these factors will 
meaningfully and cost-effectively improve CVD risk prediction in patients with RA.
4. Total cholesterol (TC) and high-density lipoprotein cholesterol (HDLc) should be 
used in CVD risk assessment in RA, AS and PsA and lipids should ideally be measured 
when disease activity is stable or in remission. Non-fasting lipids are perfectly 
acceptable (changed, LOA 8.8 (1.2)).
The relationship between serum lipid levels and CVD risk is non-linear and 
potentially paradoxical in RA. Patients with RA with highly active disease generally 
have lower serum TC and LDLc levels compared with the general population, while 
their CVD risk is elevated (73, 75–78). As described in the 2009 recommendations, 
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these patients also have reduced serum levels of HDLc and higher levels of 
triglycerides as compared with healthy controls (78–81). In general, controlling 
disease activity has widespread effects on the lipid profile. Treatment with TNFi 
and/or csDMARDs (mainly MTX) results in an overall increase of lipid components, 
but mostly HDLc, which improves the TC/ HDLc ratio (79–93). A limited number 
of studies have reported beneficial effects of RTX and tocilizumab on individual 
lipid components (64, 94-95). However, the net effect of treatment with these 
agents is an overall increase of individual lipid components without changes in 
TC/HDLc ratio (54, 96–101). The same appears to be true for tofacitinib (100). Still, 
statins are effective at reducing lipid levels in tocilizumab or tofacitinib-treated 
patients with sustained elevations of TC and LDLc (99-100). As described in the 
2009 recommendations, the TC/HDLc ratio is a better CVD risk predictor in RA than 
individual lipid components (78, 102). From a practical point of view, both TC and 
HDLc can be used when using online calculators. As lipid components appear to be 
modifiable by disease activity and anti-inflammatory therapy, assessment of the 
lipid profile should preferably be done when a patient has stable disease or is in 
remission. Finally, measurement of TC and HDLc are perfectly acceptable in non-
fasting state, as noted in the recent 2016 European Guidelines on CVD prevention 
in clinical practice: prevention guidelines (7).
5. CVD risk prediction models should be adapted for patients with RA by a 1.5 
multiplication factor, if this is not already included in the risk algorithm (changed, 
LOA 7.5 (2.2)). 
The SCORE risk calculator is recommended for CVD risk prediction in the general 
population by the ESC guidelines (103). However, CVD risk prediction models 
developed for the general population do not include non-traditional CVD risk 
factors and hence there is a possibility of underestimation of future CVD if these 
models are applied in patients with RA. It is indeed reported that several CVD 
prediction models inaccurately predict the risk of CVD in patients with RA (8 ,104-
105). The 2009 EULAR recommendations for CVD risk management suggested a 
multiplication factor of 1.5 to the calculated total CVD risk if the patient fulfilled 
certain disease-specific criteria (ie, disease duration of >10 years, RF or ACPA 
positivity and the presence of certain extra-articular manifestations).4 It has been 
argued that the application of this multiplication factor does not reclassify as many 
patients as was expected into a more appropriate risk category.9 106 In addition, 
QRESEARCH Cardiovascular Risk Algorithm (QRisk) 2, a CVD risk prediction model 
that includes RA as a risk factor with a multiplication factor of 1.4 for all patients 
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with RA (107), tended to overestimate the CVD risk in patients with RA. QRISK 2 
estimates the risk of fatal and non-fatal CVD combined (8). Currently, there are no 
alternative CVD risk prediction models with a proven accuracy and superiority for 
patients with IJD. Based on all recent epidemiology, this multiplication factor is still 
the most evidence-based way of estimating CVD risk in patients with RA. Therefore, 
the use of an RA-adapted risk prediction model is recommended over the use of 
an unadapted general population model, since there is a higher level of evidence 
on their predictive value. Based on this, the EULAR task force still recommends 
to adapt general population CVD risk algorithms (except for QRISK 2, in which the 
multiplication factor is intrinsic to the algorithm) with a 1.5 multiplication factor 
for all patients with RA. In contrast to the 2009 recommendations, the presence 
of certain RA-specific criteria is not mandatory anymore for the application of this 
multiplication factor, as evidence on the increased CVD risk in patients who are in 
the early stages of RA, patients with a recent RA diagnosis and patients without 
extra-articular manifestations (108-109).
6. Screening for asymptomatic atherosclerotic plaques by use of carotid ultrasound 
may be considered as part of the CVD risk evaluation in patients with RA (new, LOA 
5.7 (3.9)).
The presence of carotid plaques is associated with poor CVD-free survival and is 
strongly linked to future acute coronary syndrome (ACS) in patients with RA, with 
a rate of ACS of  1.1 (95% CI 0.6 to 1.7) per 100 person-years (pyrs) for patients with 
RA with no carotid plaques and 4.3 (95% CI 2.9 to 6.3) per 100 pyrs for those with 
bilateral plaques (66, 110). RA-specific factors contribute to the presence of carotid 
atherosclerosis in addition to traditional CVD risk factors (111). Disease duration 
and disease activity have been shown to be associated with plaque size and 
vulnerability in patients with RA (112-113). The most recent ESC Guidelines on CVD 
prevention in clinical practice recommend considering screening for carotid artery 
atherosclerosis in patients with moderate CVD risk (class: IIa, level of evidence: B, 
GRADE: strong)(7). Autoimmune diseases like RA, systemic lupus erythematosus 
and psoriasis were acknowledged as diseases with increased CVD risk (7). Due to the 
high pretest probability for detection of carotid artery plaques by use of ultrasound 
in patients with RA, and the clinical consequence of indication for statin treatment 
if a carotid plaque is present, this procedure could be of additional value for CVD 
risk evaluation. Ultrasound of the carotid arteries to identify atherosclerosis has 
been shown to reclassify a considerable proportion of patients with RA into a more 
appropriate CVD risk group in accordance with current guidelines (114).
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7. Lifestyle recommendations should emphasise the benefits of a healthy diet, 
regular exercise and smoking cessation (changed, LOA 9.8 (0.3)).
Since the 2009 recommendations, no new strong evidence has emerged on 
the role of smoking on CVD risk in IJD and hence this recommendation remains 
unchanged. Thus, patients should be advised to stop smoking and directed 
towards the locally defined evidence-based smoking cessation programmes, 
even if they have failed previously. The 2009 recommendations did not discuss 
diet or exercise, but it was mentioned in the research agenda (4). Research on 
the role of exercise in RA management has advanced considerably since 2009. 
Physical inactivity is common in patients with RA, and has been associated with 
an adverse CVD risk profile (115–117). There is accumulating data that structured 
exercise therapy has beneficial CVD effects in patients with RA, at least in the 
short and medium term (118–120). Exercise has been shown to reduce long-term 
inflammation in epidemiological studies conducted in the general population and 
increased physical activity was associated with lower levels of C reactive protein 
(CRP) (121). This has also been demonstrated in a study with patients with RA in 
which a 6-month exercise programme lowered CRP levels, probably related to a 
reduction in body fat (118). Moreover, improvements in both microvascular and 
macrovascular function were found after 3 months of exercise in RA.120 To date, 
no studies have shown any adverse effects as a result of exercise (119). Hence, in 
RA, high-intensity exercise is not contraindicated and should be encouraged in 
those already accustomed to activity. Physical activity that is enjoyable is more 
likely to be sustained. A Mediterranean diet is characterised by a high consumption 
of fruit, vegetables, legumes and cereals, and contains less red meat and more 
fish compared with common Western diets. Olive oil or vegetable oil is the primary 
source of fat intake. This diet has been shown to be associated with a reduced 
incidence of major CVD events in the general population (122). In RA, the positive 
effect of a Mediterranean diet may be mediated by the effect of this diet on disease 
activity (123). However, there is no specific evidence available on the effect of dietary 
modifications on CVD risk in patients with IJD. Therefore, we recommend national 
guidelines regarding a healthy diet as part of a healthy lifestyle as discussed below. 
An important issue remaining is how lifestyle interventions should be advocated to 
patients with IJD. Studies in this field demonstrate that if information is provided, 
this should be linked to behavioural education (124). A randomised controlled trial 
in patients with RA evaluated the effect of cognitive behavioural patient education 
with regard to modifiable CVD risk factors in people with RA: patients receiving this 
intervention had more knowledge, and improved behavioural intentions, however, 
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actual behaviour did not differ between groups (125). Obviously, this area is in need 
of more research.
8. CVD risk management should be carried out according to national guidelines in RA, 
AS or PsA, antihypertensives and statins may be used as in the general population 
(changed, LOA 9.2 (1.3)). 
Hypertension is a major modifiable risk factor contributing to increased CVD risk in 
IJD (126–128). Several mechanisms may lead to the development of hypertension, 
including the use of  certain antirheumatic drugs such as corticosteroids, NSAIDs, 
ciclosporin and leflunomide (129–132). It is important to realise that hypertension 
seems to be both underdiagnosed and undertreated in patients with RA (127). For 
the management of hypertension and hyperlipidaemia, there is no evidence that 
treatment thresholds should differ in patients with IJD compared with the general 
population. In the past years, no new evidence has emerged that ACE inhibitors 
and angiotensin II (ATII) receptor blockers should be the preferred treatment 
choice for hypertension in patients with RA. Therefore, the previous treatment 
preferences for ACE inhibitors and ATII receptor blockers have been omitted. 
Since the 2009 recommendations, several studies have assessed the efficacy of 
statins in patients with RA. Statins appeared to be at least as effective in reducing 
cholesterol levels, atherosclerotic burden and CVD morbidity and mortality, 
and they do not have more adverse reactions in patients with RA (133–139) when 
compared with non-RA controls (77). In addition, statins have anti-inflammatory 
properties that may result in an even greater CVD risk reduction when combined 
with anti-inflammatory therapy in RA, but studies on this effect are scarce (140–
142). A few preclinical studies found unfavourable effects of statins on RTX efficacy 
in patients with haematological malignancies (143-144). However, several clinical 
studies showed no significant differences in outcome between statin users and 
non-users receiving RTX treatment for a haematological malignancy (145–148). 
Clinical trials investigating this issue in RA are scarce. Three clinical studies in RA 
found no adverse effect of statins on RTX efficacy (149–151). Only one observational 
study reported a significant difference in disease activity 6 months after first 
RTX treatment in statin users as compared with non-users, but this finding was 
borderline significant (p=0.049) in a small sample size of statin-exposed patients 
(n=23 exposed vs n=164 non-exposed) (152). Obviously, further research is necessary 
to address this issue properly.  
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9. Prescription of NSAIDs in RA and PsA should be given with caution, especially for 
patients with documented CVD or in the presence of CVD risk factors (changed, LOA 
8.9 (2.1)). 
The 2009 recommendations advocate that NSAIDs should be used with caution in 
this population or may even be contraindicated (4, 153-154). Since the publication 
of the former recommendations, new evidence has emerged on the role of 
cyclooxygenase-2 inhibitors (COXIBs) and non-selective NSAIDs in CVD risk. A 
recent meta-analysis concluded that, overall, both non-selective NSAIDs and 
COXIBs have adverse effects on CVD outcomes in patients with RA and PsA (46). 
However, the increased CVD risk was mainly observed for rofecoxib, which was 
withdrawn from the market in 2004. There is evidence that NSAIDs might increase 
CVD risk in RA to a lesser extent in comparison to the general population than 
was previously thought (48). Hence, there is no evidence to be stricter with NSAID 
treatment in patients with RA than what is recommended in the national guidelines 
for patients with no RA. Safety data regarding the use of NSAIDs in patients with IJD 
and prevalent CVD comorbidities are lacking. Naproxen seems to have the safest 
CVD risk profile (46-48). In general, diclofenac is contraindicated in patients with 
established congestive heart failure (NYHA class II–IV), ischaemic heart disease, 
peripheral arterial disease or cerebrovascular disease, and new evidence supports 
similar restrictions for ibuprofen use (153-154). For patients with AS, NSAIDs are 
recommended as first-line drug treatment by the ASAS/EULAR group in the 
recommendations for the management of pain and stiffness in patients with AS, 
and an individual clinical evaluation regarding NSAIDs use in patients with AS with 
established CVD is therefore needed (155).
10. Corticosteroids: for prolonged treatment, the glucocorticoid dosage should 
be kept to a minimum, and a glucocorticoid taper should be attempted in case of 
remission or low disease activity; the reasons to continue glucocorticoid therapy 
should be regularly checked (unchanged, LOA 9.5 (0.7)).
Corticosteroids rapidly and effectively reduce inflammation in RA, but they have 
also been associated with an increased CVD risk, although the literature shows 
conflicting results. Since the 2009 recommendations, new studies have found 
a dose dependent and duration-dependent increase in CVD risk associated with 
corticosteroid use in RA (47, 156-157). A relatively high daily dose (ie, already 
starting from 8 to 15 mg/day), a high cumulative dose and a longer exposure to 
corticosteroids (in years) appear to be associated with a higher CVD risk (47, 
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156–158). Some authors argued that this increased CVD risk was confounded by 
indication, as it was no longer significant after correction for disease activity (53, 
159–161). On the contrary, other studies that had corrected for disease activity 
still found a (cumulative) dose-dependent and duration-dependent increase in 
CVD-related morbidity and mortality in patients with RA (47, 156). However, this 
does not mean that confounding by indication has been completely addressed 
and this is a major limitation of all safety studies on corticosteroids. There is no 
conclusive evidence about the long-term effects of corticosteroids, particularly in 
low daily dosage, on safety outcomes including CVD events in RA. In patients with 
active disease, the benefit of reducing high-grade inflammation may counteract 
the adverse CVD effects of corticosteroid use by reduction of inflammation and 
by improving mobility. In other words, steroids may help to abrogate the harmful 
effect of inflammation on the cardiovascular system, but they will still carry their 
own adverse effects on CVD risk. Altogether, from a CVD prevention point of view, 
the lowest effective dose of corticosteroids should be prescribed for the shortest 
possible duration in the treatment of active IJD. This recommendation is in line 
with the EULAR recommendations on management of glucocorticoid therapy (44).
DISCUSSION
The 2015 update of the 2009 EULAR recommendations for CVD risk management 
in IJD comprises 3 overarching principles and 10 recommendations. The first 
overarching principle reinforces and extends the evidence of an increased CVD 
risk in IJD. The second principle indicates the responsibility of the rheumatologist 
for coordinating CVD risk management in patients with IJD, whereas the last 
principle aims to put this recommendation update more in line with other (EULAR) 
recommendations.
CVD risk assessment in IJD
Presently, the enhanced CVD risk in RA, but also in AS and PsA, is widely 
acknowledged. Thus far, fully validated RA-specific CVD risk prediction models 
that both improve on general population models and are cost-effective are lacking, 
although multiple attempts have been made (8 ,105, 162). Some even question the 
need for a disease-specific CVD risk prediction model for RA, although existing 
models inaccurately estimate the CVD risk in these patients (89). In 2009, this 
led to the addition of a 1.5 multiplication factor for the calculated CVD risk in 
patients with RA if certain disease characteristics were  present (4). Meanwhile, 
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alternative approaches have also been advocated, for example, to increase the 
age of a patient with RA by 15 years (163) or adding a multiplication factor of 1.4 
(3). Currently, it is unknown what approach would be most appropriate. In the light 
of this, the task force opted to retain the 1.5 multiplication factor to correct for 
the increased CVD risk in patients with RA compared with the general population. 
However, considering that the CVD risk is already increased in early disease or 
at disease onset and in patients without extraarticular manifestations, the three 
disease-specific criteria for the application of this multiplication factor were 
removed. This makes the estimation of CVD risk in patients with RA easier and 
therefore more feasible for daily clinical practice. As no conclusive evidence has 
emerged regarding the precise CVD risk in patients with AS and PsA, the task force 
opted not to include a multiplication factor for these diseases. In line with the ESC 
Guidelines, the recommendation to perform CVD risk assessment was extended to 
once every 5 years for patients found to be at low-to-moderate cardiovascular risk 
as there is no evidence that CVD risk assessment every year for IJD reduces CVD 
risk more than screening every 5 years (164). In patients with an intermediate risk 
for CVD, screening should be performed more often. Patients at high to very high 
cardiovascular risk should promptly be treated for existing CVD risk factors. The 
new recommendation (#6) includes the option of screening for carotid plaques in 
patients with RA as a tool for CVD risk assessment, because carotid plaques are 
associated with future ACS in patients with RA. Whether routine screening of the 
carotid arteries is possible in daily clinical practice will depend on local availability. 
The LOA of 5.7 (3.9) for recommendation #6 possibly indicates the absence of 
evidence for routine screening of the carotid arteries in general. 
CVD risk reduction in IJD
Just as in the 2009 recommendations, the importance of optimal anti-
inflammatory therapy for CVD risk reduction in RA is emphasised in this update. 
There is accumulating evidence that decreasing the inflammatory burden in RA 
translates into a lower CVD risk. As inflammation is related to CVD risk in all IJD, 
we extrapolated this recommendation to AS and PsA, although further evidence 
for these types of IJD would be valuable. Equally important is the treatment 
of traditional CVD risk factors that are present in these patients according to 
national guidelines (128). However, awareness of some issues when performing 
risk estimation and management in patients with IJD is important. Active disease 
of IJD is associated with reduced lipid levels that increase (ie, normalise) during 
effective anti-inflammatory treatment. Biologics have the most pronounced 
lipid increasing effect, which has led to mandatory lipid assessment during 
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treatment with tocilizumab (100). However, it is also important to realise that 
the anti-atherogenic properties of HDLc improve during biologic treatment 
(94-95). Therefore, it is important to assess the net effect of lipid modulation by 
biologics. Currently, the effect of these changes on CVD outcomes is not known. 
In addition, awareness of possible adverse effects of certain medications such as 
NSAIDs and corticosteroids has been emphasised. Except for smoking cessation, 
lifestyle recommendations were not given in our previous guideline. Since then 
accumulating data demonstrate that regular physical activity has beneficial CVD 
effects in patients with RA and hence this has been incorporated in the updated 
recommendations. In addition, favourable CVD effects have also been observed 
with a Mediterranean diet, although a formal study in patients with IJD has not 
yet been conducted. As it is not likely that the effect of diet would be different in 
patients with IJD than in the general population, we also added this in our lifestyle 
recommendation.  
CONCLUSION
In general, the LOA for the recommendations was (very) high, except for 
recommendations #5 (LOA 7.5) and #6 (LOA 5.7). As in 2009, the level of evidence was 
moderate for most of the recommendations. Several important questions which 
arose during the development of these recommendations remain unanswered. 
These questions have been put on the research agenda (Box 1). The 2015/2016 
update of the EULAR recommendations for CVD risk management in patients 
with RA and other forms of IJD confirms and further extends the evidence of an 
increased CVD risk in the whole spectrum of IJD and reinforces the need for proper 
CVD risk management in these patients. As these updated recommendations 
are based on a pan-European consensus, it is hoped that they will facilitate CVD 
risk management in daily clinical practice, ultimately leading to a decreased CVD 
burden in our patients.
Chapter 2. EULAR recommendations for cardiovascular disease risk management
48
Box 1 Research agenda
1. Can we make adjustments to the current CVD risk models to improve estimation 
of CVD risk in patients with IJD?
2. How high is the CVD risk in patients with spondyloarthropathies or non-
radiographic axial SpA compared with the general population?
3. What is the benefit/risk ratio of intensive anti-inflammatory therapy on CVD risk 
in patients with IJD?
4. Is the increased CVD risk in patients with spondyloarthropathies independent 
of traditional risk factors and what is the association between CVD risk and 
inflammation in spondyloarthropathies?
5. Is there an increased prevalence of cardiac abnormalities, including aortic valve 
dysfunction and conduction disorders in patients with spondyloarthropathies and 
how does this affect overall CVD risk?
6. How does treatment with NSAIDs affect the CVD risk in patients with IJD, in 
particular patients with AS?
7. Should we treat patients with AS continuously or intermittently with NSAIDs from 
a CVD point of view?
8. Should treatment targets for blood pressure and lipids be different in patients 
with IJD from the general population?
9. What is the effect of different modes of action of antirheumatic drugs on CVD 
risk?
10. What is the relationship between residual disease activity and CVD risk in patients 
with RA on stable DMARD therapy?
11. Is there additional value in measuring lipid subparticles in patients with IJD for 
estimation of CVD risk?
12. What is the added value of ultrasound of the carotid arteries to measure cIMT and 
reveal presence of atherosclerotic plaques in patients with IJD regarding CVD risk 
estimation and in which (sub) population should we conduct this?
13. What is the additional value of novel biomarkers for CVD risk prediction?
14. What is the best technique for implementing lifestyle changes and education in 
patients with IJD?
15. Health economics. Are interventions cost-effective in terms of reducing the 
number of fatal and non-fatal CVD events?
16. Is the prevalence of venous thrombotic events in patients with IJD increased? If 
so, what are the underlying mechanisms?
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To assess the 10-year cardiovascular (CV) risk score and to identify treatment and 
undertreatment of CV risk factors in patients with established RA.
Methods
Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) 
were assessed by questionnaire. To calculate the 10-year CV risk score according 
to the Dutch CV risk management guideline, systolic blood pressure was measured 
and cholesterol levels were determined from fasting blood samples. Patients were 
categorized into four groups: indication for treatment but not treated; inadequately 
treated, so not meeting goals (systolic blood pressure 4140mmHg and/or low-
density lipoprotein 42.5 mmol/l); adequately treated; or no treatment necessary.
Results
A total of 720 consecutive RA patients were included, 375 from Reade and 345 
from the Antonius Hospital. The mean age of patients was 59 years (S.D. 12) and 
73% were female. Seventeen per cent of the patients had a low 10-year CV risk 
(<10%), 21% had an intermediate risk (1019%), 53% a high risk (520%) and 9% had 
CVD. In total, 69% had an indication for preventive treatment (cholesterollowering 
or antihypertensive drugs). Of those, 42% received inadequate treatment and 40% 
received no treatment at all.
Conclusion
Optimal CV risk management remains a major challenge and better awareness 




Patients with RA have an increased risk of premature death compared with the 
general population, mainly because of the risk of cardiovascular disease (CVD) [1, 
2]. The CV risk of patients with RA is comparable to the risk of patients with type 
2 diabetes mellitus (DM) [3, 4]. In addition to CV mortality, non-fatal CVD, such as 
myocardial infarction, cerebrovascular accidents and heart failure (HF) are more 
common in RA [5]. Several determinants contribute to this increased risk, including 
traditional CV risk factors such as age, gender, dyslipidaemia, hypertension, 
smoking, obesity and DM, however, these factors only partially explain the excess 
CV risk [6, 7]. In addition to traditional risk factors, systemic inflammation is an 
important independent contributor to CV risk in RA [8, 9]. Another explanation for 
the increased CV risk is that in RA (traditional), CV risk factors are undertreated, as 
comorbidity in patients with a chronic disease is often undertreated [10]. However, 
details of undertreatment in RA are sparse. In light of the strong evidence that the 
CV risk in RA is of the same order of magnitude as that in type 2 DM, the Dutch 
cardiovascular risk management (CV-RM) guideline considers RA, like type 2 DM, 
an independent risk factor for CVD, for which CV-RM is necessary [11]. Evidence 
on (pharmacological) management of traditional CV risk factors in patients with 
rheumatic diseases is limited, but there are no indications that the effects of 
statins or antihypertensives in RA would be different than in the general population 
[1216], thus CV-RM should be offered to all patients meeting the criteria set for 
risk reduction in the general population [17]. However, implementation of CV risk 
screening is still a challenge [18]. This strategy requires that all patients with 
RA, like patients with type 2 DM and/or CVD, are screened regularly (yearly) and 
CV risk managed accordingly. Since 2011, Implementation of Cardiovascular Risk 
Management in Rheumatoid Arthritis (I-CaRe) has offered CV risk screening to RA 
patients visiting Reade, a rheumatology and rehabilitation centre in Amsterdam 
or Antonius Hospital in Sneek, a small city in the northern rural area of The 
Netherlands. The goal of this project was to assess the 10-year CV risk score and to 
identify treatment and undertreatment of CV risk factors in RA patients. 
METHODS
Study population and design 
For this prospective cross-sectional cohort study, consecutive RA patients visiting 
the outpatient rheumatology clinic of Reade or Antonius Hospital were included. All 
patients were 518 years of age and diagnosed by a rheumatologist according to the 
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1987 ACR criteria for RA [19]. There were no other exclusion criteria. All patients were 
asked to sign an informed consent according to the Declaration of Helsinki before 
study participation and the study was approved by the local ethics committees of 
Slotervaart Hospital/Reade and Antonius Hospital. CV risk screening comprised a 
questionnaire, physical examination, laboratory investigations and assessment of 
the 10-year CV risk according to the Dutch CV-RM guideline. 
Patient characteristics 
Information on age, gender, smoking, disease history (with a special focus on 
CVD), CV risk factors and CV preventive medication use (including antihypertensive 
medication, statins, antidiabetic medication and anticoagulants), RA-related 
factors, disease duration, RF and ACPA positivity and the presence of erosive 
disease were collected from the medical files. Assessment of current anti-
inflammatory medication included use of NSAIDs, DMARDs and corticosteroids. 
CV risk and disease definitions
CVD history was defined as a history of coronary heart disease (including angina 
pectoris, myocardial infarction, percutaneous coronary intervention and coronary 
artery bypass surgery), HF, cerebral vascular disease [including ischaemic 
stroke (cerebrovascular accidents), transient ischaemic attack and carotid 
endarterectomy] and peripheral arterial disease. This was asked by questionnaire 
but also checked afterwards in the medical files to verify that the diagnosis was 
confirmed by a specialist (cardiologist, neurologist or vascular specialist). CV risk 
factors included self-reported DM, self-reported hypertension and/or the use of 
antihypertensives, self-reported hypercholesterolaemia and/or the use of statin 
therapy and smoking status assessed by the questionnaire or the presence of high 
blood pressure [systolic blood pressure (SBP) >140mmHg] or high cholesterol [low-
density lipoprotein (LDL) >2.5 or total cholesterol (TC):high-density lipoprotein 
(HDL) ratio >8] measured during the physical examination. Overweight was defined 
as a BMI 525 kg/m2 and obesity as a BMI 530 kg/m2. 
Physical examination
Specially trained and experienced research nurses performed a physical 
examination, including blood pressure, waist and hip circumference, height and 
weight. Blood pressure was measured twice (left and right) in a sitting position 
after 5 min of rest. Waist circumference was measured at the level of the navel 
and hip circumference at the level of the trochanter major of the hip bone (widest 
circumference). The waist:hip ratio comprised the ratio of these two circumference 
67
measurements. BMI was calculated from height and weight (clothed without 
shoes). RA was assessed by the 28-joint DAS (DAS28) [20] and physical functioning 
by the HAQ [21]. 
Laboratory tests 
The glucose and lipid profile, including TC, triglycerides, HDL and LDL, were assessed 
in fasting blood samples using the standard techniques and the atherogenic index 
(TC:HDL ratio) was calculated. All the above tests were performed the same day 
that blood was drawn. 
10-year CV risk calculation 
The 10-year CV risk was calculated with the Dutch SCORE table, which uses gender, 
age, smoking status, SBP and the TC:HDL ratio [11]. To account for RA as a risk 
factor, the Dutch CV-RM guideline adds 15 years to the actual age in order to calculate 
10-year CV risk. This is the same strategy that is used for the risk factor DM, since a 
large population-based cohort study showed that the vascular age of DM patients 
is 15 years greater than the vascular age of patients without DM [22] and other 
studies have shown that the CV risk of RA patients resembles that of DM patients 
[3, 5, 23, 24]. According to the Dutch CVRM guideline, we classified a risk of <10% 
as low, 10-20% as intermediate and 520% as high. Patients with a history of CVD 
were assessed separately, as a secondary prevention group. In high-risk patients 
and in intermediate-risk patients with a BMI 535 kg/m2, antihypertensive therapy 
is recommended when SBP is >140mmHg and/or statin therapy is recommended 
when LDL is >2.5 mmol/l. In patients with an intermediate or low 10-year CV risk 
the criteria are SPB >180 mmHg or TC:HDL ratio >8. After we calculated the 10-
year CV risk, we categorized patients into four groups: untreated patients with an 
indication for treatment, inadequately treated patients (i.e. not meeting treatment 
goals, e.g. SBP 4140mmHg or LDL 42.5 mmol/l), adequately treated patients and 
untreated patients without an indication for treatment (i.e. no increased CV risk). 
Statistical analysis
For the statistical analysis, SPSS version 22.0 (IBM, Armonk, NY, USA) was used. 
Patient characteristics were expressed as number and percentage [mean (S.D.)] 
when normally distributed or median (interquartile range) when not normally 
distributed. Independent t-tests were used to compare variables with a normal 
distribution. The Pearson chi-square test was performed on dichotomous variables. 
The threshold for significance was set at P<0.05 (two-sided). 




From 2011 to 2015 a total of 720 consecutive RA patients underwent CV risk 
screening: 375 from Reade and 345 from Antonius Hospital. Patients from Antonius 
Hospital were more often male, older, had more prevalent CVD and more frequently 
were on statins and anticoagulant drugs (Table 1). In contrast, patients from Reade 
had longer RA disease duration, were more often RF and ACPA positive and had 
more active and erosive disease. In the Reade patients, biologic treatment was 
more frequent and glucocorticoid treatment less frequent. 
Prevalence of CVD 
A history of CVD was present in 61 (8%) patients, with a slightly higher prevalence 
in those from Antonius Hospital compared with Reade (10 vs 7%). The following 
conditions were present: coronary heart disease (n = 29), HF (n = 4), cerebrovascular 
disease (n = 29) and peripheral artery disease (n = 6). Of the men, 13% had a history 
of CVD vs 7% of women. Patients with a history of CVD were significantly older; 
more often diagnosed with DM, hypertension and hypercholesterolaemia and more 
often used antidiabetic drugs, antihypertensives, statins and anticoagulants, but 
less often NSAIDs compared with patients without CVD. They also had a higher 
waist:hip ratio, lower TC, lower HDL, lower LDL and higher fasting glucose levels 
versus patients without CVD (Table 1). 
10-year CV risk assessment 
The presence of high blood pressure and high cholesterol as measured during the 
CV risk screening as well as the mean 10-year CV risk score are shown in Table 2. 
A total of 125 (17%) patients had a low 10-year CV risk, 153 (21%) patients had an 
intermediate risk and 381 (53%) patients had a high risk (Fig. 1).  
CV risk preventive treatment
In total, 500 patients (69%) had an indication to receive antihypertensives, statins 
or both (Fig. 2). Of those, 199 (40%) did not receive treatment at all and 212 (42%) 
were inadequately treated; the other 18% were adequately treated. A total of 419 
patients had an indication for statin treatment; 270 patients (64%) did not use 
statins despite having an indication and 149 received treatment. Fifty per cent 
of them reached an LDL of <2.5. A total of 378 patients had an indication for 
antihypertensive treatment; 123 patients (33%) did not receive treatment, while 
255 used antihypertensives. Fifty per cent of them reached an SBP <140 mmHg. 
Fig. 3 shows the numbers and percentages per CV risk group. 
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Table 1 | Characteristics of rheumatoid arthritis patients in Reade, Amsterdam and Antonius 
hospital, Sneek, with and without CVD






CVD (n=61) no CVD 
(n=659)
Demographics
   Females, % 73 77 69* 59 74#
   Age, years, mean (SD) 59±12 58±11 61±12* 68±8.5 59±11.7#
Cardiovascular disease history, % 8 7 10* 100 0
Cardiovascular risk factors, %
  Currently smoking 22 22 21 20 22
  Hypercholesterolemia (self-
reported)
33 38 28 54 32#
  Hypertension (self-reported) 43 47 38 67 42#
  Diabetes mellitus (self-reported) 6 6 6 18 5#
Cardiovascular preventive 
medication use, %
  Antihypertensives use 36 33 39 77 32#
  Statins use 21 15 27* 66 17#
  Anti-diabetics use 5 4 5 13 4#
  Anticoagulants use 11 8 14* 77 5#
Disease characteristics
   Disease duration, years, mean 
(SD)
7 (2-14) 10 (5-18) 4 (2-9)* 9 (4-16) 7 (2-14)
   RF positive, % 61 67 55* 60 63
   ACPA positive, % 61 64 58* 64 66
   Erosive disease, % 46 53 39* 58 46
Anti-inflammatory medication 
use, %
   NSAID use 36 36 37 21 38
   Methotrexate use 68 70 65 73 68
   Other DMARD use 24 20 28* 18 25
   Biological use 36 59 12* 45 36
   Corticosteroid use 24 18 30* 33 24
Physical examination
  Systolic blood pressure, mm/Hg 138±19 135±18 140±19* 141±19 137±19
  Waist Hip Ratio, mean (SD) 0.91±0.09 0.91±0.09 0.91±0.09 0.93±0.07 0.91±0.09#
  Body Mass Index, kg/m2 26.8±4.9 26.7±5.1 26.9±4.6 27.1±4.6 26.8±4.9
  Disease activity score of 28 joints 2.44±1.15 2.65±1.22 2.20±1.02* 2.72±1.18 2.41±1.15
Laboratory tests, mean (SD)
table continues
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CVD (n=61) no CVD 
(n=659)
  Lipid profile
    Total cholesterol, mmol/l 5.3±1.0 5.5±1.0 5.1±1.1* 4.7±1.0 5.4±1.0#
    Triglycerides, mmol/L 1.4±0.7 1.4±0.8 1.3±0.7* 1.5±1.0 1.3±0.7
    LDL-cholesterol, mmol/l 3.1±0.9 3.2±0.9 3.0±0.9* 2.5±0.8 3.2±0.9#
    HDL-cholesterol, mmol/l 1.6±0.5 1.6±0.5 1.6±0.4 1.5±0.4 1.6±0.5#
    Total cholesterol/HDL-ratio 3.6±1.2 3.7±1.3 3.4±1.1* 3.4±1.1 3.6±1.2
  Fasting glucose, mmol/l 5.5±1.5 5.6±1.7 5.5±1.2 6.0±1.9 5.5±1.4#
Results are presented as mean and standard deviation (SD), median and interquartile range 
(IQR) or percentage (%).                   
*p<0.05 between Amsterdam and Sneek  #p<0.05 between patients with cardiovascular 
disease (CVD) and patients without cardiovascular disease (no CVD)                                                                                                                             
ACPA=Anti–citrullinated protein antibodies, DMARD= Disease Modifying Anti-Rheumatic 
Drugs, HDL=High-densitity lipoproteïn, LDL= Low-densitity lipoproteïn, NSAID= Non-
Steroidal Anti-Inflammatory drugs, RF=Rheumatoid factor.
Table 2 | Cardiovascular risk score of rheumatoid arthritis patients in Reade, Amsterdam and 
Antonius hospital, Sneek
  All patients (n=720) Amsterdam (n=375) Sneek (n=345)
10-year cardiovascular risk score 22±13 21±12 23±13
Systolic bloodpressure >140 mm/Hg 40 36 45*
Systolic bloodpressure >180 mm/Hg 3 1 4*
LDL > 2,5 mmol/l 73 79 68*
Total cholesterol/HDL-ratio≥8 1 1 0
Total cholesterol ≥ 6.5 mmol/l 12 15 9*
Results are presented as mean and standard deviation (SD) or percentage (%). *p<0.05 
between Amsterdam and Sneek. LDL= Low-densitity lipoproteïn, HDL=High-densitity 
lipoproteïn.
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Figure 3  | Preventive 
medication per risk 
group
DISCUSSION
The results of this study confirm both a high prevalence of CVD risk and a very low 
prevalence of (adequate) preventive treatment in RA patients, not only in patients 
with a high CV risk (primary prevention), but also in patients who have already 
experienced CVD (secondary prevention). Our finding that 80% of RA patients are 
inadequately treated for CV risk is equal to that of another recently published Dutch 
study [25]. However, that cohort was established in 2006 and thus at a time when 
RA was not considered an independent CV risk factor. It is therefore worrisome that 
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CV-RM implementation has not improved since then. Previously a study to establish 
whether lipidlowering therapy was used appropriately or not in RA patients revealed 
that of the 115 patients who were at ‘high risk’ of CVD, only 8 were receiving statins 
[26]. In accordance with this, a cohort study using Medicare data reported that 
in RA patients with indications for annual lipid testing, this was not performed in 
one-third of patients [27]. There are several factors that might explain this lack of 
improvement. First, the current CV-RM guideline was published very shortly before 
the present study actually started. This could explain why CV-RM has not yet been 
implemented in all RA patients. Second, a potential weakness of the current Dutch 
CV-RM guideline is the addition of 15 years to account for the additive CV risk that 
comes with RA. This addition is not based on level A evidence and thus may hamper 
implementation, especially in young persons, knowing that they have to start a 
lifetime treatment. Moreover, RA patients often use many drugs to control disease 
activity and perhaps are reluctant to take additional drugs, particularly those that 
do not treat actual symptoms. Also, potential side effects, such as muscle and joint 
pain with statin use, could limit use in RA patients since they often already have 
muscle or joint pain due to active disease. Strengths of this study include the size 
of the study population and the fact that it is a two-centre study, including patients 
from rural and urban areas, making it a diverse RA population. Active disease can 
interfere with CV risk estimation, particularly because of interference with lipid 
levels. In our study population, the mean disease duration was 10 years and only 2% 
of patients had active disease (defined as a DAS28 >5.1), therefore it is likely that CV 
risk was stable for most of the patients. A limitation of this study is that we could 
not take into account some secondary CV risk factors, such as family history of 
CVD, physical activity and kidney function. These factors are, like BMI, considered 
CV risk increasing, which can serve as an additional reason to give CV risk 
prevention treatment. Thus the lack of this information could have underestimated 
our results. Ideally, blood pressure should be measured twice and the average 
used to calculate CV risk, but for practical reasons only one assessment was done. 
However, when blood pressure was too high we recommended reassessment by the 
general practitioner. Unfortunately, in this study we did not determine the reasons 
why RA patients were not treated or treated inadequately. This will be addressed in 
a followup implementation project that will be started shortly. Another study that 
we are currently undertaking is to investigate if yearly CV risk screening initiated 
by the rheumatologist improves CV-RM implementation. Two strategies will be 
tested: one strategy is to send high CV risk patients to their general practitioner 
to implement and control CV-RM, the second strategy is to send RA patients with 
a high CV risk to an internal specialist who implements CV-RM in the context of 
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a specialty CV-RM clinic. Ideally the effects of statins or antihypertensives on 
CV disease prevention in RA should be investigated in a large randomized trial; 
however, thus far no intervention trials with statins or antihypertensives and CV 
disease prevention in RA have been published. The TRACE RA trial was a placebo-
controlled study investigating the efficacy of atorvastatin in patients with RA that 
was terminated early because of a low overall event rate [28]. Nevertheless, a 
reduction of 34% in CVD events in the statin group was demonstrated, although 
this did not reach statistical significance. Furthermore, data from epidemiological 
studies and post hoc subgroup analyses of large, secondary CV prevention trials 
show that the effects of statins on cholesterol levels in RA patients appear to be 
at least equivalent to the effects of statins in the general population [15, 29, 30]. 
Other studies have shown beneficial effects of angiotensin-converting enzyme 
(ACE) inhibitors on CV risk in RA [12]. Moreover, the effects of cardioprotective 
agents might be even more pronounced in RA, as the pleiotropic effects of statins, 
ACE inhibitors and angiotensin blockers include anti-inflammatory properties [14, 
31-35]. In the future, randomized controlled intervention trials are necessary to 
assess the actual effect of statins, ACE inhibitors and other lifestyle intervention 
strategies on CV risk in RA. In conclusion, our results indicate that effective 
strategies for adequate CV-RM are urgently needed to reduce CV risk in the RA 
population. 
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In 2011, we started to offer cardiovascular (CV) risk screening to rheumatoid arthritis 
(RA) patients with a high CV risk. After 1 year, we assessed whether patients labelled 
as high CV risk had started preventive treatment when indicated, and whether the 
CV risk score had changed. 
Methods
CV risk screening was performed in both a large outpatient rheumatology clinic and 
a general hospital in the Netherlands, and the general practitioner or the internist 
was informed about the results of the CV screening, including specific advice on 
the initiation or adjustment of cardiopreventive drugs. National guidelines were 
used to assess how many patients were eligible for preventive treatment. After 1 
year, CV risk, lifestyle, and treatment were re-evaluated. Patients with a history 
of CV disease at baseline or who experienced a CV event during follow-up were 
excluded from the analyses.
Results
A high 10 year CV risk (> 20%) was present in 58%, and 55% had an indication for 
anti-hypertensives, statins, or both. At follow-up, cardiopreventive drug treatment 
had been started or adjusted in only one-third of patients with an indication for 
treatment. After screening, 42% of patients reported having changed their 
lifestyle, through more exercise (24%), diet adaption (20%), and weight loss (11%).
Conclusion
Despite clear guidelines to improve CV risk, the results of a programme comprising 
active screening, targeted advice, and referral to the general practitioner or 




Cardiovascular disease (CVD) is the main cause of death in patients with rheumatoid 
arthritis (RA) (1). Compared with the general population, in patients with RA the 
risk for incident CVD is doubled, comparable to that of patients with diabetes 
mellitus (2, 3). Both systemic inflammation and increased prevalence of traditional 
cardiovascular (CV) risk factors (including age, male gender, hypercholesterolaemia, 
hypertension, smoking, obesity, and diabetes mellitus) contribute to this increased 
CV risk. Therefore, the Dutch CV risk management guideline acknowledges RA as 
an independent risk factor for CVD, requiring CV riskmanagement (4). In addition, 
undertreatment of traditional CV risk factors may further increase the CV risk, but 
details on this subject are scarce. In 2011, Implementation of Cardiovascular Risk 
Management in Rheumatoid Arthritis (I-CaRe) started to offer CV risk screening 
to RA patients visiting Reade, a large rheumatology and rehabilitation centre 
inAmsterdam, and the Department of Rheumatology in the Antonius Hospital, 
Sneek, in the Netherlands. Previous results of the I-CaRe project demonstrated that 
an indication for preventive treatment (cholesterol-lowering or antihypertensive 
drugs) was present in over two-thirds of RA patients in whom the 10 year CV 
risk score was assessed (5). However, only 42%of those received (inadequate) 
treatment and 40% received no treatment at all. Thus, optimization of CV risk 
management remains a challenge, and better awareness and management are 
indispensable to reduce the high risk of CVD. The goal of this follow-up study was 
to assess whether patients labelled as high CV risk started preventive treatment if 
indicated, and whether their CV risk score changed after 1 year.  
METHOD 
Study population and design 
For this prospective cohort study, patients included in the I-Care project between 
2011 and 2016 were considered. The I-Care project, which started in 2011, aimed to 
assess the 10 year CV risk score and identify (under)treatment of CV risk factors 
in RA patients (5). For this follow-up study we aimed to assess whether patients 
labelled as high CV risk during the initial screening had indeed started preventive 
treatment, if indicated. All patients were aged 18 years or older and diagnosed by a 
rheumatologist, according to the American College of Rheumatology (ACR) criteria 
of 1987 for RA (6). In Reade, patients were included in the analyses if they had a 
baseline visit and a follow-up visit. Data were collected at baseline and again after 
1 year of follow-up. Patients from the Antonius Hospital had a baseline visit and 
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a follow-up visit with the internist shortly thereafter. These different strategies 
were chosen because each clinic adapted the strategy that best fitted their local 
practice. All patients signed informed consent before study participation and the 
study was approved by the local ethics committees of Slotervaart Hospital & Reade 
and Antonius Hospital Sneek (number P1042). 
Patient characteristics 
Information on demographic factors, including age, gender, smoking, disease 
history, with a special focus on CVD, CV risk factors, and CV-preventive medication 
use, including anti-hypertensive medication, statins, and anti-diabetic medication, 
RA-related factors, disease duration, rheumatoid factor (RF) and anti-citrullinated 
protein antibody (ACPA) positivity, and presence of erosive disease, were collected 
from the medical files. Patients with a history of CVD were excluded from the 
analyses. Assessment of current anti-inflammatory medication included use of 
non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic 
drugs (DMARDs), and corticosteroids. 
CV risk and disease definitions 
CVD history was defined as a history of coronary heart disease (including angina 
pectoris, myocardial infarction, percutaneous coronary intervention, and coronary 
artery bypass surgery), heart failure, cerebral vascular disease (including ischemic 
stroke, transient ischaemic attack, and carotid endarterectomy), and peripheral 
arterial disease and atherosclerosis of major arteries. This was first asked about by 
a questionnaire, and if a CVD was reported or the patient’s reply was positive for a 
history of CVD, this was checked in the medical files, to verify that the diagnosis had 
been confirmed by a specialist (cardiologist, neurologist, or vascular specialist). CV 
risk factors included self-reported diabetes mellitus, self-reported hypertension 
and/or the use of anti-hypertensives, self-reported hypercholesterolaemia and/or 
the use of statin therapy, and smoking status assessed by the questionnaire or the 
presence of high blood pressure [systolic blood pressure (SBP) > 140 mmHg] or high 
cholesterol [low-density lipoprotein (LDL) > 2.5 mmol/L or total cholesterol/high-
density lipoprotein (TC/HDL) ratio > 4] measured during the physical examination. 
Overweight was defined as a body mass index (BMI) ≥ 25 kg/m2 and obesity as a BMI 
≥ 30 kg/m2. 
Physical examination 
A physical examination, including blood pressure, waist and hip circumference, 
length and weight, was performed. Blood pressure was measured twice (left and 
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right) in a sitting position after 5 min of rest. Waist circumference was measured at 
the level of the umbilicus, and hip circumference at the level of the trochanter major 
of the hip bone (widest circumference). The waist-to-hip ratio comprised the ratio 
of these two measurements. BMI was calculated from height and weight (clothed 
without shoes). RA activity was assessed by the Disease Activity Score based on 
28- joint count (DAS28) (7) and physical functioning by the Health Assessment 
Questionnaire. 
Laboratory tests 
Glucose and lipid profiles, including TC, triglycerides, HDL, and LDL, were assessed 
in fasting blood samples using standard techniques, and the TC/HDL ratio was 
calculated. All of the above tests were performed on the same day that blood was 
drawn. 
Calculation of 10 year CV risk 
The Dutch CV risk calculator is based on the European SCORE risk model, and uses 
gender, age, smoking status, SBP, and the TC/HDL ratio to calculate the 10 year risk 
of both fatal and non-fatal CV events. To account for RA (or diabetes) as a risk factor, 
15 years is added to the actual age to calculate the 10 year CV risk (4). According to 
the Dutch CV risk management guideline, we classified a risk < 10% as low, between 
10% and 20% as intermediate, and a ≥ 20% as high. Patients with a history of CVD 
at baseline or who experienced a CV event during follow-up were excluded from 
the analyses, because in the Dutch SCORE model for primary prevention, patients 
usually already receive cardiopreventive drugs in the case of pre-existing CVD. 
For Reade patients, the results of the CV screening were reported to the general 
practitioner (GP), who decided whether to start preventive medication. GPs in 
and around Amsterdam were involved in the project and were educated about CV 
risk in RA through an interactive training session. When one of their patients was 
screened, they received the results by letter. In case of a high CV risk, the advice 
was to treat the patient according to the Dutch CV risk management guideline. CV 
risk screening was repeated after 1 year and the 10 year CV risk at follow-up was 
calculated using age at baseline. For the patients from the Antonius Hospital, the 
internist was informed about the CV risk results and all patients were referred to the 
internist for further follow-up. This method was chosen for this location because 
shortly before the initiation of the I-CaRe project, this collaboration between the 
departments of Rheumatology and Vascular Medicine of the Antonius Hospital was 
established.
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Cardiopreventive treatment
Based on the Dutch CV risk management guideline, in high-risk patients, and in 
intermediate-risk patients with a BMI ≥ 35 kg/m2, anti-hypertensive therapy is 
recommended when SBP is > 140 mmHg and/or statin therapy is recommended 
when LDL > 2.5 mmol/L. In patients with an intermediate or low 10 year CV risk, the 
criteria are SBP > 180 mmHg or TC/HDL ratio > 8. After calculation of the 10 year CV 
risk, we categorized patients into four groups: group 1, untreated patients with an 
indication for treatment; group 2, inadequately treated patients (i.e. not meeting 
treatment goals; SBP ≤ 140 mmHg or LDL ≤ 2.5 mmol/L); group 3, adequately treated 
patients; and group 4, untreated patients without an indication for treatment (i.e. 
no increased CV risk). 
Follow-up 
In Reade, CV risk screening was repeated after 1 year and the 10 year CV risk at 
follow-up was calculated using age at baseline. Patients were asked to complete a 
questionnaire about the actions that were taken following the results of the initial 
screening. All Reade patients were evaluated after 1 year, and in patients with high 
CV risk at baseline and receiving inadequate or no treatment (groups 1 and 2), we 
assessed whether they really started preventive treatment. For patients from the 
Antonius Hospital, we assessed whether the internist had started treatment after 
referral. 
Statistical analysis
For the statistical analysis, SPSS version 23.0 (IBMCorp., Armonk, NY, USA) was 
used. Patient characteristics are expressed as number and percentage, means ± 
sd, when normally distributed, or median and interquartile range when not normally 
distributed. To test for differences between baseline and follow-up, the paired 
t-test and McNemar test were used. The threshold for significance was set at p < 
0.05 (two-sided).
RESULTS 
Patient and disease characteristics 
For this study, 720 patients were included: 375 patients from Reade and 345 
patients from the Antonius Hospital. A history of CVD was present in 61 patients 
at baseline and 12 new cases of CVD occurred after 1 year. These 73 patients were 
excluded from the analyses. In Reade, 47 patients were lost to follow-up after 1 year 
for various reasons, such as refusal or inability to contact. Baseline characteristics 
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of those 47 patients were similar to those of the whole group (data not shown). 
In the Antonius Hospital, seven patients did not make an appointment with the 
internist. We tried to retrospectively collect data on CV risk factors from the 
patients from the Antonius Hospital, but this was not possible in the majority of 
patients since data on blood pressure and cholesterol were not available. Baseline 
patient characteristics are shown in Table 1. Patients in the study had longstanding 
stable disease, with mean DAS28 at baseline and after 1 year of follow-up of 2.41 and 
2.55, and 77% and 70% of the patients had low disease activity at baseline and after 
1 year of followup, respectively.
Table 1 | Patient characteristics at baseline
All patients Reade Antonius Hospital
647 346 301
Demographics
Females 482 (75) 267 (77) 215 (71)
   Age, years 58 ± 12 58 ± 11 59 ± 12
   Disease duration, years 7 (2-14) 10 (5-18) 4 (1-9)
   RF positive 400 (63) 233 (70) 167 (56)
   ACPA positive 396 (66) 221 (73) 175 (58)
   Erosive disease 293 (46) 184 (55) 109 (36)
  Disease activity score of 28 joints 2.41 ± 1.14 2.62 ± 1.20 2.17 ± 1.02
Anti-inflammatory medication use
   NSAID 245 (38) 127 (37) 118 (41)
   Methotrexate 435 (68) 243 (70) 192 (66)
   Other DMARD 160 (25) 73 (21) 87 (30)
   Biological 232 (36) 196 (57) 36 (12)
   Glucocorticoid 146 (23) 61 (18) 85 (29)
Results are presented as mean and standard deviation (SD), median and interquartile range 
(IQR) or number and percentage (%)
ACPA: Anti–citrullinated protein antibodies, DAS28: Disease activity score 28 joint count, 
DMARD: Disease Modifying Anti-Rheumatic Drug, HAQ: Health Assessment Questionnaire 
NSAID: Non-Steroidal Anti-Inflammatory drugs, RF=Rheumatoid factor.
 
CV risk and indication for cardiopreventive treatment
In Table 2, CV risk factors at baseline and after 1 year (only Reade) are shown 
separately for both centres. In Reade, mean 10 year CV did not change and the 
majority of patients remained in the same risk category. There was a significant 
decrease in TC, LDL-cholesterol, and the TC/HDL ratio. The proportion of patients 
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with high LDL and TC decreased, but no significant change in the presence of SBP 
> 140 mmHg was found. Finally, a higher percentage of patients used statins or 
anti-hypertensives after 1 year. There was a significant difference in 10 year CV risk 
score between baseline and 1 year assessment, but this was not clinically relevant. 




N 346 299 301
Cardiovascular risk
  10-year CV risk score 21 ± 12 21 ± 12 * 23 ± 13 
  CV risk: <10% 65 (19) 61 (21) * 60 (20)
                 10-20% 86 (25) 81 (27) 63 (21) 
                 >20% 195 (56) 155 (52) * 178 (59)
Physical examination
  Systolic blood pressure (mm/Hg) 135 ± 18 135 ± 18 140 ± 19
  Waist Hip Ratio 0.91 ± 0.09 0.90 ± 0.07 0.91 ± 0.09
  Body Mass Index (kg/m2) 26.6 ± 5.0 26.3 ± 4.8 27.0 ± 4.8
Laboratory tests (mmol/L or ratio)
  Total cholesterol 5.5 ± 1.0 5.2 ± 1.0 * 5.2 ± 1.1
  Triglycerides 1.4 ± 0.8 1.4 ± 0.8 1.3 ± 0.6  
  LDL-cholesterol 3.3 ± 0.9 3.1 ± 0.9 * 3.0 ± 0.9 
  HDL-cholesterol 1.6 ± 0.5 1.6 ± 0.5 1.6 ± 0.5  
  Total cholesterol/HDL 3.7 ± 1.3 3.5 ± 1.2 * 3.7 ± 1.3
  Fasting glucose 5.5 ± 1.7 5.5 ± 1.5 5.5 ± 1.7
Cardiovascular risk factors
  Currently smoking 76 (22) 60 (20) 68 (23)  
  Diabetes mellitus (self-reported) 20 (6) 13 (5) 13 (4) 
  Systolic blood pressure >140 mm/
Hg
119 (34) 102 (34) 134 (45) 
  LDL > 2.5 mmol/L 275 (80) 220 (74) * 212 (71)
  Total cholesterol ≥ 6.5 mmol/L 52 (15) 30 (10) 30 (10)
Cardiopreventive medication use
  Antihypertensives 99 (29) 94 (31) * 101 (35)
  Statins 40 (12) 56 (19) * 65 (22)
  Anti-diabetics 14 (4) 10 (3) 11 (4)
Results are presented as mean ± standard deviation (SD) or number and percentage (%).
CV: Cardiovascular, HDL: High-density lipoprotein, LDL: Low-density lipoprotein
* p <0.05 between baseline and follow up
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Of all patients, at baseline 357 patients (55%) had an indication for the use of anti-
hypertensives, statins, or both. Because follow-up assessments differed between 
Reade and the Antonius Hospital, the results are described separately. In Figure 1, 
percentages of patients receiving preventive treatment at baseline and follow-up 
in Reade are shown. In Reade, 192 patients had an indication for statin treatment 
but only 40 of them (21%) used a statin; of those, 18 patients (9%) reached an LDL < 
2.5 mmol/L. Of 160 patients with an indication for anti-hypertensive treatment, 99 
(62%) used anti-hypertensives and 61 (37%) did not. Of the patients who used anti-
hypertensives, 55 (34%) reached an SBP < 140 mmHg. After 1 year of follow-up, 105 
out of 173 patients (61%) who received inadequate or no treatment at baseline were 
still untreated or undertreated after 1 year. Of the 105 patients with an indication for 
antihypertensives without adequate treatment at baseline, 53 (50%) received no or 
inadequate treatment after 1 year. 









after one year 
of follow-up in 
Reade
 
Figure 2 shows the number of patients with an indication for treatment who started 
or adjusted cardiopreventive therapy and the number reaching treatment goals 
(only for Reade). In the Antonius Hospital, after initial screening all patients were 
referred to an internist. As a result of those referrals, 27 (23%) of the 109 patients 
Patients (n)
month 0    12 0    12 0    12 0    12 0    12 0    12 0    12 0    12
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with an indication for anti-hypertensives without adequate treatment at baseline 
started or adjusted anti-hypertensive therapy. Fifty-four of the 134 patients (40%) 
who received no statin or had not yet reached their LDL goal started with a statin 
or adjusted the dose. 
Figure 2 | Number of patients with an indication for treatment who started or adjusted 
cardiopreventive therapy and the number reaching treatment goals
Follow-up by the GP in Reade 
Of all patients in Reade without a history of CVD, 48 (16%) were contacted by their 
GP for a visit, and 37 patients (12%) made an appointment with their GP themselves. 
In total, 83 patients (24%) visited their GP after our screening. In those patients, 
monitoring of cholesterol and blood pressure was performed in 44 (53%) and 52 
patients (63%), respectively. Of the patients who visited their GP, 26 (31%) were 
prescribed statins, and 25 (30%) received a prescription for anti-hypertensives. 
Nine were referred to another specialist, mostly a cardiologist, for further follow-
up. Of the patients who visited the GP, nine had a low CV risk, 17 intermediate, and 
57 high. In the patients with an indication for starting or adjusting cardiopreventive 
medication (n = 191) at baseline, 63 (33%) visited their GP. Change in CV risk 1 year 
after the start of the CV risk management programme Analyses were performed 
only for Reade. In Reade, the majority of patients remained in the same risk category, 
regardless of whether they visited their GP. However, we did find differences in CV 
risk score in the patients who started cardiopreventive therapy. In patients with an 
indication for statin treatment at baseline (n = 174) but inadequate or no treatment, 
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mean CV risk was 29%. As shown in Table 3, at 1 year follow-up, this risk decreased 
to 24% for the patients who were on statin therapy and reached treatment goals. 
In those who used statins without reaching treatment goals, or in patients who did 
not use statins after baseline, the 10 year CV risk score remained high. Patients 
with no treatment indication had a CV risk of 13% at baseline and follow-up. Similar 
results were seen for patients with an indication for anti-hypertensives.
Table 3 | Change in 10-year Dutch CV risk score after one year sorted by treatment status
Mean 10-year Dutch CV risk score
Baseline Follow-up
Reade
  Statins; no or inadequate treatment at baseline
    Follow-up adequately treated 29% 24%
    Follow-up treatment goal not reached 29% 32%
    Follow-up treatment indication, not treated 29% 31%
  No treatment indication or adequately treated at baseline 13% 13%
  Antihypertensives;  no or inadequate treatment at baseline
    Follow-up adequately treated 33% 23%
    Follow-up treatment goal not reached 33% 35%
    Follow-up treatment indication, not treated 33% 33%
  No treatment indication or adequately treated at baseline 16% 17%
Lifestyle factors (only available for Reade) 
One year after the initial screening, patients in Reade were asked whether they had 
made any lifestyle changes as a result of the screening. In total, 42% of patients 
reported that they had adapted their lifestyle; 24% of the patients exercised 
more, 20% had adapted their diet, and 11% reported that they had lost weight. 
Nine patients had stopped smoking (3%) and two reported that they smoked less. 
However, 54% reported that they had not adopted a healthier lifestyle. The main 
reason for this was that patients reported that they already had a healthy lifestyle 
(28%); in addition, 14% did not want to make lifestyle changes, because they did not 
consider themselves to be at high CV risk, 8% felt that a lifestyle change was not 
necessary, and some patients (3%) did not know how to adopt a healthier lifestyle. 
Of the patients without cardiopreventive medication at baseline, 37% reported 
having made lifestyle changes; these percentages were 44%in the group that used 
either a statin or anti-hypertensive therapy and 40% of the patients who used both 
a statin and a antihypertensive. 
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DISCUSSION
This cohort study in the Netherlands illustrates that, despite clear recommendations 
to improve CVD risk management, adherence to guidelines in high-risk RA patients 
for primary prevention of CVD remains a major challenge. Cardiopreventive drug 
treatment was started or adjusted in only one-third of patients with an indication 
for treatment. CV risk declined after 1 year, from 29% to 24%, in the patients who 
used cardiopreventive therapy. This signals an important issue, namely the need 
for better implementation strategies to reduce and control the increased CV risk 
associated with RA. As the increased CV risk in RA is due to both the disease 
activity and increased prevalences of the ‘traditional’ CV risk factors, CV risk 
management should receive more attention. Previous studies have sent a similar 
message: a study in UK primary care patients demonstrated that although anti-
hypertensive prescription rates were higher in patients with RA than in controls, 
CV risk assessment was often incomplete and thus suboptimal. In a French cohort 
of early arthritis patients, 58% of patients at high CV risk did not reach the 
recommended LDL-cholesterol target. On the other hand, in a study in a US 
managed care setting, the measurement of blood pressure and LDL-cholesterol, 
as well as treatment with cardiopreventive medication, was higher in patients with 
RA compared with general controls, but this difference may be explained by the 
dissimilar setting. One year after the implementation of our CV risk management 
programme, we found a reduction in CV risk in the patients who started medication, 
reflecting the importance of adequate CV risk management. Moreover, some 
individual CV risk factors such as cholesterol and smoking status improved. 
However, we did not find a clinically relevant decrease in 10 year CV risk in the whole 
group. This is not surprising, as only a small proportion of patients contacted their 
GP. Our results demonstrate undertreatment of both hypertension and 
dyslipidaemia, as many patients who had an indication to use preventive 
medications did not receive adequate treatment and were still untreated or 
undertreated after 1 year of follow-up, despite instructions to both patients and 
GPs. However, it is encouraging that the intervention of screening for CV risk 
factors prompted a reasonable proportion of patients to adapt their lifestyle, 
including taking more exercise, making dietary changes, and losing weight. 
Unfortunately, we could not assess the reasons why patients did not visit their GP 
or why therapy was not initiated. This may partly be due to non-adherence by either 
patients or physicians, and since patients visited different GPs in the Amsterdam 
region, there may also be differences between physicians. However, even if the 
pros and cons of medication are well discussed by the physician, a large proportion 
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of patients still prefers not to use medication (8). Non-adherence to guidelines is 
an often reported phenomenon (9, 10). A Dutch cohort study reported that in 66% of 
statin users from the general population, statin treatment was inconsistent with 
the Dutch CV risk management guideline, especially in patients with low 10 year risk 
(8). We checked whether patients without adequate preventive therapy were 
different from those with preventive therapy, but we found no differences in age, 
gender, or RA activity between patients who started cardiopreventive therapy and 
those who did not. The issue of clinical inertia probably also contributes to 
undertreatment of CV risk factors, and is regarded as a major cause of uncontrolled 
hypertension and dyslipidaemia. This may be a particular problem in the RA 
population, where therapeutic inertia is reflected by the presence of non-
adherence to the current ACR treatment recommendations. We expected that as a 
result of our screening, patients in Amsterdam (especially those with high 10 year 
CVD risk) would be motivated to visit their GP for follow-up. However, 
cardiopreventive treatment was started in only a small proportion of patients with 
an indication for treatment. In the Antonius Hospital, this was about the same: 23% 
and 40% of patients with an indication for preventive therapy started anti-
hypertensives and statins, respectively, despite referral to the internist. Differences 
in GPs’ personal and professional attitudes may also play a role in their adherence 
to CV risk management guidelines (11). Because we used different protocols at the 
two sites, we could not compare these outcomes side by side. For both sites, we 
left the decision of whether to start medication to the GP or internist, without 
giving strict advice on this. This method was chosen in consultation with the GPs 
involved in the protocol design. Lifestyle modifications are often the first step in 
CV risk management, and although some patients adjusted their lifestyle, there is 
also room for improvement in this area. Finally, risk perception by patients needs to 
be considered. Previous studies have shown that changing one’s behaviour is a 
difficult challenge (12). This may be due to the fact that risk communication does 
not always fit within the reference framework of an individual patient, and patients 
may not fully understand themagnitude of the risk that is explained to them. 
Improving the effectiveness of health risk communications would therefore 
improve the effectiveness of risk management counselling. There are some 
limitations of our study. First, the addition of 15 years to the age of RA patients for 
the CV risk calculation is only used in the Netherlands, and therefore our results are 
difficult to compare with other studies using other calculators. For example, the 
Heart- SCORE, which calculates the 10 year risk of a fatal CV event and multiplies 
this by 1.5 for RA patients, is commonly used in Europe (13, 14). We specifically 
chose to use the Dutch SCORE method because it is widely applied in the 
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Netherlands, particularly by Dutch GPs. Furthermore, the addition of 15 years to the 
CV risk resulted, in comparison to the unadjusted (without 15 years) CV risk score, 
in reclassification of 25% and 56% of patients to the intermediate- and high-risk 
categories, respectively. When not using the 15 year addition, 26% of patients 
would be in the intermediate-risk and 22% in the high-risk category. Another 
potential limitation could be that the risk was communicated to patients differently 
in Reade and the Sneek Hospital. In Reade, we used a standard model for this and 
all staff involved received the same training, whereas in the Antonius Hospital, the 
results of the CV risk screening were also communicated to patients by the vascular 
internist. Finally, patients who had an indication for cardiopreventive treatment 
may not have been candidates for cardiopreventive therapy after a second 
evaluation by their GP or internist. However, it is unlikely that this potential issue 
fully explains the undertreatment found in this group. Furthermore, in some cases, 
the GP may have initiated a CV-preventive treatment, but the patient may have 
stopped or not have taken the medication because of an adverse effect or 
unwillingness to use it. We collected data on this issue in our questionnaire after 1 
year. However, since such a small proportion of patients visited the GP in the first 
place, and medication was not started in most of those patients, the non-adherence 
issue was present in only a very small number of patients, and we did not report 
these data in detail. Conclusion Our results show that when screening indicates the 
need for cardiopreventive treatment, this is generally not done, despite information 
being provided to patients and their primary care physicians or internists, resulting 
in suboptimal CVriskmanagement. Although both patients and GPs received 
information on CV risk, only a small proportion of patients at high CVD risk visited 
their GP. Increasing this percentage is an important first step towards improved CV 
risk management. This could be solved by more intensive counselling (e.g. by 
motivational interviewing) as well as an immediate follow-up to check whether 
appropriate therapy has been initiated. This is an implementation project that will 
be initiated shortly at our centres. 
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CHAPTER 5
Change in cardiovascular risk after 
initiation of anti-rheumatic treatment in 
early rheumatoid arthritis
S Turk, M Heslinga, J Twisk, V van der Lugt, W Lems, 
D van Schaardenburg, M Nurmohamed
A shorter version of this chapter was accepted for publication as Letter in
Clin Exp Rheumatol. 2019 May-Jun;37(3):513




To determine if cardiovascular (CV) risk scores, traditional risk factors and the 
resulting indication for preventive treatment change after initiation of anti-
rheumatic treatment in early rheumatoid arthritis (RA) patients.
Methods
Disease activity, blood pressure, acute phase proteins and lipid profile were 
evaluated in early RA patients at baseline and after four weeks of anti-rheumatic 
treatment. CV risk scores (Dutch Systematic Coronary Risk Evaluation (SCORE) and 
European Heart SCORE) and indication for preventive CV treatment (according to 
the Dutch CV risk management guidelines) were determined.
Results
One hundred and four consecutive RA patients were included, 7% had a history of 
CV disease. At baseline, 29.9% and 3.1% were classified as high risk according to 
the Dutch SCORE and Heart SCORE, respectively. According to the Dutch CV-risk 
management guidelines that use the Dutch SCORE, all high risk patients had at 
baseline an indication for (adaptations of) preventive treatment. From the CV risk 
score the components blood pressure and TC:HDL ratio decreased during anti-
rheumatic treatment and 9% of the patients switched their CV risk category. In 
total 13% of the patients had a change in advice for preventive CV treatment after 
one month of anti-rheumatic treatment.
Conclusion
CV risk management is important in RA patients, however the timing of assessment, 
as well as the use of a particular CV risk model, influences the advice about the 
need for CV preventive treatment. Further research is needed to determine which 




Ischemic heart diseases and strokes are the most common causes of death, 
accounting together for 15 million deaths in 2015 (1). Different cardiovascular 
(CV) risk models exist, which estimate the 10-year risk of fatal and non-fatal CV 
diseases (CVD), and indicate if an antihypertensive and/or statin is necessary to 
lower the chance of a future CV event (2-5). Rheumatoid arthritis (RA) is associated 
with an increased risk of CVD, with atherosclerotic diseases being the leading 
cause of death (6;7). CV risk models were developed for the general population 
and do not perform well in the RA population(4). Therefore, the European League 
Against Rheumatism (EULAR) recommends to use a modified risk score for RA 
patients, by applying a multiplication factor of 1.5 to the CV risk scores (8). In the 
Dutch Systematic COronary Risk Evaluation (SCORE) a correction for RA patients is 
already taken into account (2;4;5).
The increased risk in RA patients for CVD has multiple causes. RA and CVD are 
both multifactorial disorders, with some shared risk factors (smoking, metabolic 
syndrome), common susceptibility genes and they might even have a shared 
etiology (6;9-13). However, most interesting is the influence of inflammation on 
CVD. Current evidence supports an important role of inflammation in the formation 
of an atherosclerotic plaque (14;15). Previous literature showed that improvement 
in RA disease activity is associated with an increase in cholesterol levels, and a 
decrease in TC:HDL ratio; an important CV risk predictor (16). However, all previous 
studies assessed the change in lipid profile six months or later after initiation 
of anti-rheumatic treatment (16-19). It is unclear whether this effect is already 
present early after initiating treatment and what effect this would have on CV 
risk and optimal CV risk management. Therefore, different CV risk scores (Dutch 
SCORE and European Heart SCORE), the traditional risk factors and indication for 
preventive treatment were determined in early RA patients before and after the 
first four weeks of anti-rheumatic treatment. Exploratory analysis were performed 
to determine the effect of inflammation on CV risk score, as well as the relation 




The ‘Early Arthritis Cohort’ at Reade in Amsterdam, the Netherlands, includes 
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patients aged 18 years and older, with no prior treatment with disease-modifying 
antirheumatic drugs (DMARDs). Patients in this cohort who fulfilled the ACR/
EULAR 2010 criteria for RA (20) and started treatment with methotrexate and 
glucocorticoids, between June 2014 and March 2017, were included in this study. 
Patients with insulin-dependent diabetes mellitus were excluded. All patients gave 
written informed consent according to the Declaration of Helsinki and approval was 
obtained from the local ethics committee (Ethics Committee of the Slotervaart 
Hospital and Reade, Amsterdam, The Netherlands). 
Measurements
At baseline, patients were interviewed to record details about symptom history, 
disease history (special focus on CVD), clinical characteristics, demographics and 
medication use (including antihypertensives and statins).
At baseline and after four weeks, disease activity was measured with the Disease 
Activity Score of 44 joints (DAS44) and physical functioning by the Health 
Assessment Questionnaire (HAQ). Body mass index (BMI) was calculated from height 
and weight and blood pressure was measured manually according to the standard 
hospital procedures. Blood sample measurements at baseline were rheumatoid 
factor (RF) and anti-citrullinated protein antibody (ACPA), and at baseline and four 
weeks: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and lipid 
profile, consisting of total cholesterol (TC), triglycerides, low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL) cholesterol.
Cardiovascular risk
CVD history was defined as an objectively confirmed by specialists history of 
coronary heart disease (myocardial infarction, angina pectoris, percutaneous 
coronary intervention and coronary artery bypass surgery, cerebral vascular 
disease and peripheral arterial disease). Patients with a CVD history were excluded 
from CV risk analyses. CV risk at baseline and after four weeks of treatment was 
retrospectively determined using the official online sites, according to two different 
risk scores: Dutch Systematic COronary Risk Evaluation (SCORE) and the European 
Heart SCORE (2;3). The Dutch SCORE risk model uses gender, age, smoking status, 
systolic blood pressure (SBP) and the TC:HDL ratio. To account for RA (or diabetes) 
as risk factor the Dutch CV-risk management (CV-RM) guideline adds 15 years to 
the actual age in order to calculate the 10-year CV risk. A risk<10% is classified as 
low, between 10% and 20% intermediate and a risk ≥20% as high risk. According 
to the Dutch CV-RM guideline, preventive treatment with an antihypertensive or 
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statin is indicated in high risk patients with a SBP >140 mmHg or a LDL> 2.5 mmol/l, 
respectively (21). The European Heart SCORE risk model predicts the 10-year risk 
of a fatal heart attack, stroke or other circulatory problems in low risk regions of 
Europe by gender, age, SBP, TC:HDL ratio and smoking status. To calculate this 
Heart SCORE risk the results were multiplied with 1.5, which is suggested for RA 
patients in the updated EULAR 2015/2016 recommendations (8). The Heart SCORE 
considers a risk of <5% as low/medium, between 5 and 10% as high and ≥10% as 
very high. To be able to compare the Heart SCORE with the Dutch SCORE, we 
considered a Heart SCORE risk of <5% as low, a risk between 5 and 10% as medium 
and a risk ≥10% as high. 
Statistical analyses
Patient characteristics were expressed as number (percentage), means ± standard 
deviation (SD), when normally distributed or median [interquartile range], when 
skewed distributed. 
Changes in inflammation markers and (components of) the risk scores over 
four weeks of treatment were analyzed with a paired t-test (normal distributed) 
or Wilcoxon test (skewed distributed). The relation between the two CV risk 
scores was determined with a Spearman correlation coefficient, the percentage 
of agreement, as well as a weighted kappa. Kappa can be interpreted as the 
percentage of agreement after correcting for chance(<0 indicates no agreement, 
0 to 0.2 slight, 0.21 to 0.40 fair, 0.41 to 0.60 moderate, 0.61 to 0.80 substantial and 
0.81 to 1.0 as almost perfect agreement)(22;23). The numbers of patients that were 
reassigned to another CV risk group (low, medium or high) after four weeks of 
treatment, according to the two risk scores were calculated, and Stuart-Maxwell 
analyses were applied.
To analyse the association between CV risk score and disease activity, tobit mixed 
model analyses were performed. Tobit mixed model analysis can be used when 
the outcome is either left- or right censored (like the maximum risk score in de 
CVD models)(24). The individual components of the CV risk scores were compared 
with disease activity, by linear mixed model analyses and excluded patients who 
used antihypertensive drugs or statins in analysis which involved blood pressure 
or cholesterol, respectively. In the mixed model analyses time and the interaction 
between time and the independent variable were added to assess the relationship 
at the different time points and all analyses were performed separately for males 
and females and were adjusted for age and smoking. The tobit and Stuart-Maxwell 
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analyses were performed with Stata (version 14), all other statistical analyses were 
performed using SPSS (version 21.0).
RESULTS
In total 153 patients were eligible to participate, of which 104 were included in the 
current analyses. Reasons not to include patients for analyses were: three patients 
did not reach week four, 37 patients did not start on methotrexate in combination 
with prednisolone, four patients dropped out before week four, three patients 
had no complete data at baseline and two patients did not fulfil the ACR/EULAR 
2010 criteria for RA. The mean age of the included patients was 49 years and 67% 
was female. The mean DAS44 was 3.5 which decreased after one month of anti-
rheumatic treatment to 1.6. A history of CVD was present in seven patients (7%). 
The following conditions were present: one patient with a myocardial infarction, 
one patient with a percutaneous coronary intervention, one patient with a coronary 
artery bypass surgery, three patients with a cerebral vascular disease and one 
patient with peripheral arterial disease. No patients experienced a CV event during 
the first four weeks of anti-rheumatic treatment. Twenty-six (25.0%) patients 
smoked at baseline, and one quit smoking during these four weeks. Five patients 
used a statin and 16 patients used antihypertensive drugs, which did not change 
during follow-up (Table 1). 
Table 1 | Demographics and outcomes at baseline and after four weeks of anti-rheumatic 
treatment
Baseline After 4 weeks
Demographics
Age 48.5  (12.4)
Gender (females) 70  (67.3%)
Symptom duration (months) 7.0  [3.0-21.0]
RF positive 82  (78.8%)
ACPA positive 86  (82.7%)
RF or ACPA positive 89  (86%)
RA disease
DAS44 3.5  (3.3) 1.6  (0.9)*
VAS44 61.4  (27.2) 22.3  (22.6)*
SJC44 8.0  [3.0-13.0] 2.0  [0.0-3.3]*
TJC44 8.0  [4.0-16.0] 1.5  [1.5-5.0]*
table continues
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Baseline After 4 weeks
ESR 20.5  [9.0-32.8] 7.0  [5.0-12.0]*
CRP 7.2  [3.8-25.0] 2.0  [0.9-4.1]*
HAQ 1.0  [0.5-1.6] 0.3  [0.0-0.6]*
CV risk components
History of CV events 7  (6.7%) 7  (6.7%)
Current smoking 26  (25.0%) 25  (24%)
Statin use 5  (4.8%) 5  (4.8%)
Antihypertensive use 16  (15.4%) 16  (15.4%)
BMI 26.1  (5.3) 26.3  (5.4)
Syst RR‡ 130.8  (22.5) 127.8  (17.7)
Dia RR‡ 80.5  (11.5) 78.4  (10.0)*
TC† 5.0  (0.9) 5.7  (1.1)*
HDL† 1.4  (0.4) 1.9  (0.5)*
LDL† 3.2  (0.8) 3.3  (0.9)*
Trigly† 1.3  (0.6) 1.5  (0.8)*
TC:HDL ratio† 3.9  (1.3) 3.2  (1.0)*
CV risk scores
Dutch SCORE linear risk score ∆ 11.0  [3.5-23.5] 10.0  [3.0-22.0]*
Dutch SCORE low risk score∆ 43  (44.3%) 46  (47.4%)
Dutch SCORE medium risk score∆ 25  (25.8%) 20 (20.6%)
Dutch SCORE high risk score∆ 29  (29.9%) 31  (32.0%)
Heart SCORE linear risk score∆ 0.0  [0.0-1.5] 0.0 [0.0-1.5]*
Heart SCORE low risk score∆ 90  (92.8%) 94  (96.9%)
Heart SCORE medium risk score∆ 4  (4.1%) 1  (1.0%)
Heart SCORE high risk score∆ 3  (3.1%) 2  (2.1%)
Numbers are presented as frequency (percentage),  mean (SD) or median [IQR].
∆ Patients without cardiovascular events, n=97 
‡ Patients without antihypertensives, n=88
† Patients without statins, n=99
* Statistical difference (p<0.05) between baseline and after four weeks
ACPA: anti-citrullinated protein antibody, BMI: body mass index, CRP: C-reactive protein, 
CV: cardiovascular, DAS: disease activity score, Dia RR: diastolic blood pressure, ESR: 
erythrocyte sedimentation rate, HAQ: health assessment questionnaire, HDL: high-density 
lipoprotein, IQR: interquartile range, LDL: low-density lipoprotein, RA: rheumatoid arthritis, 
RF: rheumatoid factor, SCORE: Systematic Coronary Risk Evaluation, SD: standard deviation, 
SJC: swollen joint count, Syst RR: systolic blood pressure, TC: total cholesterol, TJC: tender 
joint count, trigly: triglycerides, VAS: visual analogue scale
Cardiovascular risk score at baseline
At baseline median Dutch SCORE and Heart SCORE were 11.0% [3.5-23.5] and 0.0% 
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[0.0-1.5], respectively, see table 1. The correlation between absolute values of the 
Dutch SCORE and Heart SCORE gave a spearman coefficient of 0.79 with a p-value 
of <0.01. The agreement between the different risk categories (low, medium, high) 
was 62.4%, and gave a slight correlation (Ƙ=0.13, p<0.01). The Dutch risk model 
classified 29.9% of the patients as high risk, were the Heart SCORE risk model 
classified 3.1% of the patients as high risk. Three patients (3.1%) had a high risk 
according to both the CV risk models. 
Of the 29 (29.9%) high CV risk patients according to the Dutch SCORE, 28 patients 
had an increased LDL and, according to the CV-RM guidelines, a statin indication. 
One patient already used a statin and thus needed dose optimization. Nineteen 
of the 29 patients had an increased SBP and therefore needed antihypertensive 
treatment, of those patients seven already had an antihypertensive, but needed 
dose optimization. In total all 29 high risk patients (29.9%) had an indication for 
(adaptations of) preventive treatment. 
The change in cardiovascular risk score after four weeks
The number of patients that changed in CV risk category (low, medium, high) was 
not significantly different in both calculators. According to the Dutch SCORE nine 
(9.3%) patients switched from risk category, of which five patients went to a lower 
category and four patients to a higher category. In the Heart SCORE four (4.1%) 
patients changed from category, see figure 1. 
The Dutch SCORE risk model showed that 31 (32.0%) patients were at high risk 
after four weeks. Twenty-seven (27.8%) patients had an increased LDL, thus an 
indication for statin treatment. Of the 27 patients, one already used a statin. Of the 
31 patients, 13 (13.4%) patients had an increased blood pressure, thus in need of 
antihypertensive treatment of which five needed dose optimization. 
In total three patients were indicated for a statin at baseline, but not anymore after 
four weeks and two patients did not need statins at baseline, but did after four 
weeks. Six patients had an antihypertensive indication at baseline and two doses 
optimization, but not at four weeks and two patients needed antihypertensives 
based at the values of four weeks, but not at baseline. This included one patient 
who was indicated for a statin and an antihypertensive at baseline, but not after 
four weeks, and one patient the other way around. In conclusion, in 13 (13.4%) 
patients the advice for (adaptations of) preventive treatment changed during the 
first four weeks of anti-rheumatic treatment.    
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Figure 1 | Number of patients that changed from cardiovascular risk score category, during 
the first month of anti-rheumatic treatment, according to the Dutch SCORE (A) and European 
Heart SCORE (B), n=97
Stuart-maxwell analyses for Dutch SCORE, p=0.247.
Stuart-maxwell analyses for Heart SCORE risk score, p=0.135.
(Components of) Cardiovascular risk scores and the association with 
disease activity
The DAS44 of all patients improved during follow-up. Lipid levels increased during 
treatment, especially HDL, which resulted in a decrease in TC:HDL ratio from 3.9 
(1.3) at baseline to 3.2 (1.0) after four weeks of anti-rheumatic treatment. The mean 
blood pressure decreased with 3 mmHg for systolic and 2 mmHg for diastolic blood 
pressure (Table 1). 
The results of the tobit mixed model analyses relating disease activity with CV 
risk scores were inconclusive. A higher DAS44 was associated with a lower CV risk 
score, which showed a stronger effect after four weeks. However, the presence of 
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a higher ESR and CRP had no effect at baseline and were after four weeks related 
with higher CV risk scores (Table 2). 
The linear mixed model analyses relating disease activity with the separated 
components of the CV risk scores showed that a higher DAS44 was associated 
with lower lipid levels, and an increase in TC:HDL ratio, especially at baseline. For 
ESR and CRP comparable results were observed. The association between disease 
activity and blood pressure gave inconclusive results (Table 3).
Table 2 |  Mean effect over time for baseline and week four values, between disease activity 
and cardiovascular risk scores (with interaction with the time)
Dutch SCORE HeartSCORE

































CI: confidence interval, CRP: C-reactive protein, DAS: disease activity score, ESR: 
erythrocyte sedimentation rate, SJC: swollen joint count
Grey values: values after four weeks of treatment
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DISCUSSION
Comparison between the Dutch SCORE and Heart SCORE CV risk models revealed a 
slight agreement between low, medium and high CV risk categories. 
According to the Dutch CV-RM guidelines, 30% of the early RA patients had an 
indication for (adaptations of) preventive treatment at baseline. However, 13% 
of all the patients had a different indication after four weeks of anti-rheumatic 
treatment. If baseline CV risk assessment would be applied, this would lead to 
potential overtreatment in 10% of all the patients.  
The risk estimation of the two different CV risk calculators resulted in a significant 
difference in CV risk score. Clinically this will have an impact on the therapy and 
prevention strategies chosen, as a patient who is regarded as low risk by one 
calculator could be classified as high risk by another, and vice versa(7). The Dutch 
SCORE estimates more patients as high risk, 10 times more often than the Heart 
SCORE. Overestimating the CV risk can lead to unnecessary treatment, while 
underestimating may result in CV diseases which could have been prevented. This 
is partly explained as the Dutch SCORE measures the 10-year risk on CV morbidity 
and mortality, and the Heart SCORE only assesses the risk on mortality and does 
not take non-fatal CV events into account (5). However, morbidity can cause 
functional limitations, therefore it is important for patients and society, and should 
be taken into account in a CV risk model. In conclusion, it is important to know the 
limitations of the CV risk calculator which estimated the CV risk of your patient.  
 
CV preventive treatment is proven to be effective, therefore it is important to assess 
CV risk (25-27). As an increased CV risk is already present in early RA, and might 
even be present in the preclinical phase, CV risk management should be applied 
early in the disease course (5;28-32). In the present study, we found that, according 
to the Dutch SCORE, already 30% of the patients were classified as high CV risk at 
the onset of RA. However, many patients were classified in a different risk category 
after the first month of anti-rheumatic treatment. In 13% of the patients, this led 
to a change in preventive treatment advice. This percentage would probably be 
lower when applying Heart SCORE, as more patients were calculated as low risk 
according to this risk model, and so less patients switched from risk category 
during follow-up. Still, both at baseline and after four weeks of anti-rheumatic 
treatment many patients needed CV preventive treatment according to the Dutch 
CV-RM guidelines and did not receive this, reflecting under-treatment, confirming 
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previous reports (33-35). 
A higher disease activity was associated with an increased TC:HDL ratio, however 
the effect of disease activity on the Dutch CV risk SCORE gave inconclusive results. 
On the one hand, an increase in DAS44 was associated with lower CV risk, but on 
the other hand, higher ESR and CRP were associated with higher CV risk scores. 
Because inflammation generally leads to an increased TC:HDL ratio, a higher CV 
risk is expected if markers of inflammation are high (18;19). This association was 
opposite for DAS44, a possibility is that other components of the DAS like the visual 
analogue scale and/or tender joint count disturb this association. The association 
between measures of inflammation and cholesterol levels, especially TC:HDL 
ratio was strongest at baseline, when all patients had a high disease activity. At 
four weeks, nearly all patients had low disease activity, which explains why this 
association was not present anymore after four weeks. Although there was no 
unambiguous association between disease activity and CV risk score, we do think 
that it is important to calculate CV risk during a time of low disease activity. 
The change in CV risk score and so the advice about preventive treatment is 
probably correlated with the reduction of disease activity or the initiation of anti-
rheumatic treatment. Previous literature described a reduction in acute myocardial 
infarction with the use of methotrexate (RR 0.81), but a dose-dependent increase 
with glucocorticoid use (RR 1.32) (36-38). An improvement in TC:HDL ratio was 
found after one and two years of COBRA-light treatment, however this did not had 
a favorable effect on CV risk prediction (18;19). Furthermore, lower disease activity 
(obtained with anti-rheumatic treatment) was associated with a lower blood 
pressure (39;40). 
Unfortunately, we could not take into account some additional CV risk factors, 
such as renal function, physical activity and family history of CVD. These factors 
are considered as CV risk modifying factors which can be an additional reason to 
give CV risk prevention treatment. Therefore, the lack of these factors may have 
influenced our results. 
In addition to  the Dutch SCORE and Heart SCORE, different CV risk scores are 
available. For example, the Framingham risk score is commonly  used in the United 
States. However, this score is not generally applied in Europe and is limited to 
estimating the 10-year risk of a myocardial infarction and coronary heart disease-
related death, thus underestimating the total atherosclerotic vascular disease 
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risk(31;41). Especially, risk calculators that correct for the Systematic inflammation 
are interesting. For example, the QRISK-2 and QRISK-3 calculators are used to 
predict CV risk in the United Kingdom, these calculators take RA into account as 
a separate CV risk factor. As a zip code is also a component of these algorithms, 
these calculators are not feasible in other countries (5;42). The Reynolds Risk 
score includes high-sensitivity CRP levels into the risk model, however this risk 
score is not recommended for patients with a Systematic inflammatory disease, 
as CRP levels will be increased due to the inflammatory disease (5). Further efforts 
were already performed to develop a RA-specific risk calculator, however, a new 
calculator (including DAS or HAQ) did not demonstrate an improvement compared 
to the current CV risk models which are used in the general population (43;44). 
The influence of fluctuations in disease activity over time in RA patients is difficult 
to incorporate in risk prediction models; single disease activity measurements 
(as DAS, CRP and ESR) are maybe not good enough, a biomarker that measures 
cumulative RA disease activity might fulfill this unmet need (44).
In conclusion, CV risk management is important early in the course of RA, as 
preventive CV treatment is proven to be effective and should be applied as early 
as possible (5;25-27;31). However, the timing of CV risk assessment, as well as 
the availability of different CV risk models, influences the advice on the need for 
(adaptations of) CV preventive treatment. Further research is needed to determine 
which risk model is optimal and when in the course of RA it should be applied. 
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This study aims to assess the prevalence proportion and incidence rate of 
cardiovascular morbidity in patients with inflammatory arthritis compared with that 
in controls, and to determine whether the co-existence of multiple autoimmune 
disorders is associated with an amplified risk of cardiovascular disease.
Methods
Data from the Nivel Primary Care Database were used to assess prevalence 
proportion and incidence rate of cardiovascular disease in patients with 
inflammatory arthritis only, patients with inflammatory arthritis coexistent with 
another autoimmune disorder, and controls. Hazard ratios were calculated using 
Cox regression models.
Results
The prevalence proportions in inflammatory arthritis patients were increased for 
type 1 diabetes [odds ratio (OR) 1.80, 95% CI: 1.27, 2.55], hypothyroidism (OR 1.49, 
95% CI: 1.37, 1.61), psoriasis (OR 2.72, 95% CI: 2.49, 2.97) and IBD (OR 2.64, 95% CI: 
2.28, 3.07) compared with that in controls. Cardiovascular disease prevalence (OR 
1.34, 95% CI: 1.28, 1.41) and incidence rates (incidence rate ratio 1.3, 95% CI: 1.23, 
1.41) were higher in inflammatory arthritis patients compared with that in controls, 
and were further increased in the presence of a second autoimmune disorder. The 
hazard ratio for cardiovascular disease was 1.32 (95% CI: 1.23, 1.41) for patients 
with inflammatory arthritis only, and 1.49 (95% CI: 1.31, 1.68) for patients with 
inflammatory arthritis co-existent with another autoimmune disorder.
Conclusion
The amplification of cardiovascular disease risk in inflammatory arthritis patients 
with multiple autoimmune disorders warrants greater awareness, and since 
autoimmune disorders often co-exist, the need for cardiovascular risk management 
in these patients is once again emphasized.
115
INTRODUCTION
Inflammatory arthritis (IA) is an overarching term used to describe a group of 
conditions defined by inflammation of the joints. These diseases include, among 
others, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. IA is 
associated with an excessive risk of cardiovascular mortality and morbidity (1-3).
Traditional and non-traditional cardiovascular risk factors, such as hypertension, 
dyslipidemia, smoking and obesity, inflammation, use of medication, e.g. NSAIDs 
and glucocorticoids, and also genetic factors contribute to this increased risk for 
cardiovascular disease (CVD)(3). A higher cardiovascular burden is not only found 
in inflammatory arthritis (IA) patients, but also in other inflammatory auto-immune 
disorders, such as psoriasis and inflammatory bowel disease (IBD), including 
Crohn’s disease and ulcerative colitis (5, 6). Diabetes mellitus is a well-known risk 
factor for CVD, both type 1 and 2 have been associated with increased CVD risk 
(7,8). Raterman et al demonstrated that the co-existence of hypothyroidism and 
rheumatoid arthritis is associated with an amplified CVD prevalence (9). In all of 
these disorders, it is considered that chronic (low grade) inflammation has a role in 
the pathogenesis of the accelerated atherosclerosis (10). This raises the question 
if cardiovascular risk is amplified in IA patients with co-existent auto-immune 
disorder. 
This study aims to assess the prevalence proportion and incidence rate of 
cardiovascular morbidity in patients with inflammatory arthritis compared to 
controls, and to determine if the co-existence of multiple autoimmune disorders is 
associated with amplified risk of CVD. An increased CVD risk for IA patients has been 
demonstrated by many studies; however it is yet unknown if other auto-immune 
disorders are more common in IA patients and how this affects CVD risk. Thus far, the 
vast majority of studies is performed on a selected group of arthritis patients from 
academic clinics. Data from a representative IA population, consisting of patients 
with both high and low disease activity, are sparse. It’s important to investigate CVD 
incidence rate and prevalence proportion in primary care patients, since data from 
a secondary setting might overestimate the magnitude of cardiovascular risk as 
patients with more severe disease exaggerate CVD rates. For this study, we used 
data originating from Dutch general practitioners (GP) electronic health records, in 
which GPs record medical information using recorded International Classification 
of Primary Care (ICPC) diagnoses (11).




Data from Nivel Primary Care Database (Nivel-PCD) were used (12). Data were 
retrieved from EHRs from a sample of approximately 500 general practices with 
more than  1.5 million registered patients spread throughout the Netherlands. 
The International Classification of Primary Care (ICPC) is used to record medical 
diagnoses (11). The EHRs contain information on consultations, morbidity, 
prescriptions and diagnostic measures. When a prescription is issued, a diagnostic 
code is recorded and the selected drug is automatically linked to the Anatomical 
Therapeutic Chemical (ATC) Classification System (13). The patients and general 
practices are representative of the Dutch population. Since almost all Dutch citizens 
are registered at a primary care practice, Nivel-PCD does also contain patients 
who do not visit their GP on a regular basis. Furthermore, it is possible to estimate 
an epidemiological denominator. This study has been approved according to the 
governance code of Nivel-PCD, under number NZR-00317.041. Dutch law allows the 
use of electronic health records for research purposes under certain conditions. 
According to this legislation, neither obtaining informed consent from patients nor 
approval by a medical ethics committee is obligatory for this type of observational 
studies containing no directly identifiable data (Dutch Civil Law, Article 7:458). 
Our study database spanned the period January 1, 2010 through January 1, 2017. 
The start of follow up was defined as the date of cohort entry or in the case of 
incident IA, controls became cases with a start of follow up from the moment of 
the diagnosis. Patients and the public were not involved in the design, conduct or 
reporting of the research.
Selection of IA patients and controls
All patients who were recorded as having inflammatory arthritis (IA), based on 
ICPC-code L88 – ‘Rheumatoid arthritis and related disorders’, were selected for 
this study (11). The date of diagnosis is recorded in the database, this holds true 
for both incident and prevalent cases in whom the diagnosis was made before 1 
January 2010. Selection based on this code might include some non-IA patients, 
and therefore we also performed our analysis using only subjects with an ICPC-
code L88 in combination with specific anti-rheumatic drug prescriptions. Since 
this yielded similar results (a stronger effect size but less power), we only show 
the analyses using  the larger group (selection on code L88 only). We matched all IA 
patients (cases) with controls (patients without ICPC code L88) in a 1:1 ratio, by age 
and sex in the same general practice. If a control subject received a diagnosis of 
IA during follow up, they became a case subject, and were subsequently matched. 
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Classification of auto-immune diseases
This study used a combination of recorded diagnoses and prescribed medication to 
determine whether the patient was diagnosed as having type 1 diabetes  (ICPC code 
T90 and the start of insulin within the first year after recording the diagnostic code), 
hypothyroidism (ICPC code T86), psoriasis (ICPC code S91), multiple sclerosis (ICPC 
code N86), Crohn’s disease and ulcerative colitis (ICPC code D94). The incidence 
rate and prevalence proportion of cardiovascular disease (CVD) were determined 
by recorded ICPC codes angina pectoris (K74), acute myocardial infarction (K75), 
other ischemic heart disease (K76), transient ischemic attack (TIA) (K89), stroke 
(K90), peripheral arterial disease (K92), decompensatio cordis (K77) and cor 
pulmonale (K82). In the tables we have used the term heart failure to include the 
diseases documented as decompensatio cordis and cor pulmonale. The composite 
variable CVD was composed of angina pectoris , acute myocardial infarction and 
other ischemic heart disease, cerebrovascular disease was composed of TIA and 
stroke, and heart failure of decompensatio cordis and cor pulmonale. When the 
outcome all CVD is used, this consist of all the above mentioned CVD diagnoses.  
Statistical analyses
First, we determined the prevalence proportion of CVD and risk factors in IA 
patients compared to controls using logistic regression techniques. We assessed 
the prevalence proportion of CVD in three groups: controls, patients with only IA, 
and patients with IA with another coexistent auto-immune disorder. We regarded 
patients with IA and any other auto-immune disorder, but also calculated risks for 
the individual other auto-immune disorders separately. Incidence rate of CVD was 
assessed in patients without CVD at baseline by calculating incidence rates and 
incidence rate ratio’s. Hazard ratios were calculated using cox regression models. 
All statistical analyses were performed with Stata/SE 15.0 (StataCorp, College 
Station, TX, USA).
RESULTS
Prevalence rate of auto-immune disorders
We identified 28,345 IA cases with 28,249 matched controls. Two-thirds of 
the patients were female, the mean age was 60 years. We found an increased 
prevalence proportion of type 1 diabetes mellitus, hypothyroidism, psoriasis 
and Crohn’s disease and ulcerative colitis in the IA population. On the other side, 
the prevalence proportion of multiple sclerosis was lower in cases compared to 
controls, but the absolute prevalence of multiple sclerosis in this cohort was very 
Chapter 6. Amplified prevalence and incidence of cardiovascular disease
118
small, only 5 cases, limiting the clinical significance of this finding. IA patients 
had an increased risk for other auto-immune diseases, with highest odds ratio 
for psoriasis [2.72 (2.49 - 2.97)] (table 1). However, the odds for prevalent multiple 
sclerosis was decreased in IA patients. Furthermore, patients with IA more often 
had one or more concomitant auto-immune disorders: in 13.5% of IA patients one 
auto-immune disorder other than IA was present vs in 7.3% of non-IA controls. 







Type 1 diabetes 0.31 0.17* 1.80 (1.27 – 2.55)*
Hypothyroidism 5.76 3.97* 1.49 (1.37 – 1.61)
Psoriasis 6.43 2.46* 2.72 (2.49 - 2.97)
Multiple sclerosis 0.15 0.24 0.64 (0.44 – 0.94)
Crohn's disease and ulcerative colitis 2.22 0.85* 2.64 (2.28 – 3.07)
1 other auto-immune disorder 13.45 7.31 1.97 (1.86 – 2.09)*
2 other auto-immune disorders 0.70 0.19 3.76 (2.77 – 5.09)*
*=p<0.001, CI = confidence interval, odds ratios are corrected for age and sex 
Prevalence proportion is displayed as absolute percentage
Prevalence proportion of cardiovascular disease
Compared with controls, patients with IA had an increased prevalence proportion 
of all cardiovascular disease (corrected OR 1.34, 95% CI 1.28 – 1.41), as well as an 
increased prevalence proportion of hypertension (OR 1.23, 95% CI 1.18 – 1.27) 
and hypercholesterolemia (OR 1.09, 95% CI 1.03 – 1.15) (table 2). Correction for 
hypertension, hypercholesterolemia and diabetes yielded similar data (data not 
shown).
 
Table 2 | Prevalence proportion (%) of cardiovascular disease and risk factors
Inflammatory arthritis Controls Odds ratio 
(95% CI)
Prevalence proportion of total CVD 18.84 15.5 1.34 (1.28 – 1.41)*
   Coronary artery disease 9.9 7.98 1.27 (1.20 – 1.35)*
   Cerebrovascular disease 4.9 4.55 1.07 (0.99 – 1.15)
   Heart failure 4.15 2.92 1.43 (1.31 – 1.58)*
   Peripheral vascular disease 3.9 2.69 1.46 (1.33 – 1.61)*
table continues
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Inflammatory arthritis Controls Odds ratio 
(95% CI)
Prevalence proportion of CV risk factors
  Hypertension 32.84 28.94 1.23 (1.18 – 1.27)*
  Hypercholesterolemia 12.16 11.23 1.09 (1.03 – 1.15)*
Use of cardiopreventive medication
  Anticoagulants 29.57 26.65 1.39 (1.34 – 1.45)*
  Antihypertensive medication 47.57 40.7 1.40 (1.35 – 1.45)*
  Statin 3.9 2.69 1.22 (1.18 – 1.27)*
Prevalence proportion is displayed as percentage 
*=p<0.001, CI = confidence interval, CVD = cardiovascular disease 
Odds ratios are corrected for age and sex 
Next, we examined if the risk for prevalent CVD was increased if there was a co-
existent other autoimmune disorder. We found that for all outcomes, the risk 
increased for IA patients and this was further amplified if another auto-immune 
disorder was present (table 3). Correction for hypertension, hypocholesteremia 
and diabetes yielded similar data (data not shown). 






Inflammatory arthritis + 
any other autoimmune 
disorder
Odds ratio (95% CI)
All CVD 1 1.34 (1.27 – 1.41)* 1.72 (1.57 – 1.89)*
Coronary heart disease 1 1.26 (1.18 – 1.35)* 1.72 (1.54 – 1.92)*
Cerebrovascular disease 1 1.07 (0.99 – 1.17) 1.22 (1.04 – 1.42)
Heart failure 1 1.44 (1.30 – 1.59)* 1.88 (1.59 – 2.22)*
Peripheral vascular disease 1 1.45 (1.31 – 1.61)* 1.70 (1.43 – 2.01)*
Prevalence proportion of CV risk 
factors
1 1.21 (1.16 – 1.26)* 1.60 (1.49 – 1.73)*
Use of cardioprotective medication 1 1.43 (1.37 – 1.49)* 1.81 (1.68 – 1.96)*
*=p<0.001, CI = confidence interval, CVD = cardiovascular disease 
Odds ratios are corrected for age and sex
The risk amplification was also found when we looked separately at the addition of 
individual auto-immune disorders. The risk increase was largest if there was co-
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existent type 1 diabetes (OR 3.55, 95% CI 2.08 – 6.06, p<0.001), but was also present 
for the co-existence of hypothyroidism (1.81 (1.59 – 2.07), p<0.001), psoriasis (1.66 
(1.45 – 1.90), p<0.001) and Crohn’s disease and ulcerative colitis (1.50 (1.16 – 1.95), 
p=0.002) and MS (2.15 (0.88 – 5.28)), although the last did not reach statistical 
significance (supplementary table 1). 
Incidence rate of cardiovascular disease
In addition to prevalence proportions, we also examined the incidence rate of 
CVD. The median duration of follow up was 3.2 years, 3.1 for IA patients and 3.7 in 
controls. In IA patients, 1,969 new cases of CVD occurred in 69,195 person years, 
resulting in an incidence rate of 28.5. In controls, 1,555 new cases of CVD occurred 
in 72,013 person years, resulting in an incidence rate of 21.6 (table 4). Incidence 
ratios and hazard ratios were increased for all types of CVD for IA patients 
compared to controls (table 4) and remained significant after correction for 
diabetes, hypertension and hypercholesterolemia (data not shown). In addition to 
an increased prevalence proportion of CVD in the presence of other autoimmune 
disorders, we also found an increased incidence rate (table 5). 
Table 4 |  Inncidence rate of cardiovascular disease in cases and controls




# PY Rate # PY Rate
All CVD 1969 69195 28.5 1555 72013 21.6 1.3 (1.23 - 1.41)* 1.32 (1.24 – 1.41)*
Coronary heart 
disease
782 71584 10.9 640 73814 8.7 1.3 (1.13 – 1. 40)* 1.26 (1.13 – 1.39)*
Cerebrovascular 
disease
645 72160 8.9 575 74163 7.8 1.2 (1.03 – 1.29)* 1.14 (1.02 – 1.28) 
(p 0.018)
Heart failure 442 72671 6.1 260 74840 3.5 1.8 (1.50 –2.05)* 1.75 (1.50 – 2.04)*
Peripheral 
vascular disease
338 72705 4.6 237 74833 3.2 1.5 (1.24 – 1.74)* 1.46 (1.24 – 1.73)*
*=p<0.001, CI = confidence interval, hazard ratios are corrected for age and sex
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Table 5 | Risk of incident CVD (hazard ratio and 95% CI) for IA patients with and without a co-





Inflammatory arthritis + any 
other autoimmune disorder
All CVD 1 1.32 (1.23 – 1.41)* 1.49 (1.31 – 1.68)*
Coronary heart disease 1 1.29 (1.16 – 1.45)* 1.25 (1.01 – 1.54) (p 0.038)
Cerebrovascular disease 1 1.13 (1.0 – 1.27) (p 0.05) 1.44 (1.17 – 1.77) (p 0.001)
Heart failure 1 1.71 (1.45 – 2.01)* 1.90 (1.44 – 2.50)*
Peripheral vascular 
disease
1 1.41 (1.18 – 1.68)* 1.81 (1.35 – 2.43)*
*=p<0.001, CI = confidence interval, CVD = cardiovascular disease, odds ratios are corrected 
for age and sex
DISCUSSION
This study demonstrates an increased prevalence proportion of type 1 diabetes, 
hypothyroidism, psoriasis and Crohn’s disease/ulcerative colitis in patients with 
IA compared to controls. Moreover,, patients with IA more often had one or more 
concomitant auto-immune disorders. 
The clustering of auto-immune disorders has been described previously for RA, 
especially the co-occurrence of type 1 diabetes and hypothyroidism, and may 
be explained by involvement of shared cytokine pathways, like the interleukin 
and tumor necrosis factor (TNF) pathways and genetic pathways like the major 
histocompatibility complex (MHC) (14-18). For example, a polymorphism in the 
protein tyrosine phosphatase non-receptor type 22 (PTPN22) pathway is associated 
with RA,  diabetes and autoimmune thyroid disease, and might contribute to auto-
immunity by altering the thresholds for T and B cell receptor signaling(19, 20). 
Furthermore, predisposing factors to autoimmunity interact with environmental 
triggers such as exposure to certain infectious agents, drugs and smoking. And last, 
the presence of one autoimmune disease might render an individual at increased 
risk of other auto-immune disease by the body’s altered immunologic mechanisms 
or exposure to immunosuppressive drugs. Our data support that clustering of 
auto- immune diseases in IA patients is common and physicians should be alert on 
this phenomenon when treating patients with IA. 
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Moreover, the prevalence proportion and incidence rate of CVD, with the exception 
of cerebrovascular disease, were increased for patients with IA, independent of 
the cardiovascular risk factors hypertension, hypercholesteremia and diabetes. 
As cerebrovascular disease includes both ischemia and bleeding, a possible 
explanation for this exception could be that IA patients have only an increased risk 
of one of the types of CVA, most likely ischemic CVA.
An increased CVD incidence rate in IA patients was already demonstrated by 
several studies, mostly hospital based, whereas our present cohort comprises 
primary care patients from the general population (21). While a large proportion 
of IA patients visits both the general practitioner and a rheumatologist, there 
are patients that are only treated in primary care, i.e. patients with low disease 
activity. It is likely that our database contains patients with lesser disease activity 
compared to secondary care cohorts, and thus better estimates CVD risk for the 
IA population. Furthermore, we were able to show a longitudinal effect, since data 
used for this study are collected in a longitudinal matter, registering all occurring 
disease episodes, prescriptions and primary care visits. 
In addition, we found that the risk for prevalent and incident cardiovascular disease 
was increased in IA patients and that this was further amplified if another auto-
immune disorder was present. Given the already high cardiovascular burden in 
IA patients, it is relevant to detect any risk enhancing factors in these patients. 
Previously, Raterman et al showed that the co-existence of hypothyroidism and 
inflammatory arthritis is associated with an amplified CVD risk (9). An increased 
cardiovascular risk has also been reported in psoriasis and psoriatic arthritis (3). 
For Crohn’s disease and ulcerative colitis, and increased CV risk has been previously 
reported (5). There are several explanatory mechanisms behind the increased risk 
in the different auto-immune disorders, but a common denominator might be 
the chronic inflammatory state leading to accelerated atherosclerosis (10, 22). 
Currently, several guidelines for cardiovascular risk management incorporate RA 
as an additional CVD risk factor, although the exact risk increase for RA patients is 
not yet determined. Our data show that when more than one autoimmune disease 
is present, CVD risk is even further amplified, and should be taken into account 
when estimating CVD risk in IA patients.  
Some limitations need to be considered. First, the use of ICPC-code L88 consists 
of different diagnoses, including for example spondyloarthropathy. Therefore, 
misclassification is possible, also because GPs are not always able to establish the 
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exact diagnosis the first time. However, this would only mean that the observed 
effects are underestimated and the true effect is even larger. Furthermore, the 
diagnosis of IA is usually made by a rheumatologist, and primary care physicians 
then register the diagnosis mentioned in the medical correspondence. Second, data 
on smoking status and certain other cardiovascular risk factors were unavailable, 
and our analysis could not be adjusted for these variables. Furthermore, we could 
not take into account all possible auto-immune disorders, since not all diseases 
have an individual ICPC-code. Nevertheless, we demonstrated that the presence of 
co-existent auto-immune disorder in IA patients increased CV risk in a longitudinal 
primary care dataset consisting of a large amount of patients and controls 
representative of the general population. Working with large datasets has some 
limitations, but these do not outweigh the benefits of analyzing longitudinal data 
over a period of 6 years with detailed registration of disease episodes. 
In conclusion, because of the increased risk of a second autoimmune disorder in 
IA patients, physicians should screen for signs or symptoms of those diseases. 
Second, the amplification of CV risk in IA patients with multiple auto-immune 
disorders warrants awareness of this phenomenon and since auto-immune 
disorders often co-exists, the need for cardiovascular risk management in not only 
RA, but all IA patients especially with co-occurrent auto-immune disorder  is once 
again emphasized.
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CHAPTER 7
Co-existent subclinical hypothyroidism 
is associated with an increased risk of 
new cardiovascular events in rheumatoid 
arthritis - an explorative study
R Agca, M Heslinga, H Raterman, S Simsek, A Voskuyl, M Nurmohamed
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Autoimmune thyroid disease often coexists with rheumatoid arthritis (RA) and is 
associated with an elevated cardiovascular(CV) risk. However, studies in RA are 
scarce. To investigate whether autoimmune thyroid disease increases the risk of 
new CV disease (CVD) in RA. 
Methods
Thyroid-stimulating hormone (TSH) and serum free thyroxine(FT4) were assessed 
in 323 RA patients participating in an ongoing prospective cohort study designed 
to assess CV risk factors, morbidity and mortality. Cox proportional hazard models 
were used to calculate hazard rates (HR) for new CVD and adjusted for age, sex, 
smoking, prevalent CVD, thyroxine replacement therapy and RA duration. 
Results
Of the 323 participants, 65.3% were females aged 63 ± 7 years. At baseline 8.1% 
was hypothyroid (n=26, 16 clinical, 10 subclinical), 6.8% was hyperthyroid (n = 22, 13 
clinical, 9 subclinical) and 85.1% (n=275) was euthyroid. 94 patients (29.1%) developed 
a new CV event during follow up. Compared to the euthyroid patients, age, sex 
and prevalent CVD adjusted HR was 2.83 (95% CI 1.13-7.09 P=0.026) for subclinical 
hypothyroidism. Further adjustment for smoking, thyroxine replacement therapy 
and RA duration resulted in a HR of 3.0 (95% CI 1.19–7.54; P=0.02) for CV events in 
patients with subclinical hypothyroidism.
Conclusion
There was no difference in CVD between RA patients with hypothyroidism and 
hyperthyroidism vs. euthyroid patients. Coexistence of subclinical hypothyroidism 
with RA was associated with a higher occurrence of new CV events. Treatment 
trials are needed to determine whether thyroxine supplementation can further 
improve cardiovascular outcome in these patients.
Keywords




In patients with rheumatoid arthritis (RA) the cardiovascular (CV) disease (CVD) risk 
is doubled, leading to an excess mortality (1-3). Several factors contribute to this 
amplified risk, such as traditional CV risk factors, inflammatory burden and the 
use of certain anti-rheumatic medications (e.g. non-steroidal anti-inflammatory 
drugs (NSAIDs) and glucocorticoids) (4). It is unclear which (combination of) 
factors eventually lead to, and fully explain the increased CVD risk in RA. Hence, 
investigating novel pathogenic mechanisms and pathways is relevant. 
Coexistence of autoimmune thyroid disease with RA has been associated with an 
elevated CVD risk, especially in hypothyroid patients, with Raterman et al. reporting 
an odds ratio (OR) of 4.1 and McCoy et al. a hazard ratio (HR) of 2.0 for new CV events (5, 
6). For subclinical hypothyroidism (defined as normal free thyroxine concentrations 
with an elevated thyroid-stimulating hormone level), this association is much less 
consistent (7, 8). In the general population, the same is observed in hypothyroid 
patients, with relative risks (RR) of 1.15 for myocardial infarction (MI) and 1.96 for 
cardiac death when compared with euthyroid persons (7, 9-11). In addition, Ning et 
al. described an increased CV risk in subclinical hypothyroidism, especially in those 
with TSH levels of 10 mU/L or higher (9).  Several other studies report an increased 
CVD risk in persons with subclinical hypothyroidism in the general population (10-
12), but not all studies have found this association (13, 14).
Thyroid hormones exert a variety of positive effects on the cardiovascular system, 
such as a positive inotropic effect on the heart and a decrease in vascular resistance 
due to increased production of nitric oxide (15). In contrast, hypothyroidism 
is associated with lipid abnormalities that might contribute to accelerated 
atherosclerosis (8, 16). In line with this, we previously reported a fourfold higher risk 
of CVD in female RA patients with clinical hypothyroidism compared with euthyroid 
RA patients (17). Since the existing literature is mostly of cross-sectional origin 
(i.e. reporting prevalence of CVD in RA patients with thyroid dysfunction instead of 
incidence), we have assessed the relationship between thyroid abnormalities and 
new CV events in a previously described cohort of RA patients (5), now with long 
term follow up.




The CARRÉ (CARdiovascular research and RhEumatoid arthritis) observational 
cohort study (n=353) was initiated to investigate the incidence of CVD and its risk 
factors in patients with longstanding RA. Study enrollment was between June 
2000 and January 2002. As previously described (1), patients were eligible if they 
fulfilled the 1987 American College of Rheumatology classification criteria, were 
diagnosed with RA between 1989 and 2001, and were aged between 50 and 75 years. 
The participants were followed for 15 years, with study visits at baseline, 3 years, 
10 years and a CV disease questionnaire in 2015 at 15 years. Study participants who 
were lost to follow up before the first study visit at 3 years were excluded from the 
analyses.  All CV events were confirmed in medical records. 
RA-related and thyroid function data
Demographic data, medical history, medication use, family history, and Disease 
Activity Score of 28 joints (DAS28) were assessed. C-reactive protein, erythrocyte 
sedimentation rate and (radiographic) erosions in hands and feet were assessed at 
all visits. Rheumatoid factor (RF), anti–citrullinated protein antibody (ACPA), TSH, 
serum free thyroxine (FT4), and thyroid peroxidase antibodies (anti-TPO) were 
only assessed at baseline and thyroid function was only available for 323 patients. 
Patients were classified into groups by their thyroid function as euthyroid, 
hyperthyroid (known diagnosis of hyperthyroidism or TSH <0.3 mU/L and FT4 
>24 pmol/L), hypothyroid (known diagnosis of hypothyroidism or TSH >4.0 mU/L 
and FT4 <10 pmol/L), subclinical hypothyroid (TSH>4.0 mU/L and normal FT4) and 
subclinical hyperthyroid (TSH<0.3 mU/L and normal FT4). 
CV risk factor assessments
Smoking status, blood pressure, body mass index (weight/height2 in kg/m2), 
total cholesterol (TC), high density lipoprotein cholesterol (HDLc), low density 
lipoprotein cholesterol (LDLc), triglycerides, TC/HDLc ratio, glucose, and HbA1c 
were assessed. 
CV disease assessment 
Fatal and non-fatal CV events verified in medical records were registered 
according to the International Statistical Classification of Diseases and Related 
Health Problems 9th revision (ICD-9 codes, 410.0 – 410.9, 435.9, 436, 443.9 and 798) 
as described previously (1). Sudden deaths were registered as CV mortality if this 
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was confirmed by autopsy. CV events were classified into prevalent CV disease at 
baseline and new CV events during follow up.  Patients were censored after the 
first fatal or non-fatal CV event or death due to other reasons. The last (event-free) 
follow up visit was used as censor date for the participants who were lost to follow 
up. At 15 years, the remaining participants were censored at study cessation time: 
March 1, 2015. Medical records of the patients lost to follow up were searched in 
order to extract data on the occurrence of CV events.
Statistical analysis
All data has been analysed with IBM SPSS statistics version 23. Data are presented 
as mean ± standard deviation, median with an interquartile range or numbers 
and percentages. Cox proportional hazard models were used to calculate hazard 
rates (HR) for new CV events in patients with RA subdivided into patients who 
are euthyroid, hyperthyroid, hypothyroid, subclinical hyperthyroid or subclinical 
hypothyroid. These models were corrected for the following confounders based on 
literature: age, sex, prevalent CVD, smoking, thyroxine replacement therapy, and 
RA duration. A p-value of below 0.05 was considered statistically significant.
RESULTS
The baseline characteristics of all patients are shown in table 1. Patients with 
missing thyroid function data, patients who were lost to follow up before the first 
study visit and non-caucasians (n= 30) were excluded. At baseline 8.1% of the 
patients had hypothyroidism (n=26, 16 clinical and 10 subclinical hypothyroidism), 
6.8% had hyperthyroidism (n = 22, 13 clinical and 9 subclinical hyperthyroidism) 
and 85.1% (n=275) was euthyroid. 12 patients with clinical hypothyroidism, 1 patient 
with hyperthyroidism and 1 patient with subclinical hyperthyroidism were receiving 
thyroxine replacement therapy (RT) and they were all female. For 13 patients the 
duration of hypothyroidism was available, which was 23 (15 – 36) years. Systolic and 
diastolic blood pressure, sex, anti-TPO levels and thyroxine replacement therapy 
differed between the different thyroid function groups at baseline (supplementary 
table 1).
Development of new CV events
94 patients with RA (29%) developed a CV event during a median follow up of 11 
years and 2916 patient years, resulting in an incidence rate of 3.22 CV events per 
100 patient years. 36% (n=9) of the hypothyroid, 30.4% (n=7) of the hyperthyroid 
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Table 1 |  Baseline characteristics of all participants
N= 323
Demographics
   Age, years 63 ± 7
   Females, no. (%) 211 (65.3)
Cardiovascular risk factors
   Previous CVD, no. (%) 47 (14.6)
   Hypertension, no. (%) 197 (61)
      Systolic BP, mmHg 142 ± 20
      Diastolic BP, mmHg 81 ± 8
   TC/HDLc ratio 4.4 ± 1.5
      TC, mmol/L 5.8 ± 1.1
      HDLc, mmol/L 1.5 ± 0.5
      LDLc, mmol/L 3.7 ± 1.0
      Triglycerides, mmol/L 1.32 (0.96 – 1.82)
   Currently smoking, no (%) 94 (29.1)
      Pack years 19 (2-38)
   Body mass index, kg/m2 26.7 ± 4.8
   Diabetes, no. (%) 14 (4.3)
Thyroid function absolute
   TSH, mU/l 1.30 (0.91 – 1.90)
   Anti-TPO positive, no. (%) 36 (11.1)
     Anti-TPO, U/mL 102 (65 – 295)
Thyroid function groups
   Euthyroid 275 (85.1)
   Hyperthyroid 22 (6.8)
   Hypothyroid 26 (8.1)
Medication
   Antihypertensive drugs 82 (25.4)
   Statins 37 (11.5)
   Aspirin 54 (16.7)
   Thyroxine replacement therapy, no. (%) 13 (4)
RA variables
   IgM-RF ≥30 U/mL 235 (72.8)
   ACPA ≥50 kU/L 167 (51.7)
   DAS28 3.9 ± 1.3
   Disease duration 7 (4 – 10)
   Erosion on radiographs 260 (80.5)
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Continuous variables are presented as mean ± SD or median (IQR). Categorical and dichotomous 
variables are presented as numbers and percentages (%). CVD = cardiovascular disease; BP = 
blood pressure; TC = total cholesterol; LDLc = low-density lipoprotein; HDLc = high-density 
lipoprotein; pack years = (packs smoked per day)*(years as a smoker); DM = type 2 diabetes 
mellitus; RA = rheumatoid arthritis; IgM-RF = immunoglobulin M rheumatoid factor; ACPA = 
Anti–citrullinated protein antibody; DAS28 = Disease Activity Score; TSH= thyroid-stimulating 
hormone; FT4= free thyroxine; anti-TPO= anti-thyroid peroxidase antibodies. 
and 28.2% (n=78) of the euthyroid RA patients developed a new CV event over time. 
Compared to the euthyroid persons, age and sex adjusted HR were 1.08 (95% CI 
0.50-2.36; P=0.84) for hyperthyroid patients and 1,48 (95% CI 0.72-3.04; P=0.28) for 
hypothyroid patients. A closer look at the subclinical hypothyroid patients revealed 
a significantly higher incidence of new CV events, with an age, sex and prevalent 
CVD adjusted HR of 2.83 (95% CI 1.13-7.09 P=0.03) (table 2, figure 1). Further 
adjustment for smoking, thyroxine replacement therapy and RA duration resulted 
in a HR of 3.0 (95% CI 1.19–7.54; P=0.02) for CV events in patients with subclinical 
hypothyroidism (figure 1).
Figure 1 | Estimated survival probability stratified by thyroid function based on the 
multivariate Cox analysis
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Table 2 |  CV risk in thyroid dysfunction groups compared to euthyroid patients
HR* 95%CI P
Hyperthyroid 1.09 0.34-3.55 0.88
Hypothyroid 0.70 0.25-1.97 0.50
Subclinical hyperthyroidism 1.36 0.50-3.72 0.55
Subclinical hypothyroidism 2.83 1.13-7.09 0.03
*adjusted for age, sex and prevalent CVD
DISCUSSION
In this explorative study, the prevalence of thyroid disorders is twice as high in RA 
patients when compared with numbers reported for the general population (18, 19). 
More importantly, coexistence of subclinical hypothyroidism in RA is associated 
with an increased risk of new CV events when compared with euthyroid RA 
patients. This is an important finding, as coexistence of subclinical hypothyroidism 
amplifies the already high CVD risk in RA patients. Interestingly, none of the 
patients with subclinical hypothyroidism was receiving thyroxine replacement 
therapy, in contrast to the majority of the patients with hypothyroidism. All 
patients on thyroxine replacement therapy were female. As patients with clinically 
overt hypothyroidism are generally treated with thyroxine supplements, this may 
decrease CVD risk, although this warrants further confirmation in treatment 
trials. Regarding CVD risk factors, a significantly higher systolic blood pressure 
was present in RA patients with hypothyroidism, compared with the other groups. 
There were no significant differences in the other traditional CVD risk factors.
Several limitations need mentioning. First, although the prevalence of thyroid 
disorders was higher in our RA population, the total number of patients was still 
small. However, the findings of this explorative study are in line with existing 
literature and underscore the necessity of further research. Second, some 
patients with subclinical hypothyroidism spontaneously convert to euthyroidism. 
Unfortunately, there was insufficient data available to investigate this further. 
Lastly, we did not have any information about therapy in the hyperthyroidism group 
and the duration of the thyroid disorder in a large number of patients, which could 
have influenced the results.
Despite these limitations, our results show that subclinical hypothyroidism may 
further amplify CVD risk in RA patients. Whether there is a direct relationship 
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between subclinical hypothyroidism (and high anti-TPO levels) and the increased 
CVD risk we identified, needs to be elucidated in treatment trials. If external 
validation can confirm this amplified CVD risk, cardiovascular risk management is 
warranted in this subgroup of patients, and the next question is whether thyroxine 
supplementation can further improve cardiovascular outcome in subclinical 
hypothyroid RA patients.
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   Age, years 63 ± 7 67 ± 7 61 ± 6 65 ± 8 64 ± 6
   Females, no. (%)* 171 16 6 13 5
Cardiovascular risk factors
   Previous CVD, no. (%) 42 3 0 0 2
   Hypertension, no. (%) 161 (58.5) 14 (87.5) 6 (60) 9 (69.2) 7 (71.8)
   Systolic BP, mmHg* 141 ± 16 157 ± 29 143 ± 18 145 ± 21 152 ± 20
   Diastolic BP, mmHg* 80 ± 8 86 ± 10 81 ± 15 83 ± 8 85 ± 7
   TC/HDLc ratio 4.38 ± 1.57 4.47 ± 1.71 4.44 ± 1.46 4.16 ± 1.13 4.23 ± 1.29
      TC, mmol/L 5.82 ± 1.13 5.56 ± 1.01 5.92 ± 1.67 5.99 ± 0.85 5.01 ± 0.63
      HDLc, mmol/L 1.46 ± 0.49 1.42 ± 0.55 1.45 ± 0.63 1.51 ± 0.30 1.27 ± 0.35
      LDLc, mmol/L 3.72 ± 1.05 3.49 ± 1.13 3.97 ± 1.18 3.95 ± 0.86 2.97 ± 0.53










   Currently smoking, no (%) 83 (30.2) 3 (18.8) 3 (30) 1 (7.7) 4 (44.4)
      Pack years 19 (2 – 40) 22 (0 – 40) 12 (0 – 18) 8 (0 – 26) 15 (2 – 24)
   Body mass index, kg/m2 27 ± 5 28 ± 4 27 ± 6.36 28 ± 6 29 ± 5
   Diabetes, no. (%) 13 (14.7) 1 (6.3) - - -
Thyroid function absolute










   Anti-TPO positive, no. (%)* 25 3 5 1 1
     Anti-TPO, U/mL* 10 (10 – 17) 10 (10 – 62) 82 (14 – 346) 10 (10 – 15) 10 (10 – 18)
Medication
   Antihypertensive drugs 68 (24.7) 6 (37.5) 1(10) 4 (30.8) 3(33.3)
   Statins 32 (11.6) 2 (12.5) 1(7.7) 2 (12.2)
   Aspirin 45 (16.4) 4 (25) 1(10) 1(7.7) 3 (3.33)
   Thyroxine replacement 
therapy, no. (%)*
- 12 (75) - 1(7.7) 1(11.1)
Continuous variables are presented as mean ± SD or median (IQR). Categorical and dichotomous 
variables are presented as numbers and percentages (%). *Statistically significant difference. 
CVD = cardiovascular disease; BP = blood pressure; TC = total cholesterol; LDLc = low-density 
lipoprotein; HDLc = high-density lipoprotein; pack years = (packs smoked per day)*(years as a 
smoker); DM = type 2 diabetes mellitus; RA = rheumatoid arthritis; IgM-RF = immunoglobulin M 
rheumatoid factor; ACPA = Anti–citrullinated protein antibody; DAS28 = Disease Activity Score; 
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Patients with rheumatoid arthritis (RA) have an increased morbidity and mortality, 
mostly caused by cardiovascular (CV) disease. Several biomarkers of CV function 
were found to be increased in RA with some suggesting a relationship with disease 
activity and improvement upon adequate antirheumatic treatment. Promising 
biomarkers include N-terminal pro-brain natriuretic peptide (NT-proBNP) and the 
soluble receptor form of advanced glycation end products (sRAGE). The objective 
of this study was to investigate associations between NT-proBNP and sRAGE levels 
with markers of inflammation and disease activity in early RA  patients and their 
changes during (effective) antirheumatic  treatment.
Methods
Data from 342 consecutive early RA patients participating in the “Parelsnoer” 
cohort were used. At baseline and after 6 months disease activity, NT-proBNP and 
sRAGE levels were assessed. 
Results
After 6 months, NT-proBNP decreased from 83 pmol/l (mean) at baseline to 69 pmol/l 
at follow up, sRAGE increased from 997 pg/mL to 1125 pg/mL. A larger decrease 
in ESR or CRP was associated with larger changes in NT-proBNP and sRAGE. For 
every point decrease in ESR, there was a 1.7 point decrease in NT-proBNP and a 2.2 
increase in sRAGE. For CRP this was 1.7 and 2.7 respectively (P <0.001). 
Conclusion
Suppressing disease activity, independent of achieving remission, increases 
sRAGE levels and decreases NT-proBNP levels. Whether this translates in a 
decrease of incident cardiovascular disease  remains to be elucidated. 
Significance and innovation
In early arthritis patients, disease activity (DAS28) is significantly associated with 
both NT-proBNP and sRAGE. 
Initiation of treatment decreases NT-proBNP and increases sRAGE, and its 
magnitude is associated with change in markers of inflammation.
Suppressing disease activity, independent of achieving remission, increases 




Patients with rheumatoid arthritis (RA) have an increased morbidity and mortality, 
mostly caused by cardiovascular disease (CVD), including myocardial infarction, 
cerebrovascular accident and heart failure.(1, 2) Previously , we demonstrated that 
the risk of developing CVD in RA was even higher than in diabetes.(3) This excess 
morbidity and mortality cannot be explained by traditional risk factors alone, as 
inflammation and medication effects also contribute.
Several markers  for RA disease activity, including levels of C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), numbers of affected joints and 
disease activity scores, are associated with CVD risk. (4-6) In the last decade, 
several biomarkers of CV function emerged that were increased in RA and related 
to disease activity. (7-9) Some of these CV function biomarkers improved upon 
optimal antirheumatic treatment. (10, 11) Thus far, data on these CV biomarkers in 
(very) early RA are sparse, particularly in this era of treat-to-target strategies.
Promising biomarkers include brain natriuretic peptide (BNP), its inactive 
metabolite N-terminal pro-brain natriuretic peptide (NT-proBNP) and advanced 
glycation end products (AGEs) and its soluble receptor form (sRAGE). BNP is a 
hormone primarily produced in atrial cardiomyocytes in the healthy heart, but in 
case of heart failure, the ventricular myocardium becomes the main site of BNP 
production. (12) NT-proBNP, the inactive N-terminal fragment of BNP, is used as 
a biomarker in CVD, mostly for heart failure (13-15). In RA patients, levels of CRP 
are correlated with levels of NT-proBNP (16, 17) and in the general population NT-
proBNP has been shown to be a predictor of cardiovascular mortality (18). 
AGEs are formed via non-enzymatic glycation of proteins and lipids in the aging 
process, but their formation is accelerated in various disorders including diabetes, 
renal disease and inflammatory diseases  (19-21), such as RA. (22) AGEs elicit  a pro-
inflammatory state and are involved in numerous pathologic situations through 
interacting with their receptor RAGE. The soluble receptor form (i.e. sRAGE) 
prevents AGE/RAGE interaction, and in RA, sRAGE levels are lower compared to 
controls. (8) AGEs are involved in the pathogenesis of atherosclerosis through 
various mechanisms (23), such as the promotion of oxidized LDL formation, 
increase in vascular wall permeability and creation of reactive oxygen species and 
are observed in atherosclerotic lesions. (24) 
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This study aimed to investigate both cross-sectional and longitudinal associations 
between RA disease activity and NT-proBNP levels and sRAGE in early arthritis 
patients and study changes in these markers during (optimal) antirheumatic 
treatment, using data from the the Parelsnoer Institute (PSI) biobanking project. 
(25)
METHODS
Study setting and patients
The Parelsnoer Institute (PSI) is a collaborative biobanking project of all eight 
University Medical Centers in the Netherlands which was launched in 2007 includes 
fifteen large disease specific cohorts in 2020 (the so-called ‘Parels’ or ‘Pearls’). 
Clinical and biochemical data collected as part of the Rheumatoid arthritis Pearl 
offers the possibility to investigate this in a cohort of early arthritis patients. (25) 
It aims to facilitate medical research, by providing an infrastructure and standard 
procedures for the establishment, expansion and optimization of clinical biobanks 
for scientific research. Fifteen ‘Pearls’ are identified within PSI, and for each 
Pearl a specific clinical dataset is established. The data in PSI are collected both 
via electronic and manual methods and are hosted in a web based application 
(ProMISe). Biomaterials are stored in UMCs according to the PSI biobanking 
protocol. All data are registered in a central database. For this study, data from 
patients included in the ‘Rheumatoid arthritis and osteoarthritis’ pearl were used. 
Patients were included in this Pearl with a non-traumatic arthritis (excluding septic 
arthritis or crystal arthritis), confirmed by a physician, and arthritis complaints less 
than two years. Diagnosis was then specified during the baseline visit: if patients 
fulfilled the 2010 ACR/EULAR Classification criteria, patients were diagnosed as 
having early RA. Data were collected at baseline, after 3, 6, 12, 18 and 24 months 
and yearly thereafter. For the purpose of this study, we used data from patients 
with early RA, i.e fulfilling the 2010 ACR/EULAR criteria. We used biobank data from 
the first 6 months of the study period. We included early RA patients if they had a 
baseline and 6 month visit, and if a DAS28-ESR score was done during both visits. 
Patients were excluded if there was no biomaterial available at baseline. 
Study outcomes
At baseline, duration of arthritis and demographic data including age, gender, 
ethnicity, height, weight and smoking status were collected. Comorbidities were 
recorded by a trained study nurse. Disease activity was assessed at every study visit 
by the disease activity score of 28 joints (DAS28-ESR). (26) Laboratory parameters 
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were assessed, including include CRP and ESR, and biomaterial including serum, 
plasma and DNA was collected and biobanked at each visit. Rheumatoid factor 
(IgM-RF) and anti-citrullinated protein antibodies (ACPA) were only assessed at 
baseline. Medication use was recorded at each visit. Improvement of disease or 
response to therapy after 6 months was defined according to the EULAR response 
criteria. (27) To establish if remission was achieved after 6 months, the criterion 
DAS28-ESR <2.6 was used. 
NT-proBNP en sRAGE assessment
Serum sRAGE concentrations were measured using an ELISA based technology that 
uses electrochemiluminescence for detection on a Meso Scale Discovery Quickplex 
SQ 120 Imager (cat. # F214Q, Meso Scale Discovery, Rockville MD;  intra-assay CV, 
1,4% ; inter-assay CV: 8,8%). Plasma levels of NT-proBNP were analysed using 
the Elecsys 1010 electrochemiluminescence immunoassay (Roche Diagnostics, 
Almere, the Netherlands). NT-proBNP values were compared to reference levels 
according to the PRIDE study guidelines (< 50 years of age, NT-proBNP ≤ 450 
pmol/L; 50 to 75 years of age, ≤ 900 pmol/L and > 75 years of age, ≤ 1800 pmol/L). (28)
Statistical analyses
Patient characteristics are described as number and percentage, means ± standard 
deviation (SD), when normally distributed, or median and interquartile range (IQR) 
when not normally distributed. 
Linear regression analyses were performed to assess univariate associations 
between disease activity as independent variable and NT-proBNP and sRAGE as 
dependent variable at baseline. Linear mixed model analyses were used to assess 
longitudinal associations between disease activity and NT-probBNP and sRAGE. All 
analyses were adjusted for age, gender, smoking status, BMI, history of diabetes, 
hypertension and previous CVD. Furthermore, we calculated the changes in DAS28, 
CRP, ESR, NT-proBNP and sRAGE after 6 months. We tested associations between 
magnitude of change in markers of disease activity (e.g. DAS28-ESR, CRP and ESR) 
after 6 months and magnitude of change in NT-proBNP and sRAGE levels after 6 
months using linear regression. We also used linear regression to detect a difference 
in change in NT-proBNP and sRAGE levels between the group in remission and the 
group not in remission at six months. For the statistical analysis SPSS version 25.0 
(SPSS IBM software, USA) was used. The threshold for significance was set at p 
<0.05 (two-sided), with no correction for multiple testing.




For this study, data from 342 consecutive patients from 4 centers was used. Patients 
had a mean disease duration at baseline of 5.3 months. Baseline characteristics 
are shown in table 1. 
Table 1 | Baseline characteristics of the early RA patients
Demographics
  Gender, female, n (%) 227 (66.4%)
  Age, mean ± SD 57 (14)
  Etnicity, Caucasian, n (%) 313 (94.8%)
Disease characteristics
  Symptom duration in months, mean ± SD 5.3 ± 8.5
  RF positive, n (%) 130 (40.6%)
  ACPA positive, n (%) 97 (32.1%)
  DAS28-ESR, mean ± SD 4.1 ± 1.0
  ESR, median (IQR) 22 (11-36)
  CRP, median (IQR) 9 (3-21)
  BMI, kg/m2, mean ± SD 26.9 ± 4.9
  Smoking status, n (%)
    Never 111 (33.9%)
    Former > 6 months 133 (40.7%)
    Former < 6 months 2 (0.6%)
    Current smoker 81 (24.8%)
Comorbidity, n (%)
  History of CVD 12 (3.5%)
  Hypertension 84 (24.6%)
  Diabetes 5 (1.5%)
Use of medication, n (%)
  NSAIDs 184 (84.8%)
  Hydroxychloroquine 5 (3.2%)
  Prednisolone 37 (23.6%)
  Methotrexate 63 (40.1%)
  Other nbDMARD 5 (2.1%)
  Biologic DMARD 4 (1.7%)
Biomarkers
  NT-proBNP (pmol/ml), median (IQR) 83.4 (43.3-158.3)
  sRAGE (pg/ml), mean ± SD 997 ± 483
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ACPA: anti citrullinated protein antibodies, BMI: body mass index, CRP: C-reactive protein, 
CVD: cardiovascular disease, DAS28: disease activity score of 28 joints, DMARD: disease 
modifying anti rheumatic drug, ESR: erythrocyte sedimentation rate, IQR: interquartile 
range, nbDMARD: non-biologic DMARD, NT-proBNP: N-terminal pro-brain natriuretic 
peptide, NSAID: non-steroidal anti-inflammatory drug, RF: rheumatoid factor, SD: standard 
deviation, sRAGE: soluble receptor advanced glycation end product
Disease activity
At baseline, 64% of the patients had moderate disease activity (DAS28-ESR 
between 3.2 and 5.1), 20% had low disease activity (DAS28-ESR between 2.6 and 3.1) 
and 15% of patients had highly active disease (DAS28-ESR above 5.1). At 6 months 
, 99 (29.3%) of the patients were non-responders, 89 (26.3%) were moderate 
responders and 150 (44.4% were good responders. After 6 months, 162 (47.6%) 
achieved remission (DAS28-ESR <2.6) (table 2).
Table 2 | Disease activity
Baseline 6 Months
Mean DAS28-ESR 4.10 ± 1.02 2.77 ± 1.13
  < 2.6 5 (1.5%) 162 (48.1%)
  < 3.2 68 (20.2%) 66 (19.6%)
  < 5.1 214 (63.5%) 99 (29.4%)
  > 5.1 50 (14.8%) 10 (3.0%)
EULAR response
  Non-responder na 99 (29.3%)
  Moderate responder na 89 (26.3%)
  Good responder na 150 (44.4%)
DAS28-ESR: disease activity score of 28 joints
Correlation of markers of disease activity with NT-proBNP and sRAGE
NT-proBNP and sRAGE were correlated with variables of disease activity, both 
at baseline and over time (table 3 and 4). A rise in DAS28-ESR, ESR and CRP was 
associated with increased NTproBNP levels values and decreased sRAGE levels. 
Remarkably, only 7 patients had a NT-proBNP value above threshold for their age. (28) 
Changes in NT-proBNP and sRAGE after 6 months
After 6 months of treatment, the median value of NT-proBNP decreased from 83 
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pmol/ml at baseline to 69 pmol/ml at follow up, the mean change in NT-proBNP 
was -28.94 (p<0.001) for all patients. sRAGE increased from 997 pg/ml at baseline 
to 1125 pg/ml after 6 months of treatment, the mean increase was 127.59 (p<0.001). 
We found no significant associations between change in DAS28 and change in NT-
proBNP or sRAGE, or between responders and non-responders after 6 months of 
treatment. However, a larger decrease in ESR or CRP levels was associated with a 
larger decrease in NT-proBNP and greater increase in sRAGE levels. For every point 
change in ESR, there was a 1.7 point decrease in NT-proBNP and a 2.2 increase in 
sRAGE. For CRP this was 1.7 and 2.7 respectively (table 4). 
Table 3 | Correlation between NT-proBNP, sRAGE and markers of disease activity at baseline
DAS28-ESR ESR CRP
NT-proBNP
  Unadjusted 1.19 (1.06-1.33)
P = 0.003
1.01 (1.01-1.02) p <0.001 1.02 (1.01-1.02) p <0.001
  Model 2 1.21 (1.03-1.43)
p = 0.022
1.01 (1.00-1.01) p <0.001 1.02 (1.01-1.02) p <0.001
  Model 3 1.21 (1.03-1.42)
p = 0.020
1.01 (1.00-1.01) p = 0.001 1.02 (1.01-1.02) p <0.001
sRAGE
  Unadjusted -73.58 (-123.50- -23.66)
P  = 0.004
-3.54 (-5.71- -1.38)
P = 0.001
-6.12 (-8.68- -3.56) p <0.001




-5.28 (-7.87- -2.70) p <0.001




-5.32 (-7.98- 2.67) p <0.001
Model 2: adjusted for age and gender
Model 3: adjusted for age, gender, smoking status, BMI and history of diabetes, 
hypertension and CVD
After 6 months, 162 (47.6%) achieved remission (DAS28 <2.6). In these patients, 
mean Δ NT-proNBP was 39, versus 29 in the patients not in remission. Changes 
in sRAGE were 168 and 122 respectively. These differences reached no statistical 
significance. 
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Table 4 |  Longitudinal correlations between disease activity and NT-proBNP and sRAGE
DAS28-ESR ESR CRP
NT-proBNP























-4.94 (-6.52- -3.36) p <0.001




-5.21 (-6.81- -3.62) p <0.001






Model 2: adjusted for age and gender
Model 3: adjusted for age, gender, smoking status, BMI and history of diabetes, hypertension 
and CVD 
Table 5 |  Associations between change in disease activity and change in NT-proBNP and 
sRAGE after 6 months
 Δ NT-proBNP Δ sRAGE
Δ DAS28 -11.0 (-23.9 - 1.8) 4.5 (-23.5 - 32.4)
Δ ESR 1.7 (0.8 - 2.6) 2.2 (-4.4  - -0.3)
Δ CRP 1.7 (0.8 - 2.6) 2.7 (-4.5 - -0.7)
DISCUSSION
In our cohort of very early RA patients, we demonstrated associations between NT-
proBNP and sRAGE and CRP, ESR and DAS28, both at baseline and during follow-
up. During 6 months of treatment with anti-inflammatory medication, NT-proBNP 
decreased and sRAGE increased. There was an association between the magnitude 
of change in inflammatory markers (ESR and CRP) and change in NT-proBNP and 
sRAGE. Also, mean NT-proBNP was lower and mean sRAGE higher in patients in 
remission. To our knowledge this is the first study that found  these longitudinal 
associations in very early RA patients. 
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A recently published study described a higher serum sRAGE in RA patients 
compared to healthy controls; serum sRAGE positively correlated with DAS28. 
(30) In this study, only cross sectional correlations were investigated. A relation 
between CRP and NT-proBNP has previously been described in a cohort of 238 
RA patients. However, these patients had a substantially longer disease duration 
(16), Moreover, the investigators analyzed their data in a dichotomous way, rather 
than with a continuous analysis, thereby limiting the interpretation. Another study 
demonstrated a higher level of BNP in RA patients, similar to our cohort, compared 
to healthy controls, and RA patients with active RA having higher BNP levels than 
RA patients with moderately active or inactive disease (17), but this was not studied 
prospectively. In the IDEA study, researchers demonstrated that NT-proBNP values 
in RA patients decreased after treatment with infliximab and methotrexate. (31). 
Thus far there have been no longitudinal studies investigating AGEs in very early RA. 
Several limitations need to be considered. Although we did demonstrate a 
decrease in NT-proBNP, all values were within normal limits for age and gender. 
Therefore, the clinical significance remains unknown. However, based on the 
mechanisms behind the production of NT-proBNP and sRAGE, we hypothesize that 
suppression of inflammation benefits the myocardium and endothelium.  In heart 
failure patients, a greater decrease in NT-proBNP declines morbidity and mortality. 
(31) A prospective study on the effects of sacubitril-valsartan on cardiac outcomes 
demonstrated that reduction in NT-proBNP concentrations over 12 months 
correlated with improvements in markers of cardiac volume and function. (32) 
Results from the ECHOES (Echocardiographic Heart of England Screening study) 
cohort demonstrated that an increased NT-proBNP level, even still within normal 
limits, increased the risk of developing heart failure over time. (33) Another limitation 
of this study is that we had no information on some of the possible confounders, for 
example cholesterol levels. However, correction for other CV confounders that are 
correlated with cholesterol levels, such as smoking,  BMI and hypertension did not 
influence our results. 
In conclusion, suppressing disease activity, independent of achieving remission, 
increases sRAGE levels and decreases NT-proBNP levels. Both of these markers 
have been associated with CVD in the general population. Our results imply that RA 
treatment might positively affect these markers, independently of whether or not 
remission is achieved.  The strength of this study is that we were able to examine 
these markers over time in a cohort of very early arthritis patients. It provides yet 
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more evidence that prompt suppression of inflammatory activity, maybe even 
particularly in early RA is essential not only to preserve synovium and cartilage, 
but also endothelium and myocardium. Obviously, the association with ‘hard’ 
cardiovascular endpoints needs to be further investigated.
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CHAPTER 9
The Effects of 5-year Etanercept 
Therapy on Cardiovascular Risk Factors 
in Patients with Psoriatic Arthritis
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To investigate the effects of etanercept on lipid metabolism and other known CVD 
risk factors in patients with PsA.
Methods
In an observational cohort of 118 consecutive patients with PsA, CVD risk factors 
were assessed over a period of 5 years. Mixed model analyses were performed to 
investigate the effects of etanercept therapy on CVD risk factors over time.
Results
Disease Activity Score (DAS28), C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) decreased during therapy with etanercept. There was an 
increase in total cholesterol (TC), high density lipoprotein cholesterol (HDLc) and low 
density lipoprotein cholesterol  (LDLc). The TC/HDLc ratio remained unaltered. The 
apolipoprotein B to apolipoprotein A-I (apoB/apoA1) ratio decreased significantly. 
An increase in CRP was associated with an increase in the apoB/apoA1 ratio. 
Conclusions
Serum lipid concentrations showed small changes over a 5 year period of 
etanercept therapy and were inversely associated with inflammatory markers. 
Other CVD risk factors remained stable. The apoB/apoA1 ratio decreased over time 
and an increase in disease activity was associated with an increase in this ratio. 
However, this modest lipid modulation cannot explain the observed beneficial 
cardiovascular effects of etanercept and etanercept likely exerts its favourable 




Psoriatic arthritis (PsA) is an inflammatory joint disorder (IJD) that occurs in 
approximately 14 to 30 percent of patients who are affected by the skin condition 
psoriasis. (1;2) In the last decade, severe psoriasis, but also rheumatic diseases 
such as rheumatoid arthritis (RA), have been associated with an increased risk of 
developing cardiovascular disease (CVD).(3) There is accumulating evidence that 
PsA should also be considered a disease that is accompanied by a heightened CVD 
risk (4;5). However, literature about the underlying mechanisms that generate 
this increased risk is scarce. In all inflammatory arthropathies, including PsA, 
accelerated atherosclerosis is observed as a consequence of inflammatory 
mediators that also play an important role in the development and progression of 
these disorders, such as tumor necrosis factor alpha (TNF-α). TNF-α is a powerful 
pro-inflammatory cytokine that induces inflammation in skin and joints, but also 
in vascular endothelium, by which it directly influences vascular morphology.
(6) Additionally, TNF-α is known to modify traditional risk factors for CVD, such 
as the lipid metabolism, insulin resistance and body weight, presumably further 
increasing CVD risk.(7) Indeed, an increased prevalence of lipid disorders, 
hypertension and obesity have been reported in both psoriasis (8) and PsA. (3;9;10) 
Yet, hyperlipidemia, an important and modifiable CVD risk factor, is rarely observed 
in its ‘classic’ form in IJD (11). Generally, inflammation induces a decrease in all 
serum lipids and this is usually reversed by effective anti-inflammatory therapy, 
though conflicting literature exists. It is suggested that other lipid measurements, 
such as apolipoprotein B (apo B) and the ratio between apolipoprotein B and 
apolipoprotein A-I (apo B/apo A1 ratio) might be better predictors of CVD risk in 
these patients, as conventional lipid profiles are difficult to interpret in the context 
of high-grade inflammation. (12;13) Optimal anti-inflammatory therapy is thought 
to reduce CVD risk in all IJD and this might be mediated by favorable changes in 
cardiovascular risk factors (e.g. the lipid profile). (14) However, the long term effects 
of anti-inflammatory treatment, especially of biological agents, on CVD risk and 
CVD risk factors in patients with PsA have not yet been adequately investigated. 
Etanercept, a potent inhibitor of TNF-α, has beneficial effects on CVD risk in 
patients with RA, an effect thought to be partially mediated by favourable effects 
on the lipid profile.(15) For PsA, literature on the association between disease 
activity and lipid levels is limited, although it is assumed that lipids are also modified 
by inflammation in PsA. (16) Thus far, long-term effects of etanercept on lipid 
levels and other CVD risk factors in PsA are unknown. Therefore, we investigated 
the effects of etanercept therapy on cardiovascular risk factors, with special 
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focus on lipid profiles, in a cohort of patients with PsA with extended follow up.
METHODS
Study population
118 consecutive patients who were diagnosed with PsA and scheduled to receive 
their first ever prescription of etanercept were recruited for an observational 
cohort at the department of Rheumatology in the Jan van Breemen Institute in 
Amsterdam between April 2004 and February 2014. The diagnosis of PsA was made 
by a rheumatologist. All patients started etanercept according to the consensus 
statement on initiation of treatment with biologicals . Treatment was with 
subcutaneous administration of etanercept alone, either 50 mg once a week or 25 
mg twice a week, or with concomitant methotrexate and/or prednisone. The study 
was conducted in compliance with the declaration of Helsinki and approved by the 
local Medical Ethics Committee of Slotervaart Hospital, approval number P0538 
was provided. Written informed consent was obtained from all patients.
Study design
Patients visited the Rheumatology outpatient clinic at the Jan van Breemen 
Institute for study assessments at baseline, 1, 3, 6 and 12 months and every 
following year up to 5 years of etanercept therapy. Disease activity was measured 
with the Disease Activity Score (DAS28), the Psoriasis Area and Severity Index 
(PASI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Prior 
and current medication use, systolic and diastolic blood pressure and body mass 
index (BMI = weight / height2, in kg/m2) were recorded at each visit. Triglycerides 
(TG) and total cholesterol (TC) were assessed using an enzymatic colorimetric test. 
High density lipoprotein cholesterol (HDLc) was measured using polyethylene glycol 
(PEG) modified enzymes. Low density lipoprotein cholesterol (LDLc) was calculated 
using the Friedewald formula when triglycerides were lower than 4.5 mmol/l. TC/
HDLc ratios were calculated. Apolipoprotein A1 (apo A) and apolipoprotein B (apo 
B) were measured in a subpopulation of 81 patients with an immunoturbidimetric 
assay. All blood samples were determined batch wise. 
Statistical analysis
Data are presented as mean ± standard deviation (SD) in case of normal distribution 
and otherwise as median and interquartile range (IQR) or numbers and percentages. 
Log transformations were done if necessary. Mixed models analyses were 
performed to assess the changes in CV risk factors over time and their relation to 
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disease activity parameters such as DAS28, CRP and ESR, because this method is 
designed for analyzing cohort data with missing values. The unstructured random 
covariance type was used. Patients were only included in the analysis if study 
assessments were performed at baseline and at least at one other visit during follow 
up. The univariate models were adjusted for potential confounders age, gender, 
disease duration, concomitant MTX, prednisone, NSAIDs, antihypertensives and 
statin use. A P-value less than 0.05 was considered statistically significant. All data 
were analyzed with SPSS version 20.0. 
 
RESULTS
The study population consisted of 118 patients with a mean age of 47 ± 13 years 
and a nearly equal proportion of men (n=58) and women (n=60). The baseline 
characteristics are presented in table 1. Patients had a median psoriasis duration 
of 13 (5 – 22) years and a median arthritis duration of 6 (2 – 13) years. 12 patients had 
previously been treated with adalimumab and 1 with infliximab. 53 patients were 
using methotrexate (MTX) and 9 patients were using prednisone concomitantly 
with etanercept. The median duration of etanercept treatment was 4 (2 – 5) years.
Table 1 |  Baseline characteristics
n=118
Demographics
   Age, years 47±13
   Females 60 (50.8)
PsA related factors
  Psoriasis duration, years 13 (5-22)
  Arthritis duration, years 6 (2-13)
  Psoriasis Area Severity Index 0 (0-2)
  Disease Assessment Score 28 4.36±1.39
  Swollen joint count 5 (2-10)
  Tender joint count 7 (3-15)
  ESR, mm/h 16 (6-28)
  CRP, mg/L 6 (2-14)
  VAS disease activity 59±24
  Health assessment questionnaire 1.0 (0.5-1.6) 
Anti-inflammatory medication use
   Use of previous biologics 13 (11.0)
table continues
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n=118
   Concomitant methotrexate use 53 (44.9)
   Methotrexate dose, mg/wk 19.0±7.5
   Concomitant prednisone use 9 (7.6)
   Prednosine dose, mg/day 7.2±3.6
   Use of other DMARDs 11 (9.3)
   NSAIDs use 58 (49.2)
CVD-related factors
   Current smoking 15 (12.7)
   Body mass index, kg/m2 27±6
     Obesity 67 (56.8)
   Systolic blood pressure, mmHg 130±22
   Diastolic blood pressure, mmHg 81±10
     Hypertension 47 (39.8)
   Diabetes mellitus 8 (6.8)
   Antihypertensive use 28 (23.7)
   Statin use 11 (9.3)
   Creatinine, umol/L 75±18
Lipid profile
   Total cholesterol, mmol/L 5.31±1.24
   HDL cholesterol, mmol/L 1.43±0.43
   LDL cholesterol, mmol/L 3.21±1.05
     LDL ≥ 2.5* 88 (74.6)
   Triglycerides, mmol/L 1.29 (0.85-1.87)
   Total cholesterol/HDLc ratio 3.99±1.37
   Apolipoprotein A1, g/L** 1.55±0.42
   Apolipoprotein B, g/L** 0.89±0.27
   ApoB/Apo A1 ratio** 0.6±0.2
Values are presented as mean ± SD, median (IQR) or numbers (percentages). VAS= visual 
analogue scale, NSAIDs= nonsteroidal anti-inflammatory drugs, HDL= high density 
lipoprotein, LDL = low density lipoprotein.
*sulfasalazine, hydroxychloroquine, leflunomide, *dyslipidemia, **Apolipoproteins were 
available for a subgroup of 81 patients
Changes in inflammatory parameters
Study assessments were performed at baseline, 4, 16, 28, 52, 104, 156, 208 and 260 
weeks. ESR, CRP and DAS28 decreased significantly over time, with the greatest 
decrease in the first month after the start of etanercept treatment (figure 1). 
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DAS28 remained high in patients who discontinued therapy after 28 (3.13±1.65 vs. 
1.98±1.08; p=0.003) and 52 weeks (2.86±1.45 vs. 1.62±0.94; p=0.001). CRP and ESR 
were significantly elevated in the patients who discontinued therapy after 28 (ESR 
9 (3-30) vs. 4 (2-8);p=0.028 and CRP 2 (1-12) vs. 2 (1-3); p=0.049) and 52 weeks (ESR 
19 (5-39) vs. 4 (2-7); p=0.009 and CRP 5 (2-10) vs 1(1-2); p=0.003). In the mixed models 
analysis patients who discontinued therapy had higher DAS28 in comparison to 
patients who continued etanercept treatment over 5 years (RC 0.56 95%CI 0.12-
0.99; p=0.013). The PASI did not differ between these patients (data not shown). 
The reasons for discontinuing therapy were remission (n=8), failure (n=11), adverse 
events (n=10), migration or non-response (n=9), pregnancy wish (n=1), and other 
unknown reasons (n=3). 
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Figure 1 | Disease activity parameters CRP= C-reactive protein, ESR= erythrocyte 
sedimentation rate, DAS28= disease assessment score 28. 
CRP and ESR are presented as median (IQR), DAS28 is presented as mean ± SD.
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Changes in CVD risk factors over time during etanercept therapy
At baseline 39.8% of the patients had hypertension, 74.6% had dyslipidemia and 
56.8% was overweight. TC/HDLc ratio was above 3.5 in 56.4% of the patients and 
6.8% had diabetes.
The mixed models analysis showed a significant increase in TC, HDLc and LDLc 
over 5 years after correction for age, gender, disease duration, concomitant MTX, 
prednisone and statin use. Apo A1 and Apo B measurements were available in a 
subpopulation of 81 patients. The ApoB/ApoA1 ratio decreased significantly over 
5 years, while the TC/HDLc-ratio remained stable (table 2). Blood pressure, BMI, 
creatinine, and triglycerides remained stable over the years (table 2). The mean 
lipid levels per visit are shown in figure 2. 
Table 2 |  Mixed models analysis of changes in CVD related factors over 5 years
Mean RC 95% CI P-value
Systolic blood pressure 130 ± 20 -0.001 -0.02 – 0.02 0.92
Diastolic blood pressure 81 ± 11 0.002 -0.01 – 0.01 0.66
BMI 27 ± 5 0.002 -0.0001 – 0.004 0.07
Creatinine 75 ± 17 -0.003 -0.01 – 0.01 0.55
Total cholesterol 5.38 ± 1.12 0.0008 0.0001 – 0.001 0.03
    Adjusted* 0.0008 -0.0001– 0.002 0.02
HDLc 1.34 ± 0.45 0.0005 0.0001 – 0.001 <0.01
    Adjusted* 0.0005 0.0002 – 0.001 <0.01
LDLc 3.19 ± 0.98 0.0008 -0.0001 – 0.002 0.03
    Adjusted* 0.0009 -0.0001 – 0.002 0.02
Triglycerides 1.37 ( 0.96 – 2.00 -0.00003 -0.0005 – 0.0005 0.99
TC/HDLc-ratio 4.01 ± 1.30 0.0006 -0.0006 – 0.002 0.31
Apo A1^ 1.59 ± 0.34 0.00001 -0.0005 – 0.0005 0.98
Apo B^ 0.89 ± 0.24 -0.0001 -0.0004 – 0.0001 0.34
ApoB/apoA1 ratio^ 0.58 ± 0.20 -0.0002 -0.0005 – 0.00001 0.06
    Adjusted* -0.0003 -0.0005 - -0.00005 0.02
BMI=body mass index, HDLc= high density lipoprotein cholesterol, LDLc= low density lipoprotein 
cholesterol, TC/HDLc- ratio = total cholesterol to high density lipoprotein cholesterol ratio, 
Apo A1= apolipoprotein A1, Apo B = apolipoprotein B, ApoB/ApoA1 ratio = apolipoprotein B to 
apolipoprotein A1 ratio.
*adjusted for age, gender, disease duration, concomitant MTX, prednisone and statin use.
^subanalysis of 81 patients at baseline with apo a1 and apo b measurements available.
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Figure 2 | Changes in lipids over a 5-year period. 
Relationship between CVD risk factors and disease activity
In the mixed models analyses changes in DAS28 were associated with changes in 
diastolic blood pressure, TC, HDLc and triglycerides (table 3). One point increase in 
DAS28 was associated with an increase in diastolic blood pressure, a decrease in 
TC and triglycerides. This association was still significant after adjustment for age, 
gender, disease duration and concomitant medication use (table 3).  There was a 
trend for an increased apo B/ apo A1 ratio with one point increase in DAS28 (p=0.057). 
A point increase in DAS28 was associated with an increase in HDLc. However, this 
was not significant after correction for above mentioned variables. The TC/HDLc 
ratio did not change significantly with changes in DAS28. When patients were split 
into responders vs. nonresponders, patients with a DAS28 above 2.6 as opposed to 
patients with a DAS28 under 2.6 had lower TC and triglycerides, while the HDLc was 
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increased (table 4). An increase in CRP was associated with a decrease in TC (RC 
-0.09, 95%CI -0.16 – -0.02, P= 0.02) and an increase in the apo B/Apo A1 ratio (RC 
0.03 95%CI 0.004 – 0.05, P=0.02). There was a trend for a decrease in triglycerides 
(RC-0.04, 95%CI -0.08 – 0.003, P=0.07) and in apo A1 (RC -0.05, 95%CI -0.09 – 0.01, 
P= 0.077) after adjustment for above mentioned confounders.
Table 3 |  Association between DAS28 and CVD related factors over 5 years
Mean RC 95% CI P-value
Systolic blood pressure 130 ± 20 0.43 -0.41 – 1.28 0.31
Diastolic blood pressure 81 ± 11 0.64 0.12 – 1.17 0.02
     Adjusted* 0.56 0.03 – 1.09 0.04
BMI 27 ± 5 -0.001 -0.099 – 0.097 0.98
Creatinine 75 ± 17 -0.18 -0.76 – 0.39 0.53
Total cholesterol 5.38 ± 1.12 -0.05 -0.09 – -0.007 0.02
    Adjusted* -0.05 -0.09– -0.01 0.02
HDLc 1.34 ± 0.45 0.04 0.01 – 0.06 0.007
    Adjusted* 0.03 0.000001 – 0.05 0.05
LDLc 3.19 ± 0.98 -0.02 -0.06 – 0.03 0.47
Triglycerides# 1.37 ( 0.96 – 2.00) -0.03 -0.05 – -0.01 0.006
   Adjusted* -0.03 -0.06 – -0.01 0.008
TC/HDLc-ratio 4.01 ± 1.30 -0.04 -0.11 – 0.02 0.21
Apo A1^ 1.59 ± 0.34 -0.0008 -0.03 – 0.03 0.96
Apo B^ 0.89 ± 0.24 0.009 -0.008 – 0.03 0.29
ApoB/apoA1 ratio^ 0.58 ± 0.20 0.01 -0.003 – 0.03 0.11
    Adjusted* 0.014 -0.0004 – 0.03 0.057
BMI=body mass index, HDLc= high density lipoprotein cholesterol, LDLc= low density lipoprotein 
cholesterol, TC/HDLc- ratio = total cholesterol to high density lipoprotein cholesterol ratio, 
Apo A1= apolipoprotein A1, Apo B = apolipoprotein B, ApoB/ApoA1 ratio = apolipoprotein B to 
apolipoprotein A1 ratio.
^subanalysis of 81 patients at baseline with apo a1 and apo b measurements available.
*adjusted for age, gender, disease duration, concomitant MTX, prednisone, nsaids, 
antihypertensives and statin use. #log transformed
165
Table 4 |  CV risk factors in DAS28>2.6 vs. DAS28<2.6 over 5 years
Responder Nonresponder RC 95% CI P-value
Systolic blood pressure 128 ± 19 133 ± 20 2.01 -0.65 – 4.67 0.14
Diastolic blood pressure 80 ± 10 82 ± 12 1.27 -0.37 – 2.92 0.13
BMI 25.9 ± 3.8 28.7 ± 5.8 -0.27 -0.55 – 0.004 0.05
Creatinine 76 ± 14 74 ± 21 -0.80 -2.26 – 0.66 0.28
Total cholesterol 5.45 ± 1.02 5.29 ± 1.25 -0.16 -0.29 – -0.02 0.03
    Adjusted* -0.017 -0.31– -0.03 0.02
HDLc 1.31 ± 0.45 1.38 ± 0.45 0.11 0.04 – 0.18 0.004
    Adjusted* 0.08 0.009 – 0.16 0.03
LDLc 3.23 ± 0.92 3.15 ± 1.07 -0.06 -0.20 – 0.07 0.35
Triglycerides# 1.37 (0.99 – 2.04) 1.38 (0.95 – 1.90) -0.09 -0.16 – -0.01 0.02
   Adjusted* -0.09 -0.16 – -0.01 0.02
TC/HDLc-ratio 4.01 ± 1.26 4.03 ± 1.34 -0.08 -0.27 – 0.11 0.41
BMI=body mass index, HDLc= high density lipoprotein cholesterol, LDLc= low density lipoprotein 
cholesterol, TC/HDLc- ratio = total cholesterol to high density lipoprotein cholesterol ratio.
*adjusted for age, gender, disease duration, concomitant MTX, prednisone, antihypertensives 
and statin use. #log transformed
DISCUSSION
Etanercept therapy effectively reduced DAS28, CRP and ESR, as markers of disease 
activity, in patients with PsA, with the greatest reduction of disease activity at six 
months. This reduction persisted until five years of therapy in those who continued 
treatment. At baseline a substantial proportion of the patients had hypertension 
(39.8%), dyslipidemia (74.6%) and was overweight (56.8%). In addition, 56.4% of the 
patients had an elevated TC/HDLc ratio and 6.8% had diabetes. This is consistent 
with previous reports of an increased prevalence of traditional CVD risk factors 
in PsA patients.(3;9) Interestingly, the majority of patients showed nearly normal 
TC, HDLc and TG values at baseline. Over a five year period of etanercept therapy, 
patients with PsA showed a significant increase in TC, HDLc and LDLc. Similarly 
as in RA, where it has been reported that during times of active inflammation, 
LDLc and HDLc decrease, while anti-inflammatory treatment, for example with 
TNF inhibitors, can reverse this. There is a non-linear relationship between lipid 
levels and CVD risk in inflammatory joint disorders (most data is available for RA). A 
decrease in lipid levels (i.e. total cholesterol, LDL cholesterol and triglycerides), is 
often seen in patients with active inflammation, while their CVD risk is increased. 
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During treatment with anti-inflammatory agents lipid levels increase in these 
patients, which is considered to be a normalization of lipid levels. In this study, 
we demonstrated that this phenomenon also holds true for PsA, i.e. treatment 
with etanercept increases lipid levels. This increase in lipids should probably be 
considered as a normalization of serum lipid levels and a reflection of effective 
anti-inflammatory therapy, rather than an adverse effect of etanercept. To avoid 
misinterpretation of cardiovascular risk status in these patients, measurement 
of lipid levels for the purpose of cardiovascular risk estimation should preferably 
be performed when disease activity is stable or in remission. The other CVD risk 
factors, i.e. blood pressure, BMI, creatinine, and TG remained stable over the 
years, although there was a trend for an increase in BMI in these patients (p=0.07). 
Increases in BMI with TNFi treatment has been described previously in patients 
with psoriasis (16-18) and PsA.(18) Furthermore, the TC/HDLc-ratio remained stable 
over 5 years, which is to be expected as these lipid values generally change in the 
same direction during inflammation and suppression of inflammation with therapy.
(17) Normally, this would indicate that the CVD risk remains stable over 5 years. 
However, there was a significant decrease in the apoB/apoA1 ratio over time, which 
could reflect a decrease in CVD risk. A previous study showed that the ApoB/ApoA1 
ratio is associated with an increased risk of fatal myocardial infarction in men 
and in women (RR 1.23, 95%CI 1.18-1.27 and 1.38, 95%CI 1.25-1.52 respectively).(18) 
Intriguingly,  elevated disease activity markers, i.e. DAS28 and CRP, were associated 
with an unfavorable lipid profile, i.e. lower TC and triglycerides but an increase in the 
apo B/apo A1 ratio (RC 0.03 95%CI 0.004 – 0.05), a possible reflection of an increase 
in CVD risk. Also, there was a trend for a decrease in apo A1, the cardio protective 
component of HDLc, with one point increase in CRP. In line with this, over time an 
increase in DAS28 was associated with a small increase in diastolic blood pressure 
(0.56 mmHg  per point increase in DAS28)  and there was a trend for an increased 
HDLc and apoB/apoA1 ratio per point increase in DAS28 (p=0.057). This might 
seem surprising, as HDLc is known as cardio protective and most studies report 
a decrease in HDLc during inflammation, although these studies have focused on 
RA and not on PsA. These ‘conflicting’ results may indicate that a raise in HDLc 
does not necessarily translate into a favorable lipid and CVD risk profile in patients 
with high disease activity, as HDL composition rather than its levels determine its 
function.(19) 
HDLc which is normally considered anti-atherogenic, could change into a pro-
atherogenic molecule due to modification of HDLc subcomponents under 
inflammatory conditions. In our study, the decrease in apo A-I (trend) and the 
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increase in apoB/apoA1 ratio, with elevation of inflammatory markers, suggest a 
change in the HDLc molecule to a more pro-atherogenic HDLc under high-grade 
inflammation. Thus, we consider the higher TC and TG in patients with low DAS28 
scores in this study a normalization of serum lipid levels and a reflection of effective 
anti-inflammatory therapy. Conversely, the patients with high DAS28 who had lower 
total cholesterol and triglycerides, and higher HDL cholesterol are considered 
to have a worse CVD risk profile, also in accordance to existing literature on this 
subject. 
Several limitations should be considered. The changes in lipid levels were small 
in this study and the clinical relevance of such small changes is probably limited. 
Additionally, apolipoprotein values were only available in a subpopulation of 
patients. Therefore, mixed models was used as it is designed to analyse this type 
of data. However, we expect that these findings will be even more significant in 
a larger group of patients, as we have already found significant differences in 
apolipoproteins in this small group of patients with PsA. 
Nevertheless, our study demonstrates stable CVD risk factors, especially a stable 
lipid profile in a heterogeneous population of patients with PsA over a five year 
period of etanercept therapy. To our knowledge, no other study has described 
changes in CVD risk factors over an extended period of time in patients with PsA 
receiving TNFi therapy, although a beneficial effect of TNFi on surrogate markers 
of atherosclerosis (i.e. carotid intima media thickness) in PsA has been reported.
(20) Furthermore, significant changes in apoB/apoA1 ratio, BMI and diastolic blood 
pressure were found over time during etanercept therapy, reflecting a possible 
beneficial effect on lipid subcomponents, blood pressure, body composition, and 
consequently CVD risk in these patients. However, these changes were only small 
and require further study. Modulation of lipids and other known CVD risk factors 
probably only partially explains the favourable effects of anti-TNF therapy on CVD 
risk. Hence, the presumed beneficial effects of TNFi on CVD risk in PsA appears to 
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Ankylosing spondylitis (AS) patients with active disease have an increased 
cardiovascular risk. Tumor necrosis factor alpha (TNF), an important mediator in 
the inflammatory pathway, induces an imbalance between clotting and fibrinolysis, 
resulting in a hypercoagulable state, thus amplifying not only the arterial 
cardiovascular risk, but also the risk for venous thromboembolism (VTE).  
Methods
In this study on  the effects of starting golimumab on the coagulation and fibrinolytic 
systems in AS patients inflammation markers erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP) were compared to coagulation and fibrinolytic 
parameters Prothrombin fragment 1+2 (F1+2), Thrombin-antithrombin complex 
(TAT), Plasmin-alpha 2-antiplasmin complex (PAP), von Willebrand factor (VWF) and 
D-Dimer, at baseline and after 4 weeks of golimumab therapy.
Results 
Thirty-five patients were included. Both median (IQR) CRP and ESR decreased after 
one month of treatment (from 5.5 (2.1-15.5) to 2.0 (1.0-5.0) and from 13 (6-25) to 4 (2-
11) respectively). All coagulation markers also decreased, F1+2 from 436 (351-508) 
to 324 (178-484), TAT from 4.7 (3.2-6.0) to 3.6 (3.0-4.9) , VWF  from 151 (61) to 132 (41) , 
PAP from 671 (459-988) to 440 (386-650)  and D-Dimer from 0.28 (0.19-0.38) to 0.23 
(0.17-0.30).
Conclusions
AS patients with active disease have signs of an activated coagulation system. 
During treatment, a larger decrease of inflammation markers induced by golimumab 
therapy was associated with a larger decrease in coagulation parameters. Whether 
the decreased coagulation status results in a lower risk for VTE remains to be 
established in long-term clinical studies. 
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INTRODUCTION
Inflammatory joint diseases are associated with increased cardiovascular risk; 
there are many studies reporting on the incidence of arterial thrombosis in clinical 
manifestations like myocardial infarction and stroke.(1) An important mediator in 
the inflammatory pathway is tumor necrosis factor alpha (TNF)(2). In the general 
population, TNF induces an imbalance between clotting and fibrinolysis resulting 
in a hypercoagulable state, thus amplifying not only the arterial cardiovascular risk, 
but also the risk for venous thromboembolism (VTE)(3-5). It is known that TNF-
inhibitors (TNFi) decrease the arterial CV risk, but the effect on risk factors for VTE 
is not known(6).  Moreover, there are only sparse data indicating that  coagulation 
activation may be  increased in AS patients and that suggests a  relationship with 
inflammation and disease activity(7).  Therefore, we investigated the effect of 
golimumab on the coagulation and fibrinolytic systems in consecutive AS patients 
treated with golimumab.
The immune and coagulation systems are closely linked by a shared origin, 
and current literature points to increased activity of both the coagulation and 
fibrinolytic systems in patients with inflammatory joint diseases(7).  TNF is a key 
player in several inflammatory joint diseases, including rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For this study, we used AS 
as a ‘human model’ to study the interplay between inflammation, anti-inflammatory 
medication and coagulation. Our objective was to examine the effect of TNFi 
therapy on coagulation and fibrinolysis makers. 
MATERIALS AND METHODS
Study protocol
Patient data from our observational cohort ‘Golimumab and AS’ were used for this 
study. This cohort included patients between March, 30th 2012 and February 12th 
2016 at the Amsterdam Rheumatology and Immunology Center (locations Reade 
and VU University Medical Center) in the Netherlands. 
All consecutive AS patients who initiated golimumab therapy, as prescribed 
by a rheumatologist in routine daily practice, were asked to participate in this 
longitudinal cohort. In this cohort, study variables including demographic variables, 
disease related outcomes and blood samples were collected at baseline (before 
the start of golimumab) and after 1 month of golimumab use. Inclusion criteria for 
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this cohort were a previous diagnosis of AS according to the 1984 modified New 
York criteria for AS, prescription of golimumab in accordance with the international 
consensus of the Assessment of Spondyloarthritis international Society (ASAS) 
for initiating TNFi in AS, age of 18 years or older and exclusion criteria were the 
prior use of golimumab or language barrier(8, 9). All patients were treated with 
golimumab 50 mg through subcutaneous injection once a month.
This study was performed in compliance with the declaration of Helsinki and 
approved on July 23th 2012 by the local Medical Ethics Committee of Slotervaart 
and Reade Hospital (NL 39155.048.11, METC P1166.) All patients gave written 
informed consent.
Outcome measures
At baseline and after 4 weeks of treatment, the patients were assessed by 
a physician or research nurse, evaluating the disease status, concomitant 
medication and adverse events. Physical examination, including height, weight, 
and blood pressure, was performed at every visit according to standard hospital 
procedures. Laboratory measurements included C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), Prothrombin fragment 1+2 (F1+2), Thrombin-
antithrombin complex (TAT), Plasmin-alpha 2-antiplasmin complex (PAP), von 
Willebrand factor (VWF) and D-Dimer. AS-specific variables included the Ankylosing 
Spondylitis Disease Activity Score–CRP (ASDAS-CRP) and the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI).
Statistical analysis
Data are presented as mean (± SD), median (with first and third quartile), or 
percentages. 
All laboratory analyses were performed in the Department of Experimental 
Vascular Medicine of the Amsterdam University Medical Centers. D-dimer levels 
were determined with a particle-enhanced immunoturbidimetric assay (Innovance 
D-Dimer, Siemens Healthcare Diagnostics, Marburg, Germany). Prothrombin 
fragment F1+2 and Thrombin-antithrombin complex were determined by Enzygnost 
monoclonal ELISAs from Siemens Healthcare Diagnostics.PAP was analyzed by 
ELISA from DRG Diagnostica. VWF antigen levels were determined with an ELISA 




Thirty-five patients were included in the cohort, 22 (63%) male, 13 (37%) female, 
with a median disease duration of 8 years. Of all patients who started golimumab, 
17 were TNFi-naïve and 18 had previously used one or more other TNFi. Baseline 
characteristics are shown in table 1.
Seventeen TNFi switchers switched because of failure of the previous TNFi, 1 
person switched because remission was achieved during treatment with the first 
TNFi but a flare occurred later on.
Table 1 | Baseline characteristics
N=35
Age, years (±SD) 45 (± 12)
Male, no (%) 22 (63 %)
Disease duration, years, median (IQR) 8 (3-19)
TNFi-naïve, no (%) 17 (49 %)
Switcher, failure on 1 TNFi, no (%) 9 (26 %)
Switcher, failure on 2 TNFi, no (%) 9 (26 %)
BASDAI, mean (±SD) 6.1 (± 1.4)
ASDAS-CRP, mean (±SD) 3.5 (± 0.9)
ESR, mm/h, median (IQR) 13 (6-25)
CRP, mg/L, median (IQR) 5.5 (2.1-15.5)
NSAID use, no (%) 27 (77 %)
Prednisone use, no (%) 4 (11 %)
History of CVD, no (%) 2 (6 %)
Smoking status
  None, no (%) 24 (69 %)
  Current, no (%) 9 (26 %)
  Past, no (%) 2 (6 %)
Continuous variables are presented as means ± SD or as medians (IQR). Categorical and 
dichotomous variables are presented as numbers and/or percentages. ASDAS = Ankylosing 
Spondylitis Disease Activity Score; TNFi = Tumor Necrosis Factor inhibitor; BASDAI = Bath 
Ankylosing Spondylitis Disease Activity Index; CRP = C-reactive protein; CVD = cardiovascular 
disease; ESR = erythrocyte sedimentation rate; NSAID = non-steroidal anti-inflammatory drug
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Association between disease activity and markers of coagulation
In comparison to historical controls, AS patients had, at baseline, higher levels of 
coagulation activation markers (10). First, we examined the association of markers 
of disease activity (ASDAS, BASDAI, CRP and ESR) at baseline with markers of 
coagulation and fibrinolysis. Results are displayed in table 2A and table 2B. We 
found that, at baseline, higher values of CRP and ESR were significantly associated 
with higher levels of PAP and D-Dimer: higher inflammatory markers means an 
increase in PAP and D-Dimer. This was also the trend for the other coagulation 
markers, although this was not statistically significant. However, we could not 
find an association between the more subjective markers ASDAS and BASDAI 
after 4 weeks of treatment. Nevertheless, we found that higher CRP and ESR were 
associated with increased coagulation markers, although this association was no 
longer statistically significant.  
Table 2A |  Association between disease activity and coagulation-markers at baseline









































ASDAS: AS Disease Activity Score, BASDAI: Bath Ankylosing Spondylitis Disease Activity 
Index, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, F1+2 = prothrombin 
fragment 1+2, TAT: thrombin-antithrombin complex, PAP: Plasmin-antiplasmin complex, 
VWF: von Willebrand factor
Table 2B | Association between disease activity and coagulation-markers at 4 weeks































BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, CRP: C-reactive protein, 
ESR: Erythrocyte sedimentation rate, F1+2 = prothrombin fragment 1+2, TAT: thrombin-
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antithrombin complex, PAP: Plasmin-antiplasmin complex, VWF: von Willebrand factor
NB Association between ASDAS and markers of coagulation was not performed due to 
missing values
Change in markers of disease activity and markers of coagulation after 1 
month of treatment
Second, we assessed how markers of inflammation, coagulation and fibrinolysis 
changed over time. We found a decrease in ESR and CRP after one month of 
treatment, and a decrease in all markers of coagulation. (Table 3)
Table 3 |  Values of markers of inflammation and coagulation at baseline and after 4 weeks
Baseline Week 4
ASDAS-CRP, mean (±SD) 3.5 ± 0.9 2.6 ± 1.1
BASDAI, mean (±SD) 6.1 ± 1.4 4.9 ± 2.4
ESR, mm/h, median (IQR) 13 (6-25) 4 (2-11)
CRP, mg/L,  median (IQR) 5.5 (2.1-15.5) 2.0 (1.0-5.0)
F1+2, pmol/L , median (IQR) 436 (351-508) 324 (178-484)
TAT, µg/L,  median (IQR) 4.7 (3.2-6.0) 3.6 (3.0-4.9)
PAP, µg/L, median (IQR) 671 (459-988) 440 (386-650)
VWF, %, median (IQR) 141 (109-187) 127 (107-155)
D-Dimer, mg/L, median (IQR) 0.28 (0.19-0.38) 0.23 (0.17-0.30)
ASDAS: AS Disease Activity Score, BASDAI: Bath Ankylosing Spondylitis Disease Activity 
Index, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, F1+2 = prothrombin 
fragment 1+2, TAT: thrombin-antithrombin complex, PAP: Plasmin-antiplasmin complex, 
VWF: von Willebrand factor 
Overall, we found that coagulation markers decreased to a larger extent in patients 
with a greater decrease in disease activity, as represented by a greater decrease 
in CRP and ESR (Table 4).
Table 4 | Association between change in CRP and ESR and markers of coagulation at week  4
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DISCUSSION
In this cohort of patients that started golimumab, we found that after 4 weeks 
of treatment, markers of disease activity decreased, as well as all markers of 
coagulation. 
At baseline, CRP and ESR were significantly associated with PAP and D-Dimer 
levels: thus a higher inflammatory load might induce coagulation activation. This is 
underscored by increased levels of the other coagulation markers albeit that this 
did not reach statistical significance. Overall, markers of coagulation decreased to 
a larger extent in patients with a greater decrease in CRP and ESR.
As far as we know, this effect has not been described in AS patients. However, 
studies in RA patients have been performed. One study in RA patients using 
infliximab suggested that TNFi therapy is accompanied with normalization of the 
prothrombotic biomarkers D-dimer and F1+2(11).  Another study, which included 
patients on TNFi therapy or methotrexate, found that after 6 weeks of therapy, levels 
of fibrinogen and D-dimer decreased in the TNFi therapy group(12). This exploratory 
study shows that there is an effect, albeit small, on coagulation markers after the 
initiation of TNFi in AS patients. As AS patients have increased risk for VTE, anti-
inflammatory therapy might not only be relevant in reducing back pain and spinal 
deformity, but may reduce VTE incidence as well. Because of the exploratory 
nature of this study, there are some limitations, like the small sample size and short 
duration of follow up. Furthermore, a control group was lacking. Nevertheless, AS 
patients with active disease appear to have an increased procoagulant state in 
comparison to healthy controls. This might have consequences for drug tapering 
as this might induce increased coagulation activation in some patients. A future 
challenge is therefore to identify these patients. 
Finally, whether or not the favourable effects of TNFi therapy on the coagulation 
system persist and ultimately result in a lower risk for VTE remains to be established 
in prospective clinical studies.
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SUMMARY
The risk for cardiovascular disease in rheumatoid arthritis (RA) patients has been a 
concern for the last two decades; since research showed that this risk is increased 
compared to the general population. In 2009, the European League Against 
Rheumatism (EULAR) task force recommended screening, identification of CVD 
risk factors and CVD risk management in RA patients. Since then, substantial new 
insights in this field has been published, largely based on expert opinion. In chapter 
two the updated recommendations on cardiovascular risk management from the 
European League Against Rheumatism (EULAR) task force are discussed. In these 
recommendations, three overarching principles and 10 recommendations were 
formulated. The first overarching principle is that clinicians should be aware of 
the higher risk for CVD in patients with RA compared with the general population. 
This was already known in 2009, but now with extended evidence. Secondly, the 
rheumatologist is responsible for the initiation of risk management in patients 
with RA and other IJD, but can/should of course involve other healthcare 
professionals other than rheumatologists, depending on the local organization of 
healthcare. Third, the use of NSAIDs and corticosteroids, which have potentially 
adverse cardiovascular effects, should be in accordance with treatment-specific 
recommendations from EULAR and ASAS. Ten recommendations were defined, 
based on a pan-European consensus. These recommendations, are meant to 
facilitate CVD risk management in daily clinical practice, ultimately leading to a 
decreased CVD burden in RA patients. 
We conducted the I-CaRe Project in Reade, Amsterdam, and Antonius Hospital, 
Sneek to investigate and optimize cardiovascular risk management. In chapter 
three, we performed a cardiovascular risk screening and calculated the 10-year 
cardiovascular (CV) risk score in 720 patients from Reade and the Antonius Hospital, 
using the Dutch cardiovascular risk guideline. Over half of these patients (53%) 
were found to have a high cardiovascular risk. Furthermore, we identified (under)
treatment of CV risk factors in these patients. In total, 69% had an indication to use 
cholesterol lowering or antihypertensive drugs. Of those, 42% received inadequate 
treatment and 40% received no treatment at all. In chapter four the results of this 
project after one year are described. The results from the baseline screening 
as described in chapter three were communicated to the general practitioner, 
including specific advice on the initiation or adjustment of cardio preventive 
drugs, whereas in the Antonius Hospital all patients were referred to the internist. 
The decision to start or adjust preventive medication was at the discretion of the 
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general practitioner or internist. After one year, we re-evaluated CV risk, lifestyle 
and treatment. After this year, cardio preventive drug treatment was only started 
or adjusted in one third of patients with an indication for treatment. However,  we 
did find lifestyle changes; 42% of patients reported to have changed their lifestyles 
including more exercise, diet adaption and weight loss. Despite clear guidelines, 
both local (Dutch guideline) and international, like the EUAR guideline, and the 
active implementation of a screening program, we have to conclude that optimal 
CV risk management remains a major challenge in the RA population.
Not only cardiovascular risk management, but also the prediction of cardiovascular 
risk itself remains a challenge in the RA population. In chapter five it is shown that 
different CV risk scores are calculated, dependent on which risk prediction tool was 
used and when, in the course of the disease, the risk was calculated. This inevitably 
leads to differences in advices on preventive medication dependent on the stage 
of disease activity. It appears to make most sense to calculate cardiovascular risk 
during the period that RA patients are in a state of low or stable disease activity. 
This of course needs to be further investigated by studies using longer follow up. 
As stated in de EULAR recommendations, patients with RA not only suffer from a 
higher cardiovascular burden, but also demonstrate increased prevalence of other 
inflammatory autoimmune disorders. In chapter six we assessed the prevalence 
proportion and incidence rate of cardiovascular morbidity in patients with 
inflammatory arthritis and co-existent autoimmune disorders. We demonstrated an 
increased prevalence proportion of type 1 diabetes, hypothyroidism, psoriasis and 
Crohn’s disease/ulcerative colitis in patients with inflammatory arthritis compared 
with controls. Moreover, patients with inflammatory arthritis more often had one or 
more concomitant autoimmune disorders. We confirmed once again the increased 
cardiovascular risk for patients with inflammatory arthritis, and found that this 
risk was further amplified in the presence of another coexistent autoimmune 
disorder. The amplification of cardiovascular disease risk in inflammatory arthritis 
patients with multiple autoimmune disorders warrants greater awareness for 
this phenomenon, and since autoimmune disorders often co-exist, the need for 
cardiovascular risk management in these patients is once again emphasized.
Although there are a few randomized trials investigating cardiovascular outcomes 
in RA disease management, it is accepted that suppression of inflammation is 
beneficial for cardiovascular risk, and tight disease control is thought to improve 
cardiovascular outcomes. Part II of this thesis puts focus on effects of treatment 
on different outcomes and markers of CVD. 
Chapter 11. Summary and discussion
184
As described in chapter six, the coexistence of inflammatory arthritis and other 
auto-immune disease, like thyroid disfunction, amplifies cardiovascular risk. In 
chapter seven, we used data from a longstanding prospective cohort to investigate 
the effect of thyroid dysfunction on incident CVD compared to euthyroid RA 
patients. We found that patients with RA and subclinical hypothyroidism had an 
increased risk for new CVD. 
In chapter eight, we demonstrated associations between RA disease activity 
and the biomarkers NT-proBNP and sRAGE in a cohort of very early arthritis 
patients that started anti-rheumatic treatment. During 6 months of treatment 
with anti-inflammatory medication, NT-proBNP decreased and sRAGE increased, 
independent of the type of medication used. Therefore, we conclude that 
suppressing disease activity, independent of the drug used, increases sRAGE 
levels and decreases NT-proBNP levels. 
In chapter nine the effects of etanercept on lipid metabolism and other 
cardiovascular risk factors in patients with psoriatic arthritis are investigated in an 
observational cohort using mixed model analyses to assess CVD risk factors over 
5 years during etanercept treatment. We found that during etanercept use, mainly 
changes in lipid levels were seen, consisting of an increase in total cholesterol 
(TC), high-density lipoprotein cholesterol (HDLc), and low-density lipoprotein 
cholesterol. The apolipoprotein B to apolipoprotein A-I (apoB/apoA-I) ratio 
decreased significantly. However, we observed only modest changes; therefore, 
we hypothesize that the previously described beneficial effects of etanercept on 
CVD is more likely exerted through other inflammation-related mechanisms. 
As coagulation and inflammation are closely linked, we investigated the changes in 
markers of coagulation in patients with AS starting the TNF-blocker golimumab, and 
the results are described in chapter ten. We found that after 4 weeks of treatment, 
markers of disease activity decreased, as well as all markers of coagulation 
activation. We found significant associations between CRP and ESR and PAP 
and D-Dimer levels at baseline, and after 4 weeks of treatment, that markers of 




This thesis adds new evidence relating to cardiovascular disease in inflammatory 
arthritis, but still, mechanisms underlying the increased cardiovascular risk 
are not yet clear, as is the influence of anti-rheumatic treatment. For example, 
we found an association between the magnitude of change in inflammatory 
markers (ESR and CRP) and change in NT-proBNP and sRAGE and hypothesized 
that suppression of inflammation benefits the myocardium and endothelium. It 
would be interesting to further unravel this mechanism and correlate it with ‘hard’ 
cardiovascular endpoints, to provide more evidence that prompt suppression of 
inflammation prevents cardiovascular disease. Furthermore, in our cohort of PsA 
patients starting etanercept, we found little change in the cardiovascular risk 
factors, suggesting that beneficial effects of etanercept on CVD are likely caused 
by suppression of inflammation, or perhaps a direct effect of the drug, but not 
mediated by improvement of cardiovascular risk factors. To study the effects of 
different treatment regimens on cardiovascular outcomes (large) randomized 
controlled trials are needed. In chapter ten, we performed a small study investigating 
markers of inflammation and coagulation. In contrast to arterial embolism, like 
CVD, less is known about the risk for venous thromboembolism. The activation of 
coagulation in active disease, and its normalization after the start of a TNFi, might 
have implications for future treatment with these drugs. But before any practical 
recommendations can be given, we first need to investigate whether or not TNFi 
therapy results in a lower risk for VTE, and therefore prospective clinical studies 
are needed. 
Moreover, this thesis showed that there is still a lot to improve in the management 
of cardiovascular disease. From the I-CaRe project we learned that cardiovascular 
risk management in RA patients is still suboptimal. Several research topics need 
to be addressed to improve this. First, current cardiovascular risk screening tools 
are insufficient for patients with inflammatory arthritis, and future research 
using, for example, large databases is needed to develop more specific tools. 
However, the tools that are currently available need to be employed properly and 
therefore we need to optimize our strategy, including systematic screening and 
collaboration between rheumatologists, (vascular) internists, cardiologists and 
general practitioners. 
Chapter 11. Summary and discussion
186
CONCLUSION
Further research must be done to delineate specific mechanisms in the 
pathogenesis of ischaemic heart disease. Prospective clinical trials are needed to 
assess the roles of antirheumatic therapies, pharmacological control of traditional 
risk factors and lifestyle-modification strategies in the potential reduction of 
cardiovascular risk. In the meantime, cardiovascular risk management in patients 
with inflammatory arthritis remains of utmost importance. The existing models for 
the prediction of cardiovascular risk are not sufficiently accurate in these patients 
and the development of disease-specific approaches is necessary—although 
very challenging. Systematic screening for cardiovascular risk and coordination 
of care between rheumatologists, (vascular) internists, cardiologists and general 
practitioners is essential to achieve optimal management of cardiovascular risk 





Patiënten met reumatoïde artritis (RA), maar ook andere auto-immuunziekten, 
hebben ongeveer tweemaal zoveel kans op het krijgen van hart- en vaatziekten 
(HVZ) als mensen zonder RA. De laatste jaren wordt steeds meer bekend over de 
mechanismen die dit veroorzaken. Zo weten we dat deze verhoogde kans op HVZ 
deels komt door de traditionele risicofactoren, zoals roken, hypertensie en een 
verhoogd cholesterol. Echter, bij patiënten met een auto immuun aandoening zoals 
RA speelt ook de chronische ontsteking een rol. Daarnaast kan ook de behandeling 
van RA een effect hebben op het risico om HVZ te ontwikkelen. Nu we steeds meer 
weten over het voorkomen van HVZ bij deze patiëntengroepen, is het logisch om 
ook onze aandacht te richten op preventie van HVZ. Hierover valt nog veel te leren.
Het eerste deel van dit proefschrift gaat over cardiovasculair risicomanagement 
bij patiënten met auto-immuunziekten, voornamelijk RA. Hoofdstuk twee bestaat 
uit een 10-tal aanbevelingen vanuit de European League Against Rheumatism 
(EULAR) werkgroep. Deze 10 aanbevelingen zijn geformuleerd op basis van de 
laatste wetenschappelijke inzichten alsmede ‘expert’ opinion, met als doel richting 
te geven aan cardiovasculair risicomanagement in de dagelijkse reumatologie 
praktijk. Daarnaast zijn er drie overkoepelende principes geformuleerd: 1. Artsen 
moeten zich bewust zijn van het verhoogde risico op HVZ bij patiënten met 
inflammatoire gewrichtsaandoeningen; 2. De reumatoloog is als hoofdbehandelaar 
van deze patiëntengroep ervoor verantwoordelijk dat cardiovasculair 
risicomanagement wordt uitgevoerd, en betrekt hier de nodige collega’s bij en 
3. Het voorschijven van NSAIDs en corticosteroïden, die potentieel nadelige 
cardiovasculaire bijwerkingen hebben, gebeurd volgens de behandelrichtlijnen 
van EULAR en ASAS. In hoofdstukken drie en vier worden de resultaten van het 
I-CaRe onderzoek beschreven. In dit onderzoek, wat een samenwerking was 
tussen Reade in Amsterdam en het Antonius ziekenhuis in Sneek, werd het 
cardiovasculaire risicoprofiel van patiënten met RA in kaart gebracht, met als doel 
het management van deze patiënten te verbeteren. We vonden dat meer dan de 
helft van onze patiënten een verhoogd risico op HVZ had, en dat een verhoogde 
bloeddruk of verhoogd cholesterol vaak onvoldoende werd behandeld. Als er bij 
patiënten een (onvoldoende behandeld) verhoogd cardiovasculair risico werd 
gevonden, werd de huisarts hiervan op de hoogte gesteld met het verzoek om 
behandeling te optimaliseren. Na een jaar evalueerden we het cardiovasculair 
risicoprofiel opnieuw. Daarbij viel op dat medicamenteuze therapie in de vorm van 
cholesterolverlagers of antihypertensiva bij slechts een derde van de patiënten 
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was aangepast. Gelukkig had 42% van de onderzochte populatie wel veranderingen 
in hun leefstijl doorgevoerd, zoals afvallen, meer bewegen of gezonder eten. Naar 
aanleiding van deze resultaten concludeerden wij dat ondanks de bestaande 
richtlijnen voor cardiovasculair risicomanagement, de praktische uitvoering 
ervan nog vele haken en ogen kent. In hoofdstuk vijf gaan we dieper in op de 
cardiovasculaire risicoberekening door het 10-jaars risico op HVZ op verschillende 
tijdstippen in het ziektebeloop en met verschillende modellen te berekenen. Dit 
laat zien dat de ‘score’ die uit deze berekening komt verschillend is afhankelijk van 
wanneer en hoe de berekening wordt gemaakt. Hierdoor kan het advies om wel 
of niet te starten met bijvoorbeeld bloeddrukverlagers verschillen. Dit was met 
name sterk afhankelijk van het moment van berekening; voor of na starten van 
anti-reumatische medicatie. Het lijkt het meest logisch om het cardiovasculaire 
risico te berekenen in de periode dat patiënten zich in een toestand van lage of 
stabiele ziekteactiviteit bevinden. Dit moet natuurlijk verder worden onderzocht 
en bevestigd door studies met een langere follow-up. Zoals al eerder genoemd in 
bijvoorbeeld de EULAR aanbevelingen, hebben niet alleen patiënten met RA een 
verhoogd risico op HVZ, maar ook patiënten met andere auto-immuunziekten. 
In hoofdstuk zes kijken we daarom naar het voorkomen van HVZ bij patiënten die 
naast een vorm van artritis ook nog een andere auto-immuunziekte hebben. We 
vonden dat bijvoorbeeld diabetes, specifiek type 1, hypothyreoïdie en psoriasis 
meer voorkwamen bij patiënten met RA dan bij gezonde controles. Daarnaast 
bleken de patiënten die RA hadden en daarnaast nog een van deze aandoeningen, 
een nog verder verhoogd cardiovasculair risico te hebben vergeleken met de 
groep met alleen RA. Omdat RA dus vaak samen met andere auto-immuunziekten 
voorkomt, willen wij ervoor pleiten om bij deze groep extra aandacht te besteden 
aan cardiovasculair risicomanagement. In hoofdstuk zeven hebben we gekeken 
naar het effect van schildklierproblemen bij RA patiënten op de kans op HVZ 
omdat deze twee aandoeningen frequent samen voorkomen. Middels analyse van 
data van een groot langlopend cohort toonden we aan dat patiënten met RA met 
tegelijk ook subklinische hypothyreoïdie een (extra) verhoogde kans hadden op het 
optreden van nieuwe HVZ. Deze groep verdient dus ook zeker extra aandacht voor 
cardiovasculair risicomanagement.
In deel twee van dit proefschrift  worden de resultaten beschreven van studies 
naar het effect van verschillende behandelregimes op uitkomstmaten gerelateerd 
aan hart en vaatziekten. In hoofdstuk acht keken we naar het verband tussen de 
ziekteactiviteit van patiënten met RA en de biomarkers NT-proBNP en sRAGE, 
zowel voor als na behandeling met anti-reumatische medicatie. We zagen daarbij 
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dat onderdrukking van inflammatie leidde tot een verbetering van deze biomarkers, 
waarbij het type medicatie in dit onderzoek niet uitmaakte. Het effect van 
behandeling van patiënten met artritis psoriatica met het anti-reumatische middel 
etanercept (een TNF blokker) op verschillende cardiovasculaire risicofactoren 
wordt beschreven in hoofdstuk negen. Daarbij vonden we dat het gebruik van 
etanercept tot vrij kleine veranderingen in cholesterolwaarden leidde. Het lijkt niet 
aannemelijk dat deze kleine veranderingen het gunstige effect van etanercept 
op HVZ verklaren; dit lijkt eerder het anti-inflammatoire effect of misschien een 
direct effect van het medicijn te zijn. In hoofdstuk tien hebben we gekeken naar 
de veranderingen die optreden in het stollingssysteem nadat patiënten met 
Bechterew werden behandeld met golimumab, (ook) een TNF blokker. Stolling en 
ontsteking zijn namelijk nauw verbonden. Na 4 weken behandeling met dit medicijn 
zagen we dat verschillende stollingswaarden, die verhoogd waren voor start van 
behandeling, normaliseerden. Of dit ook gevolgen heeft voor het optreden van 
trombose moet verder onderzocht worden. 
TOEKOMSTPERSPECTIEF
Dit proefschrift levert nieuwe inzichten in de wisselwerking tussen inflammatie en 
risico op hart en vaatziekten. Er blijven echter nog vele mechanismen onbekend. 
Wij hebben bijvoorbeeld gevonden dat veranderingen in de inflammatiewaarden 
BSE en CRP leidden tot veranderingen in NT-proBNP en sRAGE. Het is daarom 
waarschijnlijk dat het onderdrukken van de inflammatie een positief effect heeft 
op de cellen van de hartspier. Het zou interessant zijn om dit verder uit te diepen, 
en vooral om ook te laten zien dat dit daadwerkelijk leidt tot minder HVZ. Daarnaast 
wat het opvallend dat er bij patiënten met artritis psoriatica die startten met 
etanercept nauwelijks veranderingen waren in de cardiovasculaire risicofactoren, 
terwijl we weten dat etanercept over het algemeen wel een gunstig effect heeft op 
het voorkomen van HVZ. Dit impliceert dat die positieve effecten eerder zijn toe te 
schijven aan de onderdrukking van de inflammatie, of wellicht bestaat er een direct 
effect van het medicijn zelf op HVZ. Om dit verder te onderzoeken zouden (grote) 
klinische trials uitkomst kunnen bieden. 
Hoewel er al veel bekend is over het risico op arteriële trombo-embolieën, waaronder 
het myocardinfarct, weten we minder over het optreden van veneuze trombo-
embolie. In hoofdstuk tien worden de effecten van een kleine studie beschreven 
waarin we zagen dat biomarkers van de stolling geactiveerd zijn bij actieve ziekte, 
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en lijken te normaliseren na start van therapie. Het is daarom interessant om te 
kijken hoe dit zich vertaald naar de klinische praktijk. 
Uit dit proefschrift valt verder op te maken dat er in het veld van cardiovasculair 
risicomanagement bij patiënten met bijvoorbeeld RA nog veel te verbeteren is. De 
resultaten van het I-CaRe project lieten zien dat cardiovasculair risicomanagement 
vaak nog suboptimaal is. Om dit te verbeteren zijn er meerdere stappen nodig. 
Allereerst zijn de huidige modellen om het 10-jaars risico op HVZ te voorspellen 
niet voldoende gespecificeerd voor patiënten met een auto immuun aandoening. 
Door bijvoorbeeld het gebruik van grote datasets zouden meer specifieke modellen 
ontwikkeld kunnen worden. Ondertussen kunnen we beter gebruik maken van 
de modellen die er al wel zijn. Hiervoor is samenwerking tussen onder meer 
reumatologen, huisartsen en (vasculair) internisten onontbeerlijk. 
CONCLUSIE
Er is steeds meer bekend over de verschillende mechanismen die zorgen voor 
het verhoogde risico op hart en vaatziekten bij patiënten met auto-immuun 
aandoeningen, maar (inflammatie) specifieke mechanismen dienen in de toekomst 
nog verder onderzocht te worden. Wellicht kunnen de inzichten die zo verkregen 
worden helpen bij het opzetten van prospectieve klinische trials waarin de rol van 
verschillende anti-reumatische medicijnen bij het voorkomen van HVZ kan worden 
onderzocht. Daarnaast is meer onderzoek nodig naar het effect van verbetering 
van leefstijl en de behandeling van de traditionele risicofactoren, zoals hypertensie 
en hypercholesterolemie, in deze specifieke groep patiënten. 
Ondertussen moeten we ons blijven richten op verbetering van het cardiovasculair 
risicomanagement van patiënten met auto-immuun aandoeningen. Ofschoon nog 
geen optimale strategieën bestaan, is duidelijk dat samenwerking van verschillende 
specialismen zoals reumatologen, internisten en cardiologen met huisartsen 
hierbij essentieel is .
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